image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
a73d90e38bfd2173157fc5a6bff2c622d2c86c71b8936a150b531ea20b3abdd2.png | simple | <table><tr><td>NEO-PI-R scales</td><td>Never-smokers (<i>n </i>= 341)</td><td>Former-smokers (<i>n </i>= 429)</td><td>Current-smokers (<i>n </i>= 318)</td><td><i>F</i></td><td>Partial η<sup>2</sup></td></tr><tr><td>Neuroticism</td><td>48.9 (.51)<sup>a</sup></td><td>50.7 (.46)<sup>b</sup></td><td>51.6 (.55)<sup>b</sup></td><td>6.9**</td><td>.013</td></tr><tr><td>Extraversion</td><td>48.8 (.44)</td><td>49.3 (.40)</td><td>48.4 (.48)</td><td>1.0</td><td>.002</td></tr><tr><td>Openness</td><td>45.6 (.44)</td><td>46.4 (.39)</td><td>46.5 (.47)</td><td>1.2</td><td>.002</td></tr><tr><td>Agreeableness</td><td>50.9 (.49)</td><td>50.9 (.44)</td><td>49.9 (.52)</td><td>1.3</td><td>.002</td></tr><tr><td>Conscientiousness</td><td>49.4 (.52)<sup>a</sup></td><td>49.0 (.46)<sup>a</sup></td><td>47.0 (.55)<sup>b</sup></td><td>5.5**</td><td>.010</td></tr><tr><td>N1: Anxiety</td><td>49.7 (.46)<sup>a</sup></td><td>51.0 (.41)<sup>b</sup></td><td>51.7 (.50)<sup>b</sup></td><td>4.7**</td><td>.009</td></tr><tr><td>N2: Angry Hostility</td><td>49.5 (.50)<sup>a</sup></td><td>50.7 (.45)<sup>a</sup></td><td>52.3 (.54)<sup>b</sup></td><td>6.9**</td><td>.013</td></tr><tr><td>N3: Depression</td><td>49.3 (.57)<sup>a</sup></td><td>50.8 (.51)<sup>a</sup></td><td>53.1 (.61)<sup>b</sup></td><td>10.0**</td><td>.019</td></tr><tr><td>N4: Self-consciousness</td><td>48.4 (.52)<sup>a</sup></td><td>50.1 (.46)<sup>b</sup></td><td>50.0 (.56)<sup>b</sup></td><td>3.6*</td><td>.007</td></tr><tr><td>N5: Impulsiveness</td><td>48.3 (.48)<sup>a</sup></td><td>49.8 (.43)<sup>b</sup></td><td>49.7 (.52)<sup>b</sup></td><td>3.4*</td><td>.007</td></tr><tr><td>N6: Vulnerability</td><td>49.3 (.58)<sup>a</sup></td><td>50.4 (.52)<sup>a</sup></td><td>52.7 (.63)<sup>b</sup></td><td>7.9**</td><td>.015</td></tr><tr><td>E1: Warmth</td><td>48.9 (.52)</td><td>48.4 (.46)</td><td>47.2 (.56)</td><td>2.4</td><td>.005</td></tr><tr><td>E2: Gregariousness</td><td>50.5 (.50)</td><td>51.0 (.45)</td><td>49.7 (.54)</td><td>1.7</td><td>.003</td></tr><tr><td>E3: Assertiveness</td><td>50.1 (.51)</td><td>49.6 (.46)</td><td>49.2 (.55)</td><td>0.7</td><td>.001</td></tr><tr><td>E4: Activity</td><td>48.1 (.49)</td><td>47.3 (.43)</td><td>46.9 (.52)</td><td>1.5</td><td>.003</td></tr><tr><td>E5: Excitement-Seeking</td><td>46.9 (.47)<sup>a</sup></td><td>47.7 (.42)<sup>a</sup></td><td>49.0 (.50)<sup>b</sup></td><td>4.4*</td><td>.008</td></tr><tr><td>E6: Positive Emotions</td><td>48.9 (.51)<sup>a</sup></td><td>48.9 (.46)<sup>a</sup></td><td>47.0 (.55)<sup>b</sup></td><td>3.9*</td><td>.007</td></tr><tr><td>O1: Fantasy</td><td>47.8 (.44)</td><td>48.5 (.39)</td><td>48.3 (.47)</td><td>0.7</td><td>.001</td></tr><tr><td>O2: Aesthetics</td><td>48.3 (.48)</td><td>49.4 (.43)</td><td>49.4 (.52)</td><td>1.7</td><td>.003</td></tr><tr><td>O3: Feelings</td><td>46.7 (.46)</td><td>47.6 (.41)</td><td>47.0 (.50)</td><td>1.2</td><td>.002</td></tr><tr><td>O4: Actions</td><td>45.2 (.50)</td><td>46.1 (.45)</td><td>46.0 (.54)</td><td>1.0</td><td>.002</td></tr><tr><td>O5: Ideas</td><td>46.5 (.48)</td><td>46.9 (.43)</td><td>48.1 (.52)</td><td>2.7</td><td>.005</td></tr><tr><td>O6: Values</td><td>45.0 (.45)</td><td>45.6 (.40)</td><td>44.6 (.48)</td><td>1.4</td><td>.003</td></tr><tr><td>A1: Trust</td><td>47.2 (.53)</td><td>46.6 (.47)</td><td>46.2 (.57)</td><td>0.9</td><td>.002</td></tr><tr><td>A2: Straightforwardness</td><td>50.7 (.50)</td><td>51.0 (.44)</td><td>50.2 (.53)</td><td>0.7</td><td>.001</td></tr><tr><td>A3: Altruism</td><td>50.2 (.52)<sup>a</sup></td><td>51.6 (.46)<sup>b</sup></td><td>49.9 (.55)<sup>a</sup></td><td>3.5*</td><td>.007</td></tr><tr><td>A4: Compliance</td><td>50.5 (.55)<sup>a</sup></td><td>48.8 (.49)<sup>b</sup></td><td>48.4 (.59)<sup>b</sup></td><td>3.8*</td><td>.007</td></tr><tr><td>A5: Modesty</td><td>50.9 (.50)</td><td>51.5 (.45)</td><td>51.1 (.54)</td><td>0.3</td><td>.001</td></tr><tr><td>A6: Tender-mindedness</td><td>52.0 (.50)</td><td>52.4 (.44)</td><td>52.2 (.53)</td><td>0.2</td><td>.000</td></tr><tr><td>C1: Competence</td><td>50.0 (.56)<sup>a</sup></td><td>49.9 (.50)<sup>a</sup></td><td>46.7 (.60)<sup>b</sup></td><td>10.2**</td><td>.019</td></tr><tr><td>C2: Order</td><td>47.5 (.47)</td><td>47.0 (.42)</td><td>46.8 (.51)</td><td>0.5</td><td>.001</td></tr><tr><td>C3: Dutifulness</td><td>49.0 (.51)<sup>a</sup></td><td>48.5 (.45)<sup>a</sup></td><td>45.9 (.55)<sup>b</sup></td><td>9.0**</td><td>.017</td></tr><tr><td>C4: Achievement Striving</td><td>49.0 (.55)<sup>a</sup></td><td>48.4 (.49)<sup>a</sup></td><td>46.4 (.58)<sup>b</sup></td><td>5.4**</td><td>.010</td></tr><tr><td>C5: Self-Discipline</td><td>48.6 (.55)<sup>a</sup></td><td>47.7 (.49)<sup>a</sup></td><td>46.3 (.59)<sup>b</sup></td><td>3.8*</td><td>.007</td></tr><tr><td>C6: Deliberation</td><td>53.5 (.53)<sup>a</sup></td><td>52.6 (.48)<sup>a</sup></td><td>50.0 (.57)<sup>b</sup></td><td>10.1**</td><td>.019</td></tr></table> |
ddeb5f0d47f26304e664602d0f7fef23117a41c1c2198a68774a4d23a97aebc6.png | simple | <table><tr><td></td><td>2D matrix</td><td><i>N</i><sub>avg</sub></td><td><i>N</i><sub>ti</sub></td><td><i>N</i><sub>si</sub></td><td><i>N</i><sub>ring</sub></td><td>N<sub>y</sub></td><td>SBW (Hz)</td><td><i>T</i><sub>acq</sub> (min:s)</td></tr><tr><td>EPSI</td><td>32 × 32</td><td>4</td><td>1</td><td>1</td><td>NA</td><td>32</td><td>2380</td><td>8:32</td></tr><tr><td>Re‐CRT</td><td>32 × 32</td><td>4</td><td>2</td><td>1</td><td>16</td><td>NA</td><td>2500</td><td>8:32</td></tr><tr><td>DW‐CRT with <i>α</i> = 1</td><td>32 × 32</td><td>1</td><td>2</td><td>4</td><td>16</td><td>NA</td><td>2500</td><td>8:32</td></tr><tr><td>DW‐CRT with <i>α</i> = 1.71</td><td>32 × 32</td><td>1</td><td>2</td><td>4</td><td>16</td><td>NA</td><td>2500</td><td>8:32</td></tr><tr><td>Re‐CRT</td><td>48 × 48</td><td>4</td><td>2</td><td>1</td><td>24</td><td>NA</td><td>2500</td><td>12:48</td></tr><tr><td>DW‐CRT with <i>α</i> = 1</td><td>48 × 48</td><td>1</td><td>2</td><td>4</td><td>24</td><td>NA</td><td>2500</td><td>12:48</td></tr></table> |
f5ac47aaef9468874ce3513b3a5555bd841dc7f2fffd134e7a7de7d782f6aeb9.png | simple | <table><tr><td></td><td><i>E.coli</i></td><td><i>S.typhimurium</i></td><td><i>Y.pestis</i></td><td><i>Y.enterocolitica</i></td><td><i>P.luminescens</i></td></tr><tr><td><i>E.coli</i></td><td>***</td><td>66.7</td><td>28.6</td><td>33.3</td><td>52.4</td></tr></table> |
74a8d57dfab4979f5fa1af0c51d217a7f8234f0c8273858b167ddbdb8eaf7f53.png | complex | <table><tr><td rowspan="2">Age</td><td colspan="6">Males</td><td colspan="6">Females</td></tr><tr><td>%</td><td>ASR</td><td>Offered/Uptake</td><td>% Uptake Rate</td><td>CI</td><td>Sig</td><td>%</td><td>ASR</td><td>Offered/Uptake</td><td>% Uptake Rate</td><td>CI</td><td>Sig</td></tr><tr><td>40-44</td><td>25.6</td><td>-5.1</td><td>684/1345</td><td>0.51</td><td>(0.48–0.54)</td><td>***</td><td>24.0</td><td>-7.4</td><td>729/1727</td><td>0.42</td><td>(0.40–0.45)</td><td>***</td></tr><tr><td>45–49</td><td>20.8</td><td>-2.3</td><td>555/1551</td><td>0.36</td><td>(0.33–0.38)</td><td>*</td><td>21.3</td><td>2.1</td><td>645/1232</td><td>0.52</td><td>(0.50–0.55)</td><td>*</td></tr><tr><td>50–54</td><td>20.3</td><td>-1.0</td><td>543/1460</td><td>0.37</td><td>(0.34–0.40)</td><td>NS</td><td>17.5</td><td>-.3</td><td>532/1078</td><td>0.49</td><td>(0.46–0.52)</td><td>NS</td></tr><tr><td>55–59</td><td>13.4</td><td>-2.8</td><td>358/1040</td><td>0.34</td><td>(0.32–0.37)</td><td>**</td><td>11.9</td><td>-1.9</td><td>362/779</td><td>0.47</td><td>(0.43–0.50)</td><td>NS</td></tr><tr><td>60–64</td><td>10.1</td><td>7.0</td><td>270/512</td><td>0.53</td><td>(0.48–0.57)</td><td>***</td><td>11.6</td><td>2.0</td><td>351/658</td><td>0.53</td><td>(0.49–0.57)</td><td>*</td></tr><tr><td>65–69</td><td>6.7</td><td>10.9</td><td>178/250</td><td>0.71</td><td>(0.65–0.77)</td><td>***</td><td>9.4</td><td>5.3</td><td>285/463</td><td>0.62</td><td>(0.57–0.66)</td><td>***</td></tr><tr><td>70–74</td><td>3.1</td><td>6.1</td><td>81/120</td><td>0.68</td><td>(0.57–0.75)</td><td>***</td><td>4.0</td><td>7.8</td><td>130/162</td><td>0.80</td><td>(0.74–0.87)</td><td>***</td></tr><tr><td>Total</td><td>100 %</td><td></td><td>2669/6962</td><td></td><td></td><td></td><td>100 %</td><td></td><td>3034/6101</td><td></td><td></td><td></td></tr></table> |
149a2b64e6f721afc44b120dd3613a583e966af478ee4a9c3f9bd239a4efbb7b.png | simple | <table><tr><td>AE</td><td>Lacidipine (n = 162)</td><td>Amlodipine (n = 153)</td></tr><tr><td>Nervous system</td><td></td><td></td></tr><tr><td> Headache</td><td>3 (1.9)</td><td>6 (3.9)</td></tr><tr><td> Dizziness</td><td>2 (1.2)</td><td>1 (0.7)</td></tr><tr><td> Drowsiness</td><td>0</td><td>1 (0.7)</td></tr><tr><td> Hoarseness</td><td>0</td><td>0</td></tr><tr><td> Tremor</td><td>0</td><td>0</td></tr><tr><td>Cardiovascular system</td><td></td><td></td></tr><tr><td> Chest discomfort</td><td>0</td><td>0</td></tr><tr><td> Dyspnea</td><td>1 (0.6)</td><td>0</td></tr><tr><td> Palpitation</td><td>1 (0.6)</td><td>1 (0.7)</td></tr><tr><td> Syncope</td><td>0</td><td>0</td></tr><tr><td>General</td><td></td><td></td></tr><tr><td> Fatigue</td><td>0</td><td>1 (0.7)</td></tr><tr><td> Facial flushing</td><td>2 (1.2)</td><td>5 (3.3)</td></tr><tr><td> Edema, low extremity</td><td>1 (0.6)</td><td>5 (3.3)</td></tr><tr><td> Dry mouth</td><td>0</td><td>0</td></tr><tr><td>Skin</td><td></td><td></td></tr><tr><td> Rash</td><td>1 (0.6)</td><td>0</td></tr><tr><td>Laboratory</td><td></td><td></td></tr><tr><td> AST/ALT elevation</td><td>0</td><td>1 (0.7)</td></tr><tr><td> Dyslipidemia</td><td>1 (0.6)</td><td>2 (1.3)</td></tr><tr><td> Anemia</td><td>0</td><td>0</td></tr><tr><td>Total patients</td><td></td><td></td></tr><tr><td> With at least 1 AE</td><td>12 (7.4)</td><td>17 (11.1)</td></tr><tr><td> With no AEs</td><td>150 (92.6)</td><td>136 (88.9)</td></tr><tr><td> Withdrawn due to AEs</td><td>3 (1.9)</td><td>3 (2.0)</td></tr></table> |
ea4c0e8de3b165cb2c49cff704e8361b0632bca23b41e376b4b9d12c184579c8.png | simple | <table><tr><td>Species</td><td>Number of Retrocopies</td><td>Number of Parental Genes</td></tr><tr><td>Human</td><td>7,831</td><td>2,570</td></tr><tr><td>Chimpanzee</td><td>7,478</td><td>2,560</td></tr><tr><td>Gorilla</td><td>7,706</td><td>2,669</td></tr><tr><td>Orangutan</td><td>6,873</td><td>2,439</td></tr><tr><td>Rhesus</td><td>7,502</td><td>2,453</td></tr><tr><td>Marmoset</td><td>10,465</td><td>3,067</td></tr><tr><td>Squirrel monkey</td><td>9,320</td><td>2,864</td></tr><tr><td>Mouse</td><td>7,109</td><td>2,205</td></tr><tr><td>Rat</td><td>7,364</td><td>2,114</td></tr></table> |
e2cb400f2f6846bc79003f50b02b4ed27499888f5b08425fda25b395286d6492.png | simple | <table><tr><td> </td><td>HVLP group<i>N</i> = 20</td><td>Taper group<i>N</i> = 20</td></tr><tr><td>Age (years)</td><td>61.8 ± 12.9</td><td>64.9 ± 12.7</td></tr><tr><td>Gender (male/female)</td><td>10/10</td><td>10/10</td></tr><tr><td>Body weight (kg)</td><td>59.4 ± 13.7</td><td>57.3 ± 7.9</td></tr><tr><td>Height (cm)</td><td>161.6 ± 7.5</td><td>159.5 ± 9.9 </td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>22.6 ± 4.6</td><td>22.5 ± 2.5 </td></tr><tr><td>Mallampati score (1/2/3/4)</td><td>8/11/1/0</td><td>7/12/1/0</td></tr><tr><td>Cormack-Lehane grade (1/2/3/4)</td><td>11/8/1/0</td><td>9/11/0/0</td></tr><tr><td>Tracheal tube size (7.0/7.5/8.0/8.5)</td><td>2/11/6/1</td><td>3/7/8/2</td></tr></table> |
3bef57e6e39159b64b972d08f4a18a504ed3d959a84bc5f03140198fa1623c98.png | complex | <table><tr><td>Composition</td><td>Concentration</td></tr><tr><td>Sodium chloride (NaCl)</td><td>140 mM</td></tr><tr><td>HEPES</td><td>10 mM</td></tr><tr><td>Glucose</td><td>10 mM</td></tr><tr><td>Potassium chloride (KCl)</td><td>5 mM</td></tr><tr><td>Magnesium chloride (MgCl<sub>2</sub>)</td><td>1 mM</td></tr><tr><td>Calcium chloride (CaCl<sub>2</sub>)</td><td>1 mM</td></tr><tr><td colspan="2">pH 7.4</td></tr><tr><td colspan="2">300 mOsm (310 for SMG)</td></tr></table> |
8c17f493bf4470a51ff4f2e5c6dceab108ba7baf55eaab19ef02958c915ab5bb.png | simple | <table><tr><td></td><td>Child normal weight</td><td>Child overweight*†</td><td>Child obese†</td></tr><tr><td></td><td>(n = 7349; 85%)</td><td>(n = 1272; 15%)</td><td>(n = 264; 3%)</td></tr><tr><td><i>Sociodemographic factors</i></td><td></td><td></td><td></td></tr><tr><td> Male sex (%)</td><td>51.2</td><td>44.8‡</td><td>46.2‡</td></tr><tr><td> Both parents born outside Sweden (%)</td><td>28.7</td><td>28.8</td><td>34.2‡</td></tr><tr><td> Mother low education (%)</td><td>13.2</td><td>13.8</td><td>19.9‡</td></tr><tr><td> Father low education (%)</td><td>14.3</td><td>15.6</td><td>22.1‡</td></tr><tr><td> Firstborn (%)</td><td>46.1</td><td>44.8</td><td>41.9</td></tr><tr><td> No day care (%)</td><td>4.6</td><td>4.1</td><td>7.5</td></tr><tr><td> Crowded living (%)</td><td>10.8</td><td>11.1</td><td>15.5‡</td></tr><tr><td> Not taken part of parental education (%)</td><td>47.4</td><td>49.7</td><td>54.4‡</td></tr><tr><td><i>Parental overweight</i></td><td></td><td></td><td></td></tr><tr><td> Mother overweight (%)</td><td>27.3</td><td>37.6‡</td><td>49.3‡</td></tr><tr><td> Father overweight (%)</td><td>52.1</td><td>69.3‡</td><td>73.7‡</td></tr><tr><td> Both parents overweight (%)</td><td>17.0</td><td>29.1‡</td><td>40.0‡</td></tr><tr><td><i>Life style factors</i></td><td></td><td></td><td></td></tr><tr><td> Child's intake of sweetened beverages (%)</td><td>10.5</td><td>12.0</td><td>12.7</td></tr><tr><td> Secondhand tobacco smoke at 4 years of age (%)</td><td>22.6</td><td>26.4‡</td><td>32.6‡</td></tr><tr><td><i>Early life factors</i></td><td></td><td></td><td></td></tr><tr><td> Mother smoking during pregnancy (%)</td><td>9.6</td><td>13.6‡</td><td>20.0‡</td></tr><tr><td> Secondhand tobacco smoke at 0-4 weeks (%)</td><td>22.3</td><td>26.1‡</td><td>33.6‡</td></tr><tr><td> Secondhand tobacco smoke at 8 months (%)</td><td>24.8</td><td>28.2‡</td><td>37.0‡</td></tr><tr><td> High birth weight (>4000 g) (%)</td><td>15.8</td><td>24.0‡</td><td>25.6‡</td></tr><tr><td> Not breastfed (%)</td><td>3.9</td><td>5.0</td><td>6.5‡</td></tr><tr><td><i>Economic and psychosocial factors (%)</i></td><td></td><td></td><td></td></tr><tr><td> Parental low emotional support (%)</td><td>21.1</td><td>22.3</td><td>26.3</td></tr><tr><td> Parental low practical support (%)</td><td>29.8</td><td>29.5</td><td>28.9</td></tr><tr><td> Parental economic stress (%)</td><td>6.1</td><td>8.0‡</td><td>9.6‡</td></tr></table> |
03d5358a77f4856a31cf4081a968c91aa630b5a414cbb6545fc68be81de1268d.png | simple | <table><tr><td>Season</td><td>Similarity (%)</td><td>Nseqs</td><td>Sobs</td></tr><tr><td>amoA D∗</td><td>90</td><td>87</td><td>7</td></tr><tr><td>amoA T∗∗</td><td>90</td><td>82</td><td>3</td></tr></table> |
1e06d71778e6b005c1e9934b89e83f45e288971eb85426ad4eefa5e2ae124b05.png | simple | <table><tr><td>Artery size measurement method</td><td>Tortuosity < 0.1</td><td>All subjects</td></tr><tr><td>A</td><td>1.23 (1.09-1.34)</td><td>1.32 (1.24-1.40)</td></tr><tr><td>B</td><td>1.35 (1.20-1.46)</td><td>1.30 (1.13-1.42)</td></tr></table> |
8d5fdcc156ff00e75a31373e071d9238d98085bf0eec1202b95b912d67f4be37.png | simple | <table><tr><td>Pathway name</td><td># input genes in the pathway</td><td><i>P</i> value</td></tr><tr><td>Long adhesion</td><td>13</td><td>1.02<i>E</i> − 06</td></tr><tr><td>Long-term depression</td><td>6</td><td>3.85<i>E</i> − 04</td></tr><tr><td>ECM-receptor interaction</td><td>6</td><td>6.59<i>E</i> − 04</td></tr><tr><td>Small cell lung cancer</td><td>5</td><td>0.004769</td></tr><tr><td>Regulation of actin cytoskeleton</td><td>8</td><td>0.005003</td></tr><tr><td>Prostate cancer</td><td>5</td><td>0.005006</td></tr><tr><td>Tight junction</td><td>6</td><td>0.007175</td></tr><tr><td>Melanoma</td><td>4</td><td>0.012134</td></tr><tr><td>Bladder cancer</td><td>3</td><td>0.015551</td></tr><tr><td>MAPK signaling pathway</td><td>8</td><td>0.016136</td></tr><tr><td>Axon guidance</td><td>5</td><td>0.022646</td></tr><tr><td>Endometrial cancer</td><td>3</td><td>0.027335</td></tr><tr><td>mTOR signaling pathway</td><td>3</td><td>0.027335</td></tr><tr><td>Gap junction</td><td>4</td><td>0.02851</td></tr><tr><td>Insulin signaling pathway</td><td>5</td><td>0.029243</td></tr><tr><td>Non-small cell lung cancer</td><td>3</td><td>0.030129</td></tr><tr><td>GnRH signaling pathway</td><td>4</td><td>0.031564</td></tr><tr><td>Alzheimer's disease</td><td>2</td><td>0.033214</td></tr><tr><td>Wnt signaling pathway</td><td>5</td><td>0.03603</td></tr><tr><td>p53 signaling pathway</td><td>3</td><td>0.048047</td></tr><tr><td>Glioma</td><td>3</td><td>0.048047</td></tr><tr><td>Cell cycle</td><td>4</td><td>0.048272</td></tr><tr><td>B cell receptor signaling pathway</td><td>3</td><td>0.049885</td></tr><tr><td>Long-term potentiation</td><td>2</td><td>0.049885</td></tr><tr><td>Neurodegenerative diseases</td><td>2</td><td>0.050764</td></tr><tr><td>Wnt signaling pathway</td><td>7</td><td>0.001962</td></tr><tr><td>B cell receptor signaling pathway</td><td>4</td><td>0.00836</td></tr><tr><td>VEGF signaling pathway</td><td>4</td><td>0.011283</td></tr><tr><td>Natural killer cell mediated cytotoxicity</td><td>5</td><td>0.01976</td></tr><tr><td>Hedgehog signaling pathway</td><td>3</td><td>0.026203</td></tr><tr><td>Neuroactive ligand-receptor interaction</td><td>7</td><td>0.036606</td></tr><tr><td>T cell receptor signaling pathway</td><td>4</td><td>0.037492</td></tr><tr><td>Dorsoventral axis formation</td><td>2</td><td>0.039028</td></tr></table> |
afb8ed25ff0d1f54c3ed7b4ec9ea23519f0a42902373849b71b386b5e2ad234a.png | complex | <table><tr><td>Experimental Model/Method</td><td>Exposure</td><td>Mechanism of Resveratrol</td><td>Dosage of Resveratrol</td><td>Duration of Resveratrol Treatment</td><td>Reference</td></tr><tr><td>PC12 cells</td><td>Aβ<sub>25–35</sub> induced</td><td>attenuated Aβ-induced cytotoxicity, apoptotic features, and intracellular ROI accumulation.</td><td>25 μM</td><td>24 h</td><td>[13]</td></tr><tr><td rowspan="3">PC12 cells</td><td rowspan="3">Aβ<sub>25–35</sub> induced</td><td>inhibited the cell apoptosis</td><td rowspan="3">12.5–100 μM</td><td rowspan="3">24–48 h</td><td rowspan="3">[14]</td></tr><tr><td>prevented the LDH leakage</td></tr><tr><td>maintained the intracellular Ca<sup>2+</sup> homeostasis</td></tr><tr><td>Purified baculovirus-expressed BACE-1</td><td>-</td><td>inhibition of BACE-1</td><td>11.9 μM (IC<sub>50</sub>)</td><td>-</td><td>[30]</td></tr><tr><td>TRF assay</td><td>-</td><td>inhibition of BACE-1</td><td>28 μM (IC<sub>50</sub>)</td><td>30 min</td><td>[31]</td></tr><tr><td rowspan="2">Neuro2a cells HEK293</td><td rowspan="2">transfected with a plasmid containing APPsw</td><td>reduced γ-secretase activity</td><td rowspan="2">2.5–20 μM</td><td rowspan="2">24 h</td><td rowspan="2">[32]</td></tr><tr><td>induced MMP-9 activation</td></tr><tr><td rowspan="3">autophagy-related 5 knockdown HEK293</td><td rowspan="3">-</td><td>induced conversion of LC3-I to LC3-II</td><td rowspan="3">60 μM</td><td rowspan="3">24 h</td><td rowspan="3">[33]</td></tr><tr><td>suppression of Presenilin-1 induction</td></tr><tr><td>suppressed Aβ production</td></tr><tr><td>SK-N-SH cells</td><td>-</td><td>induction of NEP and ACE activity</td><td>10 μM</td><td>4 days</td><td>[34]</td></tr><tr><td>Hippocampal samples from AD patients</td><td>AD</td><td>binds to both fibril and monomer Aβ</td><td>1.56–100 μM</td><td>-</td><td>[35]</td></tr></table> |
68c32bb1fd98c817c2f7eddd423128e5d32406e8e059ba1c4341facd9d81bdef.png | simple | <table><tr><td>Variable</td><td>Significance (p)</td><td>Relative risk</td><td>95% CI</td></tr><tr><td>Diabetes mellitus</td><td>0.009</td><td>4.0232</td><td>1.417–11.424</td></tr><tr><td>Duration of dialysis (years)</td><td>0.008</td><td>1.2499</td><td>1.059–1.475</td></tr></table> |
2352b20d449f01ca5d884c1eb3f3a1acc5185f579a139649a0364ddc5ea16d94.png | complex | <table><tr><td></td><td colspan="2">Treatment assignment</td><td colspan="2">Follow-up status</td></tr><tr><td></td><td>Calcium</td><td>Placebo</td><td>Included<sup>a</sup></td><td>Not included</td></tr><tr><td></td><td>(N = 334)</td><td>(N = 336)</td><td>(N = 563)</td><td>(N = 107)</td></tr><tr><td>Variable</td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td></tr><tr><td>Age (years)</td><td>26.9 (5.6)</td><td>25.9 (5.3)<sup>b</sup></td><td>26.5 (5.5)</td><td>26.2 (5.3)</td></tr><tr><td>Education (years)</td><td>10.8 (2.9)</td><td>11.0 (3.2)</td><td>10.9 (3.1)</td><td>10.6 (2.9)</td></tr><tr><td>Number of pregnancies</td><td>2.0 (1.0)</td><td>2.1 (1.1)</td><td>2.1 (1.0)</td><td>2.0 (0.9)</td></tr><tr><td>Number of children</td><td>0.8 (0.8)</td><td>0.8 (0.9)</td><td>0.8 (0.9)</td><td>0.7 (0.7)</td></tr><tr><td>Number of months previous breastfeeding (cumulative lifetime)</td><td>5.6 (8.9)</td><td>6.8 (9.0)</td><td>6.4 (9.2)</td><td>5.1 (7.2)</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>25.9 (4.1)</td><td>25.8 (3.7)</td><td>25.9 (3.9)</td><td>25.9 (3.9)</td></tr><tr><td>Energy intake (kcal/day)</td><td>1888 (592)</td><td>1862 (637)</td><td>1860 (613)</td><td>1951 (619)</td></tr><tr><td>Calcium intake (mg/day)</td><td>1108 (492)</td><td>1083 (532)</td><td>1096 (515)</td><td>1091 (497)</td></tr><tr><td>Hematocrit (%)</td><td>39.1 (3.3)</td><td>39.1 (3.0)</td><td>39.1 (3.2)</td><td>39.1 (2.7)</td></tr><tr><td>NTx (nM BCE/mM creatinine)<sup>c</sup></td><td>62.3 (1.7)</td><td>62.9 (1.7)</td><td>62.9 (1.7)</td><td>52.2 (1.7)</td></tr></table> |
f74448f78f14f02b8a2ad986cc3e6a7bfac69958c4d7502f2afdcd01f2ef6b6a.png | simple | <table><tr><td></td><td>"Successful" States</td><td>"Unsuccessful" States</td></tr><tr><td>Political arrangement</td><td>Varied: democracy (Senegal, multiparty), authoritarian (Uganda)</td><td>Varied: democracy (multiparty, Zambia), others including authoritarian (Namibia, Ethiopia)</td></tr><tr><td>Institutional structures</td><td>Centralised (now decentralising)</td><td>Varied (decentralised and centralised)</td></tr><tr><td>Technology achieved</td><td>STIs, some ARV through centralised institution</td><td>Some behaviour/education, centralised STIs, sparse centralised ARVs</td></tr></table> |
1c7c9b2ea287278fd9ed6bb95398bf9aef3da82fccef9797f74117a2e0f8e6c0.png | simple | <table><tr><td>Method</td><td>Bias</td><td></td><td>MSE</td><td></td></tr><tr><td>LA</td><td>0.42</td><td>(0.14)</td><td>2.06</td><td>(0.21)</td></tr><tr><td>LDLA</td><td>0.31</td><td>(0.14)</td><td>2.15</td><td>(0.23)</td></tr><tr><td>LD decay</td><td>0.31</td><td>(0.14)</td><td>2.02</td><td>(0.21)</td></tr><tr><td>Two-marker</td><td>0.16</td><td>(0.13)</td><td>1.82</td><td>(0.18)</td></tr><tr><td>IBD</td><td>0.23</td><td>(0.13)</td><td>1.69</td><td>(0.20)</td></tr></table> |
55908da66535c91f52a09be154753b7ea3f415d19ae44b6c8d7352b944963841.png | complex | <table><tr><td>Autoimmune disease</td><td>Autoimmune target</td><td>Mean age of onset (range) years</td><td>Female:male ratio</td><td>Reference</td></tr><tr><td colspan="5">Mid-adult onset</td></tr><tr><td>Multiple sclerosis</td><td>Myelin sheath</td><td>37 (25–45)</td><td>1.8:1</td><td>(205)</td></tr><tr><td>Myasthenia gravis</td><td>Neuromuscular junction</td><td>40</td><td>2.7:1</td><td>(205)</td></tr><tr><td>Systemic lupus erythematosus</td><td>Nuclear contents (systemic)</td><td>40 (30–50)</td><td>9:1</td><td>(205, 206)</td></tr><tr><td>Neuromyelitis optica</td><td>Optic nerve/spinal cord</td><td>32.6–45.7</td><td>2.4:1ratio highest after age 65</td><td>(207, 208)</td></tr><tr><td>Graves’ disease</td><td>Thyroid</td><td>48</td><td>7.3:1</td><td>(205)</td></tr><tr><td>Systemic sclerosis</td><td>Connective tissue (systemic)</td><td>50 (35–65)</td><td>11.5:1</td><td>(209)</td></tr><tr><td colspan="5">Late-adult onset</td></tr><tr><td>Granulomatosis with polyangiitis (GPA) (formerly Wegener’s granulomatosis)</td><td>Cytoplasmic contents of neutrophils (systemic, vascular)</td><td>55 (40–70)</td><td>1:1M > F after age 70</td><td>(205)</td></tr><tr><td>Rheumatoid arthritis</td><td>Joints</td><td>58 (42–74)</td><td>3:1</td><td>(210)</td></tr><tr><td>Polymyalgia rheumatica</td><td>Selected muscle groups</td><td>70–80</td><td>2.3:1</td><td>(211)</td></tr><tr><td>Giant cell arteritis</td><td>Vascular system</td><td>70–80</td><td>2.3:1</td><td>(211)</td></tr></table> |
b60e7ee57f4cbb70bf8f59dbfd29c03f9fe08969433eb3e29919dc8bab505da4.png | complex | <table><tr><td>COOH-MWCNTs</td><td>Criterion</td><td><i>E</i> (GPa)</td><td>σ<sub>u</sub> (MPa)</td><td><i>T</i>-3% (MPa.mm/mm)</td></tr><tr><td rowspan="2">0 wt% (neat)</td><td>Mean</td><td>21.70</td><td>320</td><td>6.70</td></tr><tr><td>STD</td><td>0.7</td><td>11.93</td><td>0.25</td></tr><tr><td rowspan="2">0.5 wt%</td><td>Mean (% increase)</td><td>20.40 (−6%)</td><td>348 (8%)</td><td>6.96 (3.9%)</td></tr><tr><td>STD</td><td>0.61</td><td>6.24</td><td>0.52</td></tr><tr><td rowspan="2">1.0 wt%</td><td>Mean (% increase)</td><td>19.33 (−10%)</td><td>340 (6%)</td><td>6.77 (1.04%)</td></tr><tr><td>STD</td><td>0.85</td><td>23.90</td><td>0.45</td></tr><tr><td rowspan="2">1.5 wt%</td><td>Mean (% increase)</td><td>20.40 (−6%)</td><td>344 (7%)</td><td>6.94 (3.48%)</td></tr><tr><td>STD</td><td>0.82</td><td>29.28</td><td>0.36</td></tr></table> |
7a903216b3601da8344f4b13b30ea0fef2af4990efcfd461832c941fd53727f4.png | complex | <table><tr><td></td><td colspan="2">ARC</td><td colspan="4">WHOQOL-BREF</td><td colspan="4">Social Network</td></tr><tr><td>Variable</td><td>Personal</td><td>Social</td><td>Physical</td><td>Psych</td><td>Social</td><td>Enviro</td><td>Group substance use</td><td>Non-using groups identification</td><td>Heavy using groups identification</td><td>Non-using groups importance</td></tr><tr><td>ARC</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Personal</td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Social</td><td>.87<sup>***</sup></td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WHOQOL-BREF</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Physical</td><td>.74<sup>***</sup></td><td>.54<sup>**</sup></td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Psychological</td><td>.62<sup>**</sup></td><td>.52<sup>*</sup></td><td>.61**</td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Social</td><td>.39<sup>†</sup></td><td>.52<sup>*</sup></td><td>.24</td><td>.68<sup>***</sup></td><td>–</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Environmental</td><td>.58<sup>**</sup></td><td>.72<sup>***</sup></td><td>.49<sup>*</sup></td><td>.46<sup>*</sup></td><td>.41<sup>†</sup></td><td>–</td><td></td><td></td><td></td><td></td></tr><tr><td>Social Network</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Groups substance use status</td><td>-.50<sup>*</sup></td><td>-.47<sup>*</sup></td><td>-.39</td><td>-.10</td><td>.02</td><td>-.44<sup>†</sup></td><td>–</td><td></td><td></td><td></td></tr><tr><td> Non-using groups identification</td><td>.37</td><td>.44<sup>†</sup></td><td>.24</td><td>.03</td><td>.05</td><td>.53<sup>*</sup></td><td>-.81<sup>***</sup></td><td>–</td><td></td><td></td></tr><tr><td> Heavy-using groups identification</td><td>-.32</td><td>-.29</td><td>-.25</td><td>-.08</td><td>-.14</td><td>-.38</td><td>.66<sup>**</sup></td><td>-.41</td><td>–</td><td></td></tr><tr><td> Non-using groups importance</td><td>.33</td><td>.38<sup>†</sup></td><td>.26</td><td>-.07</td><td>-.08</td><td>.48<sup>*</sup></td><td>-.88<sup>***</sup></td><td>.94<sup>***</sup></td><td>-.44<sup>†</sup></td><td>–</td></tr><tr><td> Heavy-using groups importance</td><td>-.43<sup>†</sup></td><td>-.39<sup>†</sup></td><td>-.38<sup>†</sup></td><td>-.10</td><td>-.08</td><td>-.47<sup>*</sup></td><td>.67<sup>**</sup></td><td>-.42<sup>†</sup></td><td>.90<sup>***</sup></td><td>-.47<sup>*</sup></td></tr></table> |
14b6384f6dc41ac2f591644f27c9601a8c391cef5433361bd313326e0f69638a.png | simple | <table><tr><td>Study</td><td> </td><td>Number</td><td>Metabolic syndrome</td><td>Htn</td><td>High TG</td><td>Impaired FBS</td><td>Low HDL</td><td>High WC</td></tr><tr><td>Iran</td><td>Gorgan</td><td>100</td><td>31%</td><td>16%</td><td>16%</td><td>17%</td><td>30%</td><td>29%</td></tr><tr><td> </td><td>North East</td><td>160</td><td>20.62%</td><td>3.12%</td><td>20%</td><td>14.30%</td><td>29.37%</td><td>34.37%</td></tr><tr><td> </td><td>Babol</td><td>984</td><td>31%</td><td>12.1%</td><td>41.5%</td><td>12.1%</td><td>48.6%</td><td>76.6%</td></tr><tr><td> </td><td>Tehran</td><td>940</td><td>53.5%</td><td>16.5%</td><td>104.4%</td><td>66.2%</td><td>12.5%</td><td>9.8%</td></tr><tr><td>Brazil</td><td> </td><td>323</td><td>44.4%</td><td>65%</td><td>12.4%</td><td>11.8%</td><td>79.6%</td><td>50.9%</td></tr><tr><td>Argentina</td><td> </td><td>124</td><td>22%</td><td>8%</td><td>8%</td><td>2%</td><td>10%</td><td>13%</td></tr><tr><td>Ecuador</td><td> </td><td>325</td><td>41.5%</td><td>65.9%</td><td>83%</td><td>29.6%</td><td>80%</td><td>83.7%</td></tr><tr><td>Korea</td><td> </td><td>778</td><td>54.6%</td><td>63.6%</td><td>39.3%</td><td>26%</td><td>69.8%</td><td>67.1%</td></tr></table> |
01f15db8eb9fb767f8b78df5e1bcd884999c51bc4dc7af4ed65a3e6379868312.png | simple | <table><tr><td>Genome Effect</td></tr><tr><td>Changes in ploidy (mostly WGD)</td></tr><tr><td>Alteration of epigenetic modifications to the genome</td></tr><tr><td>Alterations in expression patterns across the genome</td></tr><tr><td>Activation and spread of mobile DNA elements</td></tr><tr><td>Genome restructuring involving mobile DNA elements</td></tr><tr><td>Changes in chromosome structure and karyotype</td></tr><tr><td>Alteration of tandem repetitive DNA arrays and centromeres</td></tr></table> |
38557d1b0629b5159d4350b523d412e2ede1fd85708d2862f731d07abdb73593.png | complex | <table><tr><td>Insomnia</td><td>With (<i>N</i> = 159,989)</td><td>Without (<i>N</i> = 319,979)</td><td rowspan="2"><i>P</i>-value</td></tr><tr><td><i>X</i>-year(s) of suicide attempts</td><td colspan="2">Numbers of suicide attempts</td></tr><tr><td>1</td><td>285</td><td>101</td><td>< 0.001</td></tr><tr><td>2</td><td>525</td><td>157</td><td>< 0.001</td></tr><tr><td>3</td><td>700</td><td>195</td><td>< 0.001</td></tr><tr><td>4</td><td>808</td><td>222</td><td>< 0.001</td></tr><tr><td>5</td><td>890</td><td>248</td><td>< 0.001</td></tr><tr><td>6</td><td>965</td><td>265</td><td>< 0.001</td></tr><tr><td>7</td><td>1020</td><td>276</td><td>< 0.001</td></tr><tr><td>8</td><td>1052</td><td>286</td><td>0.001</td></tr><tr><td>9</td><td>1070</td><td>295</td><td>< 0.001</td></tr><tr><td>10</td><td>1084</td><td>296</td><td>< 0.001</td></tr><tr><td>11</td><td>1198</td><td>297</td><td>< 0.001</td></tr><tr><td>12</td><td>1198</td><td>297</td><td>< 0.001</td></tr><tr><td>13</td><td>1198</td><td>297</td><td>< 0.001</td></tr></table> |
c9856ab54ee1c51f132148c1aecf55fc8edf1d8022d53278f9fffd2e421d1d83.png | complex | <table><tr><td>Determinant</td><td>Ready to enroll/re-enroll, <i>n</i> (%)</td><td><i>P</i>-Value</td><td>COR</td><td>AOR</td></tr><tr><td colspan="5">Region CHF enrolment rate</td></tr><tr><td> Low</td><td>186(81.6)</td><td>0.513</td><td>1</td><td></td></tr><tr><td> High</td><td>190(81.9)</td><td></td><td>1.0(0.6-1.6)</td><td></td></tr><tr><td colspan="5">Locality</td></tr><tr><td> Rural</td><td>185(78.7)</td><td>0.056</td><td>1</td><td>1</td></tr><tr><td> Urban</td><td>191(84.9)</td><td></td><td>1.5(0.9-2.5)<sup>a</sup></td><td>1.5(0.9-2.4)</td></tr><tr><td colspan="5">Sex</td></tr><tr><td> Male</td><td>157(78.5)</td><td>0.073</td><td>1</td><td>1</td></tr><tr><td> Female</td><td>219(58.2)</td><td></td><td>1.5(0.9-2.4)<sup>a</sup></td><td>1.4(0.8-2.2)</td></tr><tr><td colspan="5">Age group</td></tr><tr><td>< 35 years</td><td>218(83.5)</td><td>0.155</td><td>1</td><td></td></tr><tr><td> 35+ years</td><td>158(79.4)</td><td></td><td>0.8(0.5-1.2)</td><td></td></tr><tr><td colspan="5">Marital status</td></tr><tr><td> Single</td><td>40(72.7)</td><td>0.056</td><td>1</td><td>1</td></tr><tr><td> Married, divorced, widow etc</td><td>336(83.0)</td><td></td><td>1.8(1.0-3.5)<sup>a</sup></td><td>2.0(1.1-3.8)</td></tr><tr><td colspan="5">Education</td></tr><tr><td> None/primary</td><td>310(82.2)</td><td>0.330</td><td>1</td><td>1</td></tr><tr><td> Secondary/above</td><td>66(79.5)</td><td></td><td>0.84(0.5-1.5)</td><td></td></tr><tr><td colspan="5">Family monthly average income</td></tr><tr><td> Low (< median)</td><td>170(82.5)</td><td>0.507</td><td>1</td><td></td></tr><tr><td> High (≥median)</td><td>193(82.1)</td><td></td><td>1.0(0.6-1.6)</td><td></td></tr><tr><td colspan="5">Family size (number of members)</td></tr><tr><td> Small (<median 6)</td><td>174(78.7)</td><td>0.061</td><td>1</td><td>1</td></tr><tr><td> Larger(≥median 6)</td><td>200(84.7)</td><td></td><td>1.5(0.9-2.4)<sup>a</sup></td><td>1.5(1.0-2.5)</td></tr><tr><td colspan="5">Number of marketing strategies ever exposed</td></tr><tr><td> Never/one strategy</td><td>113(83.1)</td><td>0.366</td><td>1</td><td></td></tr><tr><td> Two & more strategies</td><td>263(81.2)</td><td></td><td>0.9(0.5-1.5)</td><td></td></tr><tr><td colspan="5">Influence of leaders ever heard CHF message community leaders</td></tr><tr><td> No</td><td>175(79.5)</td><td>0.126</td><td>1</td><td></td></tr><tr><td> Yes</td><td>167(84.3)</td><td></td><td>1.4(0.8-2.4)</td><td></td></tr></table> |
7972ff1e505b825ba512f3ed0b96e601bc8621b06c46a59a17c406c5d7845808.png | simple | <table><tr><td>All subjects (<i>N</i>=30)</td><td>6.25-12.5 Hz</td><td>12.5-25 Hz</td><td>25-50 Hz</td></tr><tr><td>Global Efficiency</td><td>-0.13</td><td>-0.25</td><td>0.15</td></tr><tr><td>Local Efficiency</td><td>-0.21</td><td>-0.33</td><td>0.08</td></tr><tr><td>Interdensity</td><td>-0.15</td><td>-0.13</td><td>0.02</td></tr><tr><td>Intradensity Unaffected Hemi</td><td>-0.26</td><td>* -0.46</td><td>-0.07</td></tr><tr><td>Intradensity Affected Hemi</td><td>-0.07</td><td>-0.14</td><td>0.23</td></tr><tr><td>Cortex Subjects (<i>N</i>=17)</td><td></td><td></td><td></td></tr><tr><td>Global Efficiency</td><td>-0.05</td><td>* -0.60</td><td>0.08</td></tr><tr><td>Local Efficiency</td><td>-0.26</td><td>* -0.66</td><td>-0.20</td></tr><tr><td>Interdensity</td><td>0.08</td><td>-0.21</td><td>0.01</td></tr><tr><td>Intradensity Unaffected Hemi</td><td>-0.24</td><td>* -0.75</td><td>-0.40</td></tr><tr><td>Intradensity Affected Hemi</td><td>0.04</td><td>-0.39</td><td>0.49</td></tr></table> |
2e22f0e33379969097d165792570d753a216b06699477a9a3c542c544acf37a1.png | simple | <table><tr><td>Significant consensus genes from continuous and extreme data, excluding children data</td><td>No. of overlap</td><td>No. not overlapping</td><td>% Overlap</td></tr><tr><td>Single-probe analysis</td><td>232</td><td>9085</td><td>2.49</td></tr><tr><td>Region analysis</td><td>39</td><td>364</td><td>9.70</td></tr></table> |
611447fd04c958aeafc15152365dd8f0a00054ce48b00b04db87f8c2b1b5980e.png | complex | <table><tr><td colspan="5">P-values for small group</td></tr><tr><td>Genes in small group</td><td>Known genes</td><td>Known genes in data set</td><td>Genes in data set</td><td>P-value</td></tr><tr><td>6</td><td>2</td><td>7</td><td>129</td><td>0.0342</td></tr><tr><td>50</td><td>6</td><td>7</td><td>129</td><td>0.0136</td></tr></table> |
edd7458a50ce7b1a2bf4462f6a625e80c3af937460c5cbc9fb9ba65c8ddbd99d.png | simple | <table><tr><td>Region</td><td>PS-DHA</td><td>Placebo</td><td><i>p</i> Value</td></tr><tr><td>Left Frontal Cortex</td><td>52.23 ± 1.31</td><td>42.89 ± 0.94</td><td>0.054</td></tr><tr><td>Right Frontal Cortex</td><td>51.67 ± 1.22</td><td>37.69 ± 0.76</td><td>0.011</td></tr><tr><td>Left Hippocampus</td><td>59.50 ± 2.93</td><td>39.74 ± 2.53</td><td>0.016</td></tr><tr><td>Right Hippocampus</td><td>55.91 ± 2.81</td><td>38.37 ± 2.22</td><td>0.008</td></tr><tr><td>Globus Pallidus</td><td>46.44 ± 0.35</td><td>34.13 ± 0.26</td><td>0.001</td></tr><tr><td>Hypothalamus</td><td>66.27 ± 3.26</td><td>52.09 ± 0.43</td><td>0.013</td></tr><tr><td>Thalamus</td><td>47.24 ± 0.58</td><td>36.25 ± 0.07</td><td>0.004</td></tr><tr><td>Corpus Callosum</td><td>49.34 ± 0.79</td><td>31.23 ± 0.27</td><td>0.059</td></tr><tr><td>Left Internal Capsule</td><td>43.77 ± 0.64</td><td>30.60 ± 0.38</td><td>0.052</td></tr><tr><td>Right Internal Capsule</td><td>42.70 ± 0.34</td><td>30.46 ± 0.29</td><td>0.032</td></tr></table> |
c63f6c0c456bc1052327ab4c5c0e46590e3a7b437e4175322387afe627ddf94d.png | simple | <table><tr><td> </td><td>B</td><td>SE B</td><td>OR</td><td>[95% CI]</td><td>p-value</td></tr><tr><td>Child’s BMI, kg/ <i>m</i><sup>2</sup></td><td>.63</td><td>.06</td><td>1.88</td><td>[1.66, 2.13]</td><td>.000</td></tr><tr><td>Migration background(child), <i>yes</i></td><td>.47</td><td>.20</td><td>1.60</td><td>[1.07, 2.37]</td><td>.020</td></tr><tr><td>Self-efficacy to influencechild’s physical activity,<i>high</i></td><td>-.54</td><td>.19</td><td>0.58</td><td>[0.40, 0.85]</td><td>.005</td></tr></table> |
3f83b920fb99d3228b09008decd9ed1d76dbbf6e5d6c8295c345085d9c3ccbb3.png | complex | <table><tr><td></td><td colspan="5">Univariate analysis</td><td colspan="3">Multivariate</td></tr><tr><td></td><td>Gametocytes</td><td>No gametocytes</td><td>OR</td><td>95% CI</td><td>P value</td><td>OR</td><td>95% CI</td><td>P value</td></tr><tr><td>Placental malaria (haemozoin or qPCR)</td><td>14/15 (93.3%)</td><td>89/295 (30.2%)</td><td>32.4</td><td>4.2 - 250.2</td><td><0.01</td><td>--</td><td>--</td><td>--</td></tr><tr><td>Haemozoin</td><td>12/15 (80.0%)</td><td>58/295 (19.7%)</td><td>16.3</td><td>4.5-59.8</td><td><0.01</td><td>10.3</td><td>1.9 – 55.1</td><td><0.01</td></tr><tr><td>qPCR</td><td>9/15 (60.0%)</td><td>62/304 (20.4%)</td><td>5.9</td><td>2.0-17.1</td><td><0.01</td><td>2.8</td><td>0.8 – 9.3</td><td>0.09</td></tr><tr><td>Mean maternal haemoglobin (g/dL) at enrolment (standard deviation)</td><td>10.9 (1.5)</td><td>11.8 (1.6)</td><td>0.7</td><td>0.6 – 1.0</td><td>0.02</td><td>1.1</td><td>0.7 – 1.5</td><td>0.76</td></tr><tr><td>Asexual stage parasitaemia at enrolment</td><td>12/22 (54.5%)</td><td>48/424 (11.3%)</td><td>9.4</td><td>3.9 – 22.9</td><td><0.01</td><td>1.4</td><td>0.4 – 5.8</td><td>0.62</td></tr><tr><td>Malaria treatment prior to enrolment</td><td>6/22 (27.3%)</td><td>56/422 (13.2%)</td><td>2.5</td><td>0.9 – 6.5</td><td>0.09</td><td>2.8</td><td>0.8 – 10.1</td><td>0.11</td></tr><tr><td>Mean maternal age in years (standard deviation)</td><td>20.3 (3.1)</td><td>20.1 (3.2)</td><td>1.0</td><td>0.9 – 1.2</td><td>0.77</td><td>--</td><td>--</td><td>--</td></tr><tr><td>Primigravid</td><td>13/22 (59.1%)</td><td>268/424 (63.2%)</td><td>1.2</td><td>0.5 – 2.8</td><td>0.70</td><td>--</td><td>--</td><td>--</td></tr><tr><td>Mean gestational age in weeks at the time of enrolment (standard deviation)</td><td>20.1 (4.0)</td><td>20.1 (4.4)</td><td>1.0</td><td>0.9 – 1.1</td><td>0.97</td><td>--</td><td>--</td><td>--</td></tr><tr><td>Mother slept under a bed net the previous night</td><td>9/22 (40.9%)</td><td>211/422 (50.0%)</td><td>1.4</td><td>0.6 – 3.5</td><td>0.40</td><td>--</td><td>--</td><td>--</td></tr><tr><td>Maternal axillary temperature (°C) at enrolment (standard deviation)</td><td>36.5 (0.4)</td><td>36.6 (0.4)</td><td>0.8</td><td>0.3 – 2.2</td><td>0.72</td><td>--</td><td>--</td><td>--</td></tr></table> |
aa85619eb39fed838e986366d1c4afd3749dad4a0c226b220916fa9d52b3e5ce.png | simple | <table><tr><td>Comparison and protein</td><td>Entrez gene name</td><td><i>P</i> value</td><td>Fold change</td></tr><tr><td>LMP1 vs pBabe: no inhibitors (<i>P</i> = 1.92E−05)</td><td></td><td></td><td></td></tr><tr><td>DNAJC7</td><td>DnaJ (Hsp40) homologue, subfamily C, member 7</td><td>3.90E−02</td><td>−1.852</td></tr><tr><td>HSPA14</td><td>Heat shock 70-kDa protein 14</td><td>1.98E−02</td><td>−1.667</td></tr><tr><td>HSPB1</td><td>Heat shock 27-kDa protein 1</td><td>1.20E−02</td><td>3.427</td></tr><tr><td>PSMD2</td><td>Proteasome (prosome, macropain) 26S subunit, non-ATPase, 2</td><td>5.38E−03</td><td>1.171</td></tr><tr><td>PSMD8</td><td>Proteasome (prosome, macropain) 26S subunit, non-ATPase, 8</td><td>1.92E−02</td><td>−1.728</td></tr><tr><td>THOP1</td><td>Thimet oligopeptidase 1</td><td>3.73E−02</td><td>−1.982</td></tr><tr><td>UBE2V1</td><td>Ubiquitin-conjugating enzyme E2 variant 1</td><td>1.10E−03</td><td>1.739</td></tr><tr><td>USP5</td><td>Ubiquitin-specific peptidase 5</td><td>2.61E−02</td><td>−1.490</td></tr><tr><td>USP14</td><td>Ubiquitin-specific peptidase 14</td><td>2.57E−02</td><td>−2.353</td></tr><tr><td>LMP2 vs pBabe: no inhibitors (<i>P</i> = 1)</td><td></td><td></td><td></td></tr><tr><td>None</td><td></td><td></td><td></td></tr><tr><td>LMP1 vs pBabe: with inhibitors (<i>P</i> = 2.35E−06)</td><td></td><td></td><td></td></tr><tr><td>BAG1</td><td>BCL2-associated athanogene</td><td>2.96E−03</td><td>2.613</td></tr><tr><td>BIRC3</td><td>Baculoviral IAP repeat-containing 3</td><td>1.58E−02</td><td>−1.760</td></tr><tr><td>CUL1</td><td>Cullin-1</td><td>3.57E−03</td><td>−1.414</td></tr><tr><td>DNAJC5</td><td>DnaJ (Hsp40) homologue, subfamily C, member 5</td><td>2.41E−02</td><td>−2.692</td></tr><tr><td>HLA-B</td><td>Major histocompatibility complex, class I, B</td><td>2.06E−02</td><td>4.993</td></tr><tr><td>HSP90AA1</td><td>Heat shock protein 90-kDa alpha (cytosolic), class A member 1</td><td>3.43E−02</td><td>−1.335</td></tr><tr><td>HSPA6</td><td>Heat shock 70-kDa protein 6 (HSP70B′)</td><td>5.54E−03</td><td>−1.492</td></tr><tr><td>HSPA8</td><td>Heat shock 70-kDa protein 8</td><td>4.62E−02</td><td>−2.934</td></tr><tr><td>HSPA1A</td><td>Heat shock 70-kDa protein 1A</td><td>2.34E−03</td><td>−1.242</td></tr><tr><td>PSMB1</td><td>Proteasome (prosome, macropain) subunit, beta type, 1</td><td>1.08E−03</td><td>2.223</td></tr><tr><td>PSMB8</td><td>Proteasome (prosome, macropain) subunit, beta type, 8</td><td>9.89E−03</td><td>2.207</td></tr><tr><td>PSMB10</td><td>Proteasome (prosome, macropain) subunit, beta type, 10</td><td>1.03E−02</td><td>2.319</td></tr><tr><td>PSMC2</td><td>Proteasome (prosome, macropain) 26S subunit, ATPase, 2</td><td>1.89E−02</td><td>1.127</td></tr><tr><td>PSMD14</td><td>Proteasome (prosome, macropain) 26S subunit, non-ATPase, 14</td><td>4.95E−02</td><td>−1.390</td></tr><tr><td>RBX1</td><td>Ring box 1, E3 ubiquitin protein ligase</td><td>2.30E−02</td><td>−1.494</td></tr><tr><td>TCEB1</td><td>Transcription elongation factor B (SIII), polypeptide 1</td><td>4.49E−02</td><td>−1.414</td></tr><tr><td>TCEB2</td><td>Transcription elongation factor B (SIII), polypeptide 2</td><td>1.33E−03</td><td>−1.690</td></tr><tr><td>UBE2I</td><td>Ubiquitin-conjugating enzyme E2I</td><td>1.19E−02</td><td>−1.485</td></tr><tr><td>UBE2L3</td><td>Ubiquitin-conjugating enzyme E2L 3</td><td>1.42E−02</td><td>4.031</td></tr><tr><td>UBE3B</td><td>Ubiquitin protein ligase E3B</td><td>6.61E−03</td><td>1.659</td></tr><tr><td>UBE4A</td><td>Ubiquitination factor E4A</td><td>1.94E−02</td><td>−2.941</td></tr><tr><td>USP38</td><td>Ubiquitin-specific peptidase 38</td><td>3.60E−02</td><td>−3.717</td></tr><tr><td>LMP2 vs pBabe: with inhibitors (<i>P</i> = 4.26E−05)</td><td></td><td></td><td></td></tr><tr><td>CDC34</td><td>Cell division cycle 34</td><td>3.99E−02</td><td>−2.274</td></tr><tr><td>DNAJA1</td><td>DnaJ (Hsp40) homologue, subfamily A, member 1</td><td>5.00E−02</td><td>−1.763</td></tr><tr><td>HSCB</td><td>HscB mitochondrial iron-sulfur cluster cochaperone</td><td>4.67E−02</td><td>−2.333</td></tr><tr><td>PSMB1</td><td>Proteasome (prosome, macropain) subunit, beta type, 1</td><td>1.73E−02</td><td>1.456</td></tr><tr><td>PSMC2</td><td>Proteasome (prosome, macropain) 26S subunit, ATPase, 2</td><td>2.62E−03</td><td>1.287</td></tr><tr><td>PSMD2</td><td>Proteasome (prosome, macropain) 26S subunit, non-ATPase, 2</td><td>2.70E−02</td><td>−1.227</td></tr><tr><td>TAP2</td><td>Transporter 2, ATP-binding cassette, subfamily B</td><td>3.16E−02</td><td>−2.098</td></tr><tr><td>TCEB2</td><td>Transcription elongation factor B (SIII), polypeptide 2</td><td>1.27E−02</td><td>−1.275</td></tr><tr><td>TRAF6</td><td>TNF receptor-associated factor 6, E3 ubiquitin protein ligase</td><td>5.71E−03</td><td>−1.943</td></tr><tr><td>UBA1</td><td>Ubiquitin-like modifier activating enzyme 1</td><td>2.85E−03</td><td>−1.117</td></tr><tr><td>UBE2C</td><td>Ubiquitin-conjugating enzyme E2C</td><td>1.21E−02</td><td>−5.242</td></tr><tr><td>UBE2L6</td><td>Ubiquitin-conjugating enzyme E2L 6</td><td>2.87E−02</td><td>−2.430</td></tr><tr><td>UBE3B</td><td>Ubiquitin protein ligase E3B</td><td>4.58E−02</td><td>1.134</td></tr><tr><td>UBE4A</td><td>Ubiquitination factor E4A</td><td>9.86E−03</td><td>−7.551</td></tr><tr><td>USP38</td><td>Ubiquitin-specific peptidase 38</td><td>2.81E−02</td><td>−5.336</td></tr><tr><td>USP48</td><td>Ubiquitin-specific peptidase 48</td><td>8.21E−03</td><td>−1.919</td></tr></table> |
3d6e895822b608325ac303c383c4be3898a3aebbb76e3d737ffb19b80b081f6b.png | simple | <table><tr><td>CRHR1 antagonist</td><td>Studies</td><td>Dosage</td><td>Outcome</td><td>Comments</td></tr><tr><td>Antalarmin</td><td>Rissman et al. (2012) [59], Dong et al. (2014) [43], Park et al. (2015) [44],</td><td>20 mg/kg</td><td>Rissman (2012) - Able to block acute stress induced tau phosphorylation but not that induced by chronic stress [59]. Dong (2014) - Able to decrease Aβ levels and plaque load in a chronic stress paradigm [43]. Park (2015) - Unable to block rises in Aβ in response to acute stress [44].</td><td>Dong (2014) measured PBS soluble Aβ, which represents roughly 5% of total Aβ.</td></tr><tr><td>A-helical CRH</td><td>Park et al. (2015) [44]</td><td>5 & 10 μM</td><td>Unable to block CRH induced Aβ increases in vitro.</td><td></td></tr><tr><td>Astressin</td><td>Park et al. (2015) [44]</td><td>5 & 10 μM</td><td>Unable to block CRH induced Aβ increases in vitro.</td><td></td></tr><tr><td>NBI 30775/R121919</td><td>Rissman et al. (2012) [59], Campbell et al. (2015) [51], Dong et al. (2014) [43], Zhang et al. (2016) [64]</td><td>20 mg/kg. Zhang (2016) utilized osmotic mini pump</td><td>Campbell (2015) [51] – able to decrease AT8 and PHF-1 phosphorylation in CRH overexpressing mice but not at S262 and S422. Rissman (2012) [59] – Able to decrease stress induced AT8 and PHF-1 increases in phosphorylation</td><td></td></tr><tr><td>NBI27914</td><td>Park et al. (2015) [44], Lee et al. (2009) [83], Carroll et al. (2011) [54]</td><td>10 mg/kg</td><td>Carroll (2011) [54] - NBI27914 rescued freezing and decreased AT8 phosphorylation and decreased neurodegeneration in PS1 tau transgenic mice.Lee (2009) [83] – NBI27914 reduced stress induced increases in Aβ levels and plaque load.Park (2015) [44] – NBI27914 increased secreted Aβ42/ Aβ40 ratio in vitro</td><td></td></tr></table> |
95e0de98b226da026797a851cac5d02bf96adc267856495440936f1d36fda515.png | simple | <table><tr><td>d— difference between G values</td><td>Selection rate2.5 %</td><td>5.0 %</td><td>10.0 %</td><td>Effect of divergent selection (χ<sup>2</sup> test)</td></tr><tr><td>3 %</td><td>1.8-2.0</td><td>1.6-1.9</td><td>1.6-2.0</td><td>Not significant at any of the tested selection rates</td></tr><tr><td>5 %</td><td>2.7-4.2*</td><td>2.1-3.2</td><td>1.9-2.2</td><td>Significant at 2.5 % selection rate</td></tr><tr><td>7.5 %</td><td>3.5-5.5*</td><td>2.5-3.1</td><td>2.3-2.5</td><td>Significant at 2.5 % selection rate</td></tr><tr><td>10 %</td><td>7.6-10.5*</td><td>4.7-5.7*</td><td>3.5-4.0*</td><td>Significant at each assessed selection rate</td></tr><tr><td>Population size</td><td>1200</td><td>600</td><td>300</td><td>30 extreme RILs from each tail</td></tr></table> |
e5ca10404db7759e0a43807095067e2c4ccb5333147f81e79ec6a811798b838d.png | simple | <table><tr><td>Variable</td><td>Descriptive statistic</td></tr><tr><td>Age</td><td>27.1 ± 5.8 years</td></tr><tr><td>Age group</td><td></td></tr><tr><td>15–24</td><td>37.8%</td></tr><tr><td>25–34</td><td>48.3%</td></tr><tr><td>35–44</td><td>13.5%</td></tr><tr><td>< 15 and > 44</td><td>0.4%</td></tr><tr><td>Marital status</td><td></td></tr><tr><td>Married</td><td>86.9%</td></tr><tr><td>Single</td><td>12.0%</td></tr><tr><td>Widow or separated or divorced</td><td>1.2%</td></tr><tr><td>Years of formal education</td><td>10.3 ± 3.3 years</td></tr><tr><td>None</td><td>0.4%</td></tr><tr><td>Primary (1–8)</td><td>35.9%</td></tr><tr><td>Secondary (9–12)</td><td>42.9%</td></tr><tr><td>Tertiary (> 12)</td><td>20.8%</td></tr><tr><td>Total number of pregnancies</td><td>2.6 ± 1.7 pregnancies</td></tr><tr><td>1–4</td><td>86.1%</td></tr><tr><td>> 4</td><td>13.9%</td></tr><tr><td>Living children</td><td>2.5 ± 1.6 children</td></tr><tr><td>Male</td><td>1.2 ± 1.1</td></tr><tr><td>Female</td><td>1.3 ± 1.2</td></tr></table> |
2fc24236435bbfd06eeb3db9381927642d84488d4b902e197faaa59a4b6d191c.png | complex | <table><tr><td>Gene Name</td><td>Primer Sequence</td><td>Length of Product (bp)</td></tr><tr><td colspan="3">Reverse Transcription Quantitative PCR (RT-qPCR)</td></tr><tr><td rowspan="2"><i>CmCHS1</i></td><td>F: CTGGAACAGCAACGGAAACT</td><td rowspan="2">190</td></tr><tr><td>R: TCCGTTGTTGATGAGCCAGA</td></tr><tr><td rowspan="2"><i>CmCHT1</i></td><td>F: TGCTGGCAACAACAACTACAATC</td><td rowspan="2">231</td></tr><tr><td>R: ATCTCCACGCTCTTAGGGTCTT</td></tr><tr><td rowspan="2"><i>CmCDA1</i></td><td>F: AAGAAATGGCGGGTATGAGGGTG</td><td rowspan="2">142</td></tr><tr><td>R: AGTGGTGGATTAGACAAAGGTGCG</td></tr><tr><td rowspan="2"><i>CmActin</i></td><td>F: GAGCGTGGTTACTCATTCA</td><td rowspan="2">283</td></tr><tr><td>R: TGTCAACATCGCACTTCA</td></tr><tr><td rowspan="2"><i>CmCYPA792</i></td><td>F: TTGATGCGGATGTTGACG</td><td rowspan="2">164</td></tr><tr><td>R: ATGCCCTTTGGAGTTGGA</td></tr><tr><td rowspan="2"><i>CmGST</i></td><td>F: AACTGTATTCGGCTTTATCC</td><td rowspan="2">234</td></tr><tr><td>R: ACACACTTGCTGCCTTTTCC</td></tr><tr><td colspan="3">PCR for cDNA Sequencing</td></tr><tr><td rowspan="6"><i>CmCDA1</i></td><td>F1: GTCTACGGTTGCGTTGCTCC</td><td rowspan="2">911</td></tr><tr><td>R1: GAGCAACGCAACCGTAGACGACTGG</td></tr><tr><td>F2: CATCATCGTTGTGCGTGACAGAGTG</td><td rowspan="2">970</td></tr><tr><td>R2: ACGACAGCACAATCACCGCACCTT</td></tr><tr><td>F3: GCCGTCCTCGGAGCAGAAACAGTCA</td><td rowspan="2">830</td></tr><tr><td>R3: CCAACAACGA CGAATATCTTCCAGG</td></tr><tr><td rowspan="4"><i>CmCHT1</i></td><td>F1: TGTCCTCGATGCCGTACCTGCCCAC</td><td rowspan="2">1300</td></tr><tr><td>R1: AAGGGGTGCTGACCGCTGCTGTGCCGCT</td></tr><tr><td>F2: CACGCCGGGGCGGTACACCGCC</td><td rowspan="2">300</td></tr><tr><td>R2: TGGGAAGACAAGGGCTGTCCAACCAACA</td></tr><tr><td rowspan="6"><i>CmCHSA</i></td><td>F1: ACTATGTGGCACGAAACGAA</td><td rowspan="2">354</td></tr><tr><td>R1: TAGTACATGTACAT</td></tr><tr><td>F2: CATTTGAAAGATAAGGC</td><td rowspan="2">580</td></tr><tr><td>R2: ACCAACATRAGRAADAT</td></tr><tr><td>F3: CGCCTTACATCGCTTACC</td><td rowspan="2">1258</td></tr><tr><td>R3: ACBARACCRATNGGYTCC</td></tr></table> |
8e0eb7c8536c50f35d8c22b3b58e15770bcdbb3176439ae6f57c00fee24113be.png | simple | <table><tr><td>Oligonucleotide designation</td><td>Oligonucleotide (5′→3′)</td><td>Genome position</td></tr><tr><td>p1167</td><td>ACCCTACTGACTGACGAACAGATTGCTTC</td><td>6816−6847</td></tr><tr><td>p1168</td><td>TGTTGTTGAGCGTAATGAGTCCGTCCT</td><td>6230–6256</td></tr><tr><td>p1303</td><td>GTCTTGTCAAACGTTTATAATCTATGGCAAATACGTGA</td><td>6549–6586</td></tr><tr><td>p1305</td><td>TCAGCTCCACAAACATGTCATGAAAATTCGCATAGG</td><td>6503–6538</td></tr><tr><td>p1321</td><td>GTTATAAACAGTTTCCATGGTGCATCACACTTATC</td><td>3466–3500</td></tr><tr><td>p1322</td><td>ACGGGACTTGACAAATATTCCATAATTAACTGCCT</td><td>4502–4536</td></tr><tr><td>p1338</td><td>ATTGCTCACCCTTGTTGGGAACGTTACCCTT</td><td>1303–1333</td></tr><tr><td>p1343</td><td>AACTTAAACCTTTCGACACTTGGGAAGAAGTA</td><td>7001–7032</td></tr><tr><td>p1362</td><td>AACGGCACAATAGTCATCGTCCCG</td><td>6469–6492</td></tr><tr><td>p1363T</td><td>TGGCCGTCATGGTGGCGAATAATGTCAACCTAATCT-ACGGTAAGATGAGTCT</td><td>6051–6080</td></tr><tr><td>p1438</td><td>AGATGCAAAGGAACTGACAATGACGAACTT</td><td>1011–1040</td></tr><tr><td>p1439</td><td>TTCATTTGAGCAAGATATAATGAGCGTCTATAGTGGGT</td><td>1150–1187</td></tr></table> |
a495d4169426b1b2877b7a5df27d937331138b6315889bb2b47b32f6da60929f.png | complex | <table><tr><td>Condition</td><td>Brain region</td><td colspan="3">MNI coordinate</td><td>BA</td><td><i>T</i>-value</td></tr><tr><td></td><td></td><td><i>x</i></td><td><i>y</i></td><td><i>z</i></td><td></td><td></td></tr><tr><td>Resting-state</td><td>PCC</td><td>−6</td><td>−60</td><td>28</td><td>31</td><td>18.17</td></tr><tr><td></td><td>Left IPC (lIPC)</td><td>−42</td><td>−66</td><td>44</td><td>40</td><td>15.45</td></tr><tr><td></td><td>MPFC</td><td>1</td><td>50</td><td>24</td><td>9, 10</td><td>10.97</td></tr><tr><td></td><td>Right IPC (rIPC)</td><td>48</td><td>−57</td><td>36</td><td>39, 40</td><td>9.25</td></tr><tr><td></td><td>Right ITC (rITC)</td><td>63</td><td>−27</td><td>−20</td><td>20</td><td>7.43</td></tr><tr><td></td><td>Left ITC (lITC)</td><td>−59</td><td>−21</td><td>−20</td><td>20, 21</td><td>6.43</td></tr><tr><td></td><td>Left HC (lHC)</td><td>−24</td><td>−12</td><td>−28</td><td>35</td><td>5.82</td></tr><tr><td></td><td>Right HC (rHC)</td><td>24</td><td>−30</td><td>−16</td><td>36</td><td>6.77</td></tr><tr><td>Task-state</td><td>PCC</td><td>−1</td><td>−63</td><td>24</td><td>7, 31</td><td>15.81</td></tr><tr><td></td><td>Left IPC (lIPC)</td><td>−45</td><td>−69</td><td>39</td><td>39, 40</td><td>9.38</td></tr><tr><td></td><td>MPFC</td><td>−6</td><td>54</td><td>28</td><td>9</td><td>15.18</td></tr><tr><td></td><td>Right IPC (rIPC)</td><td>52</td><td>−66</td><td>28</td><td>39</td><td>5.12</td></tr><tr><td></td><td>Right ITC (rITC)</td><td>54</td><td>6</td><td>−36</td><td>21</td><td>9.43</td></tr><tr><td></td><td>Left ITC (lITC)</td><td>−51</td><td>−9</td><td>−28</td><td>20, 21</td><td>10.39</td></tr><tr><td></td><td>Left HC (lHC)<sup>*</sup></td><td>−24</td><td>−12</td><td>−28</td><td>35</td><td>5.82</td></tr><tr><td></td><td>Right HC (rHC)<sup>*</sup></td><td>24</td><td>−30</td><td>−16</td><td>36</td><td>6.77</td></tr></table> |
82cc1ed00f12de5b1375c8e1a8fda6e1e53001be4c269ab1235439b464bdf364.png | complex | <table><tr><td rowspan="2">SSR Pattern</td><td rowspan="2">SSR Numbers in Non-redundant White Clover ESTs</td><td rowspan="2">Frequency (%)</td><td colspan="4">Designed EST-SSR Primers</td></tr><tr><td>Mismatch 0</td><td>Mismatch 1</td><td>Mismatch 2</td><td>Total</td></tr><tr><td>AG</td><td>211</td><td>16.67</td><td>30</td><td>19</td><td>44</td><td>93</td></tr><tr><td>AT</td><td>22</td><td>1.74</td><td>7</td><td>3</td><td>15</td><td>25</td></tr><tr><td>AC</td><td>8</td><td>0.63</td><td>4</td><td>6</td><td>11</td><td>21</td></tr><tr><td>GC</td><td>0</td><td>0.00</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>AAC</td><td>182</td><td>14.38</td><td>49</td><td>64</td><td>139</td><td>252</td></tr><tr><td>AAG</td><td>179</td><td>14.14</td><td>35</td><td>90</td><td>246</td><td>371</td></tr><tr><td>GGT</td><td>170</td><td>13.43</td><td>27</td><td>63</td><td>157</td><td>247</td></tr><tr><td>ATC</td><td>113</td><td>8.93</td><td>30</td><td>49</td><td>151</td><td>230</td></tr><tr><td>AAT</td><td>86</td><td>6.79</td><td>17</td><td>21</td><td>66</td><td>104</td></tr><tr><td>AGC</td><td>79</td><td>6.24</td><td>8</td><td>33</td><td>90</td><td>131</td></tr><tr><td>GGA</td><td>36</td><td>2.84</td><td>10</td><td>34</td><td>89</td><td>133</td></tr><tr><td>GGC</td><td>19</td><td>1.50</td><td>2</td><td>8</td><td>47</td><td>57</td></tr><tr><td>ACT</td><td>16</td><td>1.26</td><td>5</td><td>12</td><td>21</td><td>38</td></tr><tr><td>ACG</td><td>4</td><td>0.32</td><td>0</td><td>5</td><td>21</td><td>26</td></tr><tr><td>AATG</td><td>26</td><td>2.05</td><td>3</td><td>12</td><td>19</td><td>34</td></tr><tr><td>AAAT</td><td>23</td><td>1.82</td><td>4</td><td>13</td><td>30</td><td>47</td></tr><tr><td>AAAG</td><td>20</td><td>1.58</td><td>3</td><td>5</td><td>44</td><td>52</td></tr><tr><td>AGTG</td><td>8</td><td>0.63</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>ATAG</td><td>8</td><td>0.63</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>AATT</td><td>8</td><td>0.63</td><td>3</td><td>2</td><td>17</td><td>22</td></tr><tr><td>ATAC</td><td>5</td><td>0.39</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>AACC</td><td>4</td><td>0.32</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>AAAC</td><td>4</td><td>0.32</td><td>0</td><td>9</td><td>34</td><td>43</td></tr><tr><td>AACT</td><td>3</td><td>0.24</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Other tetra-nucleotide repeats</td><td>32</td><td>2.53</td><td>4</td><td>8</td><td>35</td><td>47</td></tr><tr><td>Total</td><td>1266</td><td>100</td><td>241</td><td>456</td><td>1276</td><td>1973</td></tr></table> |
09187983631a73f69d4db2bec52f2208bbd91df03e0be75149b33626a5d9e811.png | complex | <table><tr><td></td><td>Informant</td><td>Area of expertise</td><td>Recruitment</td><td>Interview setting</td><td>Informant characteristics</td></tr><tr><td rowspan="4">STEP 1 EXPERTS (<i>N</i> = 4) (key informant interviews)</td><td>Professor Peter Krustrup (PK)</td><td>Extensive knowledge and experience in human physiology and soccer research</td><td>Personal contact at a meeting</td><td>The informant’s office</td><td>Professor of Team Sport and Health; main research areas include muscle physiology, prevention and treatment of lifestyle diseases through physical activity, and training and testing in elite sport.</td></tr><tr><td>Professor Klaus Brasso (KB)</td><td>Extensive experience with clinical research and medical treatment of prostate cancer patients</td><td>Personal email</td><td>Meeting room, Department of Urology, Copenhagen University Hospital, Rigshospitalet</td><td>Professor, senior consultant/resident, M.D., Ph.D.; previously involved in research on the efficacy of recreational soccer in men with prostate cancer undergoing androgen deprivation therapy and a member of the FCPC Steering Committee</td></tr><tr><td>Dr. Svend Aage Madsen (SM)</td><td>Extensive knowledge and clinical experience in male psychology and gender-sensitive health promotion</td><td>Personal email</td><td>Telephone interview</td><td>Licensed specialist in psychotherapy, Ph.D.; co-founder and board member of the Danish Network on Research in Men and Masculinities and co-founder and president of the Danish Men’s Health Society</td></tr><tr><td>Professor Michael Borre (MB)</td><td>Extensive experience with clinical research and medical treatment of prostate cancer patients</td><td>Personal email</td><td>Office, Health Research Department, Copenhagen University Hospital, Rigshospitalet</td><td>Professor, senior consultant/resident, D.M.Sc., M.D., Ph.D.; chair of the executive board of the Danish Multidisciplinary Cancer Group (DMCG) and the Danish Prostate Cancer Group (DaProCa)</td></tr></table> |
2a8adb2d014b068dd17e0f247e1ebbf66bf16448955506a6c0973e4e0ca0b02d.png | complex | <table><tr><td></td><td>Est</td><td>SE</td><td>β</td><td>p</td><td>Lower CI</td><td>Upper CI</td><td>FMI</td><td>Δ R<sup>2</sup></td></tr><tr><td colspan="8">MVPA: (F(9,171) = 1.97, R<sup>2=</sup>.09)</td><td></td></tr><tr><td>(Intercept)</td><td>19.22</td><td>18.56</td><td>0.00</td><td>0.30</td><td>−17.16</td><td>55.60</td><td>0.06</td><td rowspan="3">Covariates = .07</td></tr><tr><td>Female</td><td>−9.04</td><td>3.22</td><td>−0.21</td><td><0.01</td><td>−15.34</td><td>−2.74</td><td>0.03</td></tr><tr><td>Age</td><td>−0.76</td><td>0.80</td><td>−0.08</td><td>0.34</td><td>−2.33</td><td>0.80</td><td>0.06</td></tr><tr><td>Self-efficacy</td><td>1.44</td><td>3.25</td><td>0.04</td><td>0.66</td><td>−4.93</td><td>7.80</td><td>0.05</td><td>Individual = .004</td></tr><tr><td>Parent support</td><td>0.82</td><td>1.85</td><td>0.04</td><td>0.66</td><td>−2.81</td><td>4.46</td><td>0.06</td><td rowspan="4">Social = .012</td></tr><tr><td>Nurturance</td><td>0.44</td><td>1.85</td><td>0.02</td><td>0.81</td><td>−3.19</td><td>4.07</td><td>0.08</td></tr><tr><td>Limit-setting</td><td>0.99</td><td>2.00</td><td>0.05</td><td>0.62</td><td>−2.93</td><td>4.91</td><td>0.06</td></tr><tr><td>Monitoring</td><td>0.90</td><td>2.33</td><td>0.04</td><td>0.70</td><td>−3.67</td><td>5.47</td><td>0.10</td></tr><tr><td>Home resources</td><td>0.13</td><td>0.67</td><td>0.01</td><td>0.85</td><td>−1.19</td><td>1.45</td><td>0.05</td><td rowspan="2">Environmental = .008</td></tr><tr><td>Neighborhood support</td><td>3.47</td><td>3.16</td><td>0.09</td><td>0.27</td><td>−2.71</td><td>9.66</td><td>0.04</td></tr><tr><td colspan="8">Light PA: (F(9,171) = 5.23, R<sup>2=</sup>.22)</td><td></td></tr><tr><td>(Intercept)</td><td>350.23</td><td>58.42</td><td>0.00</td><td><0.01</td><td>235.71</td><td>464.75</td><td>0.04</td><td rowspan="3">Covariates = .143</td></tr><tr><td>Female</td><td>−17.39</td><td>10.48</td><td>−0.12</td><td>0.10</td><td>−37.95</td><td>3.16</td><td>0.07</td></tr><tr><td>Age</td><td>−11.33</td><td>2.51</td><td>−0.33</td><td><0.01</td><td>−16.25</td><td>−6.40</td><td>0.03</td></tr><tr><td>Self-efficacy</td><td>−9.47</td><td>10.31</td><td>−0.07</td><td>0.36</td><td>−29.69</td><td>10.74</td><td>0.04</td><td>Individual = .001</td></tr><tr><td>Parent support</td><td>15.67</td><td>5.88</td><td>0.21</td><td>0.01</td><td>4.14</td><td>27.21</td><td>0.05</td><td rowspan="4">Social = .045</td></tr><tr><td>Nurturance</td><td>−8.66</td><td>5.85</td><td>−0.11</td><td>0.14</td><td>−20.13</td><td>2.81</td><td>0.06</td></tr><tr><td>Limit-setting</td><td>2.30</td><td>6.36</td><td>0.03</td><td>0.72</td><td>−10.17</td><td>14.77</td><td>0.06</td></tr><tr><td>Monitoring</td><td>7.24</td><td>7.36</td><td>0.09</td><td>0.33</td><td>−7.19</td><td>21.66</td><td>0.08</td></tr><tr><td>Home resources</td><td>−3.47</td><td>2.14</td><td>−0.12</td><td>0.10</td><td>−7.66</td><td>0.71</td><td>0.04</td><td rowspan="2">Environmental = .027</td></tr><tr><td>Neighborhood support</td><td>19.97</td><td>10.15</td><td>0.14</td><td>0.049</td><td>0.08</td><td>39.87</td><td>0.06</td></tr></table> |
c50a7c999a75218f6a216d11413e07f88719a911932a1f0800d36e0f4ca39671.png | simple | <table><tr><td></td><td>Foot pain in last month n (%)</td><td>No foot pain in last month n (%)</td><td>Unadjusted OR (95 % CI)</td><td>Adjusted<sup>a</sup> OR (95 % CI)</td></tr><tr><td>N</td><td>248</td><td>875</td><td>-</td><td>-</td></tr><tr><td>Age, mean (SD)</td><td>66.6 (11.7)</td><td>65.0 (12.7)</td><td>1.11<sup>b</sup> (0.99, 1.24)</td><td>1.14<sup>b</sup> (0.94, 1.38)</td></tr><tr><td>Gender:</td><td></td><td></td><td></td><td></td></tr><tr><td> Male</td><td>190 (76.6)</td><td>752 (85.9)</td><td>1.0</td><td>1.0</td></tr><tr><td> Female</td><td>58 (23.4)</td><td>123 (14.1)</td><td>1.87 (1.31, 2.65)</td><td>1.33 (0.77, 2.30)</td></tr><tr><td>Neighbourhood deprivation tertiles:</td><td></td><td></td><td></td><td></td></tr><tr><td> Most deprived</td><td>93 (37.5)</td><td>258 (29.5)</td><td>1.0</td><td>1.0</td></tr><tr><td> Mid-deprived</td><td>78 (31.5)</td><td>304 (34.7)</td><td>0.71 (0.50, 1.00)</td><td>0.81 (0.50, 1.31)</td></tr><tr><td> Least deprived</td><td>77 (31.1)</td><td>313 (35.8)</td><td>0.68 (0.48, 0.96)</td><td>1.14 (0.71, 1.82)</td></tr><tr><td>BMI (kg/m<sup>2</sup>):</td><td></td><td></td><td></td><td></td></tr><tr><td> <25.0</td><td>34 (15.2)</td><td>177 (21.1)</td><td>1.0</td><td>1.0</td></tr><tr><td> 25.0–29.9</td><td>90 (40.2)</td><td>397 (47.2)</td><td>1.18 (0.77, 1.82)</td><td>1.64 (0.89, 2.99)</td></tr><tr><td> 30.0–34.9</td><td>62 (27.7)</td><td>182 (21.6)</td><td>1.77 (1.11, 2.83)</td><td>2.23 (1.16, 4.27)</td></tr><tr><td> ≥35.0</td><td>38 (17.0)</td><td>85 (10.1)</td><td>2.33 (1.37, 3.95)</td><td>2.61 (1.25, 5.45)</td></tr><tr><td>Anxiety:</td><td></td><td></td><td></td><td></td></tr><tr><td> None</td><td>133 (60.7)</td><td>677 (81.8)</td><td>1.0</td><td>1.0</td></tr><tr><td> Mild</td><td>41 (18.7)</td><td>96 (11.6)</td><td>2.17 (1.44, 3.28)</td><td>1.05 (0.57, 1.95)</td></tr><tr><td> Moderate</td><td>25 (11.4)</td><td>34 (4.1)</td><td>3.74 (2.16, 6.48)</td><td>1.38 (0.56, 3.39)</td></tr><tr><td> Severe</td><td>20 (9.1)</td><td>21 (2.5)</td><td>4.85 (2.56, 9.19)</td><td>1.21 (0.41, 3.51)</td></tr><tr><td>Depression:</td><td></td><td></td><td></td><td></td></tr><tr><td> None</td><td>93 (47.0)</td><td>644 (80.2)</td><td>1.0</td><td>1.0</td></tr><tr><td> Mild</td><td>52 (26.3)</td><td>90 (11.2)</td><td>4.00 (2.67, 6.00)</td><td>3.02 (1.78, 5.11)</td></tr><tr><td> Moderate</td><td>20 (10.1)</td><td>43 (5.4)</td><td>3.22 (1.82, 5.71)</td><td>1.42 (0.58, 3.46)</td></tr><tr><td> Moderately severe</td><td>20 (10.1)</td><td>18 (2.2)</td><td>7.69 (3.93, 15.08)</td><td>3.41 (1.22, 9.57)</td></tr><tr><td> Severe</td><td>13 (6.6)</td><td>8 (1.0)</td><td>11.25 (4.54, 27.88)</td><td>4.55 (1.20, 17.18)</td></tr><tr><td>Comorbidity:</td><td></td><td></td><td></td><td></td></tr><tr><td> Diabetes mellitus</td><td>59 (23.8)</td><td>134 (15.3)</td><td>1.73 (1.22, 2.44)</td><td>1.00 (0.60, 1.66)</td></tr><tr><td> Hypertension</td><td>166 (66.9)</td><td>529 (60.5)</td><td>1.32 (0.98, 1.78)</td><td>0.98 (0.62, 1.57)</td></tr><tr><td> Hyperlipidaemia</td><td>117 (47.2)</td><td>374 (42.7)</td><td>1.20 (0.90, 1.59)</td><td>1.12 (0.74, 1.71)</td></tr><tr><td> Ischaemic heart disease</td><td>56 (22.6)</td><td>140 (16.0)</td><td>1.53 (1.08, 2.17)</td><td>1.43 (0.87, 2.35)</td></tr><tr><td> Cerebrovascular disease</td><td>18 (7.3)</td><td>62 (7.1)</td><td>1.03 (0.60, 1.77)</td><td>0.83 (0.40, 1.69)</td></tr><tr><td>Gout characteristics:</td><td></td><td></td><td></td><td></td></tr><tr><td> Duration, mean (SD)</td><td>12.7 (13.4)</td><td>11.8 (11.8)</td><td>1.06<sup>c</sup> (0.94, 1.20)</td><td>1.05<sup>c</sup> (0.88, 1.25)</td></tr><tr><td> Current attack</td><td>62 (26.1)</td><td>65 (7.7)</td><td>4.21 (2.87, 6.19)</td><td>2.38 (1.35, 4.20)</td></tr><tr><td> Number of attacks in last 12 months:</td><td></td><td></td><td></td><td></td></tr><tr><td>0</td><td>63 (27.2)</td><td>313 (37.5)</td><td>1.0</td><td>1.0</td></tr><tr><td>1–2</td><td>77 (33.2)</td><td>323 (38.7)</td><td>1.18 (0.82, 1.71)</td><td>0.96 (0.58, 1.59)</td></tr><tr><td>≥3</td><td>92 (39.7)</td><td>199 (23.8)</td><td>2.30 (1.59, 3.31)</td><td>1.17 (0.66, 2.05)</td></tr><tr><td> Oligo/polyarticular attacks</td><td>132 (56.4)</td><td>289 (34.4)</td><td>2.47 (1.84, 3.32)</td><td>1.67 (1.11, 2.51)</td></tr><tr><td> Current allopurinol use</td><td>144 (62.1)</td><td>463 (55.6)</td><td>1.31 (0.97, 1.76)</td><td>1.11 (0.72, 1.72)</td></tr></table> |
6cfa12730dfab40348178bef705b36ebf56582472cc5b1bb4b4b3542e4dbacb2.png | complex | <table><tr><td><i>2008 Criteria for PMF</i></td><td><i>2016 Criteria for pre-PMF</i></td><td><i>2016 Criteria for overt PMF</i></td></tr><tr><td colspan="3"><i>Major criteria</i></td></tr><tr><td> MK proliferiferation and atypia with fibrosis (reticulin and/or collagen) or increased marrow cellularity, granulocytic proliferation and decreased erythropoesis in the absence of fibrosis</td><td>MK proliferation and atypia without reticulin fibrosis with increased marrow cellularity, granulocytic proliferation and often decreased erythropoesis</td><td>MK proliferiferation and atypia with fibrosis (reticulin and/or collagen)</td></tr><tr><td> Does not meet WHO criteria for other myeloid neoplasms</td><td>Does not meet WHO criteria for other myeloid neoplasms</td><td>Does not meet WHO criteria for other myeloid neoplasms</td></tr><tr><td> Presence of <i>JAK2V617F</i> or other clonal marker or no evidence of reactive fibrosis.</td><td>Presence of JAK2, CALR or MPL mutation or other clonal marker with no evidence of reactive fibrosis</td><td>Presence of JAK2, CALR or MPL mutation or other clonal marker with no evidence of reactive fibrosis</td></tr><tr><td colspan="3"><i>Minor criteria</i></td></tr><tr><td> Leukoerythroblastosis</td><td>Leukocytosis (⩾11 × 10<sup>9</sup>/L)</td><td>Leukoerythroblastosis</td></tr><tr><td> Increased serum lactate dehydrogenase</td><td>Increased serum lactate dehydrogenase</td><td>Increased serum lactate dehydrogenase</td></tr><tr><td> Anemia</td><td>Anemia (not due to comorbidities)</td><td>Anemia (not due to comorbidities)</td></tr><tr><td> Palpable splenomegaly</td><td>Palpable splenomegaly</td><td>Palpable splenomegaly</td></tr><tr><td> </td><td> </td><td>Leukocytosis (⩾11 × 10<sup>9</sup>/L)</td></tr></table> |
b7cd63b4356aa4440bf75482076cad1a367d53fb868c2b341107532f8a4c4290.png | simple | <table><tr><td>Test Method</td><td>ASTM Standard</td><td>Dimension (<i>L</i> × <i>W</i> × <i>T</i>, mm<sup>3</sup>)</td><td>Calibrating Length (mm)</td></tr><tr><td>90°/0° tensile</td><td>D3039/D3039M-08</td><td>220 × 20 × 2.5</td><td>140</td></tr><tr><td>±45° tensile</td><td>D3518/D3518M-13</td><td>180 × 20 × 2.5</td><td>100</td></tr><tr><td>±45°/90°/0° compression</td><td>D3410/D3410M-95</td><td>160 × 20 × 2.5</td><td>80</td></tr><tr><td>DCB</td><td>D5528-13</td><td>220 × 25 × 2.5</td><td>25 (precrack)</td></tr><tr><td>3ENF</td><td>D7905/D7905M-14</td><td>100 × 25 × 2.5</td><td>80</td></tr><tr><td>Mode III</td><td>E1922-04</td><td>100 × 25 × 2.5</td><td>25 (precrack)</td></tr></table> |
823739d04c344f61d5c75e745f3747f059a22961a185b3c9340876d04ef8dc3a.png | complex | <table><tr><td>Question</td><td>Responses</td><td>Frequency</td><td>%</td><td>Total/350</td><td>Recoding/Routing</td></tr><tr><td rowspan="8">A1. In which of the following is the property situated?</td><td>Centre of a large city</td><td>0</td><td>0.0</td><td rowspan="8">336</td><td rowspan="8"></td></tr><tr><td>Suburbs/Outskirts of a large city</td><td>257</td><td>73.4</td></tr><tr><td>Large town or small city</td><td>76</td><td>21.7</td></tr><tr><td>Small town</td><td>3</td><td>0.9</td></tr><tr><td>Village</td><td>0</td><td>0.0</td></tr><tr><td>Countryside</td><td>0</td><td>0.0</td></tr><tr><td>Other</td><td>0</td><td>0.0</td></tr><tr><td>Missing</td><td>14</td><td>4.0</td></tr><tr><td rowspan="6">B4. Looking at this card [show card 1], overall, how satisfied or dissatisfied are you personally with living in this neighbourhood? Would you say that you are very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied or very dissatisfied?</td><td>Very satisfied</td><td>112</td><td>32.0</td><td rowspan="6">350</td><td rowspan="6"></td></tr><tr><td>Satisfied</td><td>160</td><td>45.7</td></tr><tr><td>Neither satisfied nor dissatisfied</td><td>25</td><td>7.1</td></tr><tr><td>Dissatisfied</td><td>27</td><td>7.7</td></tr><tr><td>Very dissatisfied</td><td>26</td><td>7.4</td></tr><tr><td>Missing</td><td>0</td><td>0.0</td></tr><tr><td rowspan="6">C2. Looking at this card [show card 1], overall, how satisfied or dissatisfied are you personally with living in this home? Would you say that you are very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied or very dissatisfied?</td><td>Very satisfied</td><td>138</td><td>39.4</td><td rowspan="6">350</td><td rowspan="6"></td></tr><tr><td>Satisfied</td><td>163</td><td>46.6</td></tr><tr><td>Neither satisfied nor dissatisfied</td><td>21</td><td>6.0</td></tr><tr><td>Dissatisfied</td><td>16</td><td>4.6</td></tr><tr><td>Very dissatisfied</td><td>12</td><td>3.4</td></tr><tr><td>Missing</td><td>0</td><td>0.0</td></tr><tr><td rowspan="6">C9. Looking at this list [show card 3], which best describes your current situation with this home? Do you or your family:</td><td>Own outright or with a mortgage</td><td>228</td><td>65.1</td><td rowspan="6">348</td><td rowspan="6">Responses to this questions were recoded as to whether they had some stake in the property or not, i.e., A: (Own/Mortgage/Part mortgage), B: (Private Rent/Association Rent).</td></tr><tr><td>Part-rent and part-own with a mortgage</td><td>9</td><td>2.6</td></tr><tr><td>Rent from a private landlord/letting agency</td><td>53</td><td>15.1</td></tr><tr><td>Rent from a Housing Association or Council</td><td>53</td><td>15.1</td></tr><tr><td>Other</td><td>5</td><td>1.4</td></tr><tr><td>Missing</td><td>2</td><td>0.6</td></tr><tr><td rowspan="3">C12. From any room in this home, can you see:Construction Activity</td><td>No</td><td>202</td><td>57.7</td><td rowspan="3">345</td><td rowspan="3"></td></tr><tr><td>Yes</td><td>143</td><td>40.9</td></tr><tr><td>Missing</td><td>5</td><td>1.4</td></tr></table> |
b690a6cf2ad9fa19487e4c330a6b4b7923345a1993fb0ec91de40970951409c4.png | complex | <table><tr><td>Variables</td><td>Total</td><td colspan="3">Progastrin staining in HP epithelial cells</td><td> </td></tr><tr><td> </td><td>N = 48</td><td>No/Low expression</td><td>Moderate expression</td><td>High expression</td><td>p-value</td></tr><tr><td> </td><td> </td><td>N = 21</td><td>N = 12</td><td>N = 15</td><td> </td></tr><tr><td>Percentage of p-ERK1/2 stained cells, N mean (SD)</td><td>N = 43 33% (30)</td><td>N = 18 27% (29)</td><td>N = 12 23% (22)</td><td>N = 13 53% (29)</td><td>0.015<sub>a</sub></td></tr><tr><td>Expression of p-ERK1/2</td><td> </td><td> </td><td> </td><td> </td><td>0.008<sub>b</sub></td></tr><tr><td>No/low expression</td><td>35% [21%-51%]</td><td>50% [26%-74%]</td><td>42% [15%-72%]</td><td>8% [0%-36%]</td><td> </td></tr><tr><td>Moderate expression</td><td>37% [23%-53%]</td><td>33% [13%-59%]</td><td>42% [15%-72%]</td><td>38% [14%-68%]</td><td> </td></tr><tr><td>High expression</td><td>28% [15%-44%]</td><td>17% [4%-41%]</td><td>16% [2%-48%]</td><td>54% [25%-81%]</td><td> </td></tr><tr><td>Percentage of pY-STAT3 stained cells, N mean (SD)</td><td>N = 35 10% (23)</td><td>N = 15 11% (29)</td><td>N = 7 3% (7)</td><td>N = 13 12% (23)</td><td>0.297</td></tr><tr><td>Expression of pY-STAT3</td><td> </td><td> </td><td> </td><td> </td><td>0.3116</td></tr><tr><td>No/low expression</td><td>77% [60%-90%]</td><td>80% [52%-96%]</td><td>86% [42%-100%]</td><td>69% [39%-91%]</td><td> </td></tr><tr><td>Moderate expression</td><td>14% [5%-30%]</td><td>7% [0%-32%]</td><td>14% [0%-58%]</td><td>23% [5%-54%]</td><td> </td></tr><tr><td>High expression</td><td>9% [2%-23%]</td><td>13% [2%-40%]</td><td>0% [0%-41%]</td><td>8% [0%-36%]</td><td> </td></tr></table> |
43d6811c7d95c72547fd13130b03e83ad5116ecdc3b192f0e36076a81b6a3abf.png | simple | <table><tr><td>From</td><td>To</td><td>Rate (95% HPD)*</td><td>No. of Jumps (95% HPD)†</td><td>Jump proportion‡</td><td>BF§</td></tr><tr><td>Elk</td><td>Bison</td><td>0.59 (0.02–1.42)</td><td>5.24 (2.05–7.71)</td><td>0.021</td><td>110</td></tr><tr><td> </td><td>Livestock</td><td>1.68 (0.25–3.46)</td><td>16.36 (14.23–19.16)</td><td>0.070</td><td>44,206</td></tr><tr><td>Bison</td><td>Elk</td><td>1.85 (0.27–3.79)</td><td>12.24 (7.26–18.50)</td><td>0.053</td><td>44,206</td></tr><tr><td> </td><td>Livestock</td><td>0.33 (0.00–2.32)</td><td>0.00 (0.00–1.56)</td><td>0.002</td><td><3</td></tr><tr><td>Livestock</td><td>Bison</td><td>0.31 (0.00–2.30)</td><td>0.00 (0.00–0.29)</td><td>0.000</td><td><3</td></tr><tr><td> </td><td>Elk</td><td>0.36 (0.00–1.96)</td><td>0.06 (0.00–2.41)</td><td>0.002</td><td><3</td></tr></table> |
0d4a3e825d8e58f30db641532b6849c77e88c3ea22d8ad60eb6d561dcbecf2fe.png | simple | <table><tr><td>Adverse event</td><td>Estimated incidence</td></tr><tr><td>a) death</td><td>20%*</td></tr><tr><td>b) necrotising enterocolitis or focal intestinal perforation diagnosed on clinical grounds, or at surgery</td><td>15%*</td></tr><tr><td>c) intracranial abnormality (parenchymal haemorrhage or focal white matter damage) on cranial ultrasound</td><td>15%*</td></tr><tr><td>d) requirement for supplementary oxygen 28 days after birth</td><td>55%*</td></tr><tr><td>e) patent ductus arteriosus requiring medical or surgical management</td><td>25%*</td></tr><tr><td>f) retinal surgery for retinopathy of prematurity</td><td>5%*</td></tr><tr><td>g) sustained tachycardia (greater than 220 beats per minute for more than 30 minutes in a 60 minute period)</td><td>20%**</td></tr><tr><td>h) pulmonary haemorrhage</td><td>5%**</td></tr><tr><td>i) persistent weight loss after 14 days after birth in the absence of infection.</td><td>10%**</td></tr></table> |
a48217a04c790661014d91b33b2a9768684495c48d8b75217f3ed17eb1c68448.png | complex | <table><tr><td></td><td colspan="3">PCr/ATP</td></tr><tr><td>Subject</td><td>MaxV</td><td>MaxV‐50V</td><td>Mean</td></tr><tr><td>1</td><td>1.96 ± 0.29</td><td>1.94 ± 0.43</td><td>1.95 ± 0.35</td></tr><tr><td>2</td><td>2.01 ± 0.37</td><td>1.85 ± 0.47</td><td>1.93 ± 0.38</td></tr><tr><td>3</td><td>1.93 ± 0.37</td><td>2.08 ± 0.38</td><td>2.00 ± 0.30</td></tr><tr><td>4</td><td>2.27 ± 0.28</td><td>2.23 ± 0.58</td><td>2.25 ± 0.39</td></tr><tr><td>5</td><td>2.14 ± 0.52</td><td>2.13 ± 0.64</td><td>2.13 ± 0.55</td></tr><tr><td>6</td><td>2.02 ± 0.45</td><td>2.20 ± 0.55</td><td>2.11 ± 0.47</td></tr><tr><td>7</td><td>2.19 ± 0.27</td><td>2.11 ± 0.35</td><td>2.15 ± 0.27</td></tr><tr><td>8</td><td>2.47 ± 0.59</td><td>2.38 ± 0.66</td><td>2.42 ± 0.61</td></tr><tr><td>9</td><td>2.22 ± 0.29</td><td>2.33 ± 0.31</td><td>2.28 ± 0.29</td></tr><tr><td>Mean</td><td>2.13 ± 0.17</td><td>2.14 ± 0.17</td><td>2.14 ± 0.16</td></tr></table> |
e046430754189423d15266c734756dcab91d7ae569163838b5b84f998a567338.png | simple | <table><tr><td>Strain</td><td>Growth rate</td><td>masses</td><td>terminal phenotype</td></tr><tr><td>w1118</td><td>+++</td><td>-</td><td>viable</td></tr><tr><td>da-Gal4</td><td>+++</td><td>-</td><td>viable</td></tr><tr><td>tub-Gal4</td><td>+++</td><td>-</td><td>homozygous lethal</td></tr><tr><td>act5c-Gal4</td><td>+++</td><td>-</td><td>homozygous lethal</td></tr><tr><td>UAS-Dis3 (35090)</td><td>+++</td><td>-</td><td>viable</td></tr><tr><td>UAS-Dis3 (35091)</td><td>+++</td><td>-</td><td>homozygous lethal</td></tr><tr><td>da-Gal4/UAS-Dis3 (35090)</td><td>+</td><td>+</td><td>2nd instar larva lethal</td></tr><tr><td>da-Gal4/UAS-Dis3 (35091)</td><td>+</td><td>+</td><td>2nd instar larva lethal</td></tr><tr><td>tub-Gal4/UAS-Dis3 (35090)</td><td>+</td><td>+</td><td>2nd instar larva lethal</td></tr><tr><td>act5c-Gal4/UAS-Dis3 (35090)</td><td>+</td><td>+</td><td>2nd instar larva lethal</td></tr></table> |
f5e7ca5fb7de687d5fc626bbddd6d4586e3e4b8728bec44799441e6a8bb6ba18.png | complex | <table><tr><td rowspan="2">Number</td><td colspan="3">Mixtures Composition (wt %)</td></tr><tr><td>Stellite 6</td><td>WS<sub>2</sub></td><td>NbC</td></tr><tr><td>Coating 1</td><td>100</td><td>-</td><td>-</td></tr><tr><td>Coating 2</td><td>85</td><td>15</td><td>-</td></tr><tr><td>Coating 3</td><td>70</td><td>-</td><td>30</td></tr><tr><td>Coating 4</td><td>60</td><td>10</td><td>30</td></tr><tr><td>Coating 5</td><td>55</td><td>15</td><td>30</td></tr><tr><td>Coating 6</td><td>50</td><td>20</td><td>30</td></tr></table> |
58b5ca22ceea3518f88a8a46ca191b0e43361759aea2a848d64f53f7cc4f4743.png | complex | <table><tr><td rowspan="2">Region</td><td rowspan="2">R/L/M</td><td rowspan="2">BA</td><td colspan="3">MNI coordinate</td><td colspan="2">Stats</td></tr><tr><td><i>x</i></td><td><i>y</i></td><td><i>z</i></td><td><i>T</i></td><td>Size<sup>a</sup></td></tr><tr><td colspan="8">Group difference</td></tr><tr><td>IGO < Control</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> rACC/vmPFC</td><td>L</td><td>32</td><td>−6</td><td>50</td><td>12</td><td>18.8</td><td>29</td></tr><tr><td>IGO > Control</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> NS</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Group × reward-type interaction</td></tr><tr><td>IP region</td><td>L</td><td>39</td><td>−46</td><td>−56</td><td>20</td><td>20.5</td><td>26</td></tr><tr><td>mOFC/vmPFC</td><td>M</td><td>11</td><td>−2</td><td>44</td><td>−10</td><td>19.8</td><td>24</td></tr></table> |
ac6191089fac3998fd6326bce833aa4d9fe17a35a301ec26e7fea940767aeb74.png | simple | <table><tr><td>Characteristics</td><td>Group-1 (n = 53) No SG</td><td>Group-2 (n = 27) Mild SG</td><td>Group-3 (n = 65) Severe SG</td><td><i>p</i>-value</td></tr><tr><td>Age (years)</td><td>31 (27-34)</td><td>27 (25-29)</td><td>28 (24-30)</td><td>0.001</td></tr><tr><td>Gravidity (2 / 3 / 4 / >4)</td><td>40/10/3/0</td><td>20/6/1/0</td><td>53/11/1/0</td><td>0.826</td></tr><tr><td>Abortus (0 / 1 / 2)</td><td>39/11/3</td><td>20/6/1/0</td><td>51/13/1/0</td><td>0.952</td></tr><tr><td>Education (≤ 5 years / middle / high / university)</td><td>14/15/11/13</td><td>6/6/9/6</td><td>17/20/12/6</td><td>0.433</td></tr><tr><td>Level of income(low / middle / high)</td><td>17/21/15</td><td>4/17/6</td><td>18/33/14</td><td>0.322</td></tr><tr><td>Smoking habit (-/+)</td><td>49/4</td><td>25/2</td><td>54/11</td><td>0.215</td></tr><tr><td>SG in first pregnancy (-/+)</td><td>52/1</td><td>6/21</td><td>3/62</td><td><0.001</td></tr><tr><td>Family history of SG (-/+)</td><td>27/26</td><td>16/11</td><td>21/44</td><td>0.027</td></tr><tr><td>Striae on buttocks (-/+)</td><td>3/50</td><td>4/23</td><td>18/47</td><td>0.007</td></tr><tr><td>Striae on leg (-/+)</td><td>8/45</td><td>8/19</td><td>31/34</td><td>0.001</td></tr><tr><td>Striae on breasts (-/+)</td><td>0/53</td><td>0/27</td><td>6/59</td><td>0.021</td></tr><tr><td>Period between two C/S (years)</td><td>4.99±2.87</td><td>4.09±1.91</td><td>4.82±2.90</td><td>0.516</td></tr><tr><td>GW at first C/S</td><td>39 (38-40)</td><td>40 (38-40)</td><td>40 (39-41)</td><td>0.039</td></tr><tr><td>Birth weight of first baby (gram)</td><td>3309±581</td><td>3281±587</td><td>3327±586</td><td>0.884</td></tr><tr><td>BMI at previous C/S (kg/m<sup>2</sup>)</td><td>27 (25-29)</td><td>29 (24-31)</td><td>30 (26-33)</td><td>0.003</td></tr><tr><td>BMI at present C/S (kg/m<sup>2</sup>)</td><td>27 (26-30)</td><td>29 (27-31)</td><td>32 (30-35)</td><td><0.001</td></tr><tr><td>GW at present C/S</td><td>38.42±1.08</td><td>38.63±0.88</td><td>38.74±0.67</td><td>0.335</td></tr><tr><td>Birth weight of second baby (gram)</td><td>3315±297</td><td>3270±458</td><td>3351±381</td><td>0.658</td></tr></table> |
709f50f80b585151f2837f61ab789c5573898f40ab82846b0f73210c8fc380e3.png | complex | <table><tr><td rowspan="2">Pregnancy and Neonatal Outcomes</td><td colspan="4">Cobalt (μg/L)</td><td colspan="4">Copper (μg/dL)</td><td colspan="4">Zinc (μg/dL)</td><td colspan="4">Selenium (μg/L)</td></tr><tr><td>High (<i>n</i> = 9)</td><td>Not High (<i>n</i> = 236)</td><td><i>p</i><sup>a</sup></td><td><i>p</i><sup>b</sup></td><td>High (<i>n</i> = 172)</td><td>Not High (<i>n</i> = 73)</td><td><i>p</i><sup>a</sup></td><td><i>p</i><sup>b</sup></td><td>Low (<i>n</i> = 187)</td><td>Not Low (<i>n</i> = 58)</td><td><i>p</i><sup>a</sup></td><td><i>p</i><sup>b</sup></td><td>Low (<i>n</i> = 5)</td><td>Not Low (<i>n</i> = 240)</td><td><i>p</i><sup>a</sup></td><td><i>p</i><sup>b</sup></td></tr><tr><td>Gestational diabetes, <i>n</i> (%)</td><td>0 (0)</td><td>18 (7.6)</td><td>0.76</td><td>0.80</td><td>15 (8.7)</td><td>3 (4.1)</td><td>0.22</td><td>0.45</td><td>15 (8.0)</td><td>3 (5.2)</td><td>0.47</td><td>0.58</td><td>0 (0)</td><td>18 (7.5)</td><td>0.96</td><td>0.79</td></tr><tr><td>Preeclampsia, <i>n</i> (%)</td><td>0 (0)</td><td>5 (2.1)</td><td>0.62</td><td>0.43</td><td>2 (1.2)</td><td>3 (4.1)</td><td>0.16</td><td>0.03</td><td>5 (2.7)</td><td>0 (0)</td><td>0.40</td><td>0.54</td><td>0 (0)</td><td>5 (2.1)</td><td>0.42</td><td>0.44</td></tr><tr><td>Gestational age at delivery, weeks, median</td><td>39.6</td><td>39.5</td><td>0.43</td><td>0.27</td><td>39.4</td><td>39.6</td><td>0.37</td><td>0.99</td><td>39.6</td><td>39.5</td><td>0.88</td><td>0.44</td><td>39.6</td><td>39.4</td><td>0.39</td><td>0.64</td></tr><tr><td>Baby weight, g, median</td><td>3540</td><td>3180</td><td>0.08</td><td>0.03</td><td>3180</td><td>3190</td><td>0.76</td><td>0.47</td><td>3180</td><td>3175</td><td>0.59</td><td>0.30</td><td>3440</td><td>3180</td><td>0.04</td><td>0.03</td></tr><tr><td>Preterm, <i>n</i> (%)</td><td>0 (0)</td><td>11 (4.7)</td><td>0.98</td><td>0.65</td><td>10 (5.8)</td><td>1 (1.4)</td><td>0.16</td><td>0.18</td><td>7 (3.7)</td><td>4 (6.9)</td><td>0.32</td><td>0.66</td><td>0 (0)</td><td>11 (4.6)</td><td>0.72</td><td>0.64</td></tr><tr><td>Low birth weight, <i>n</i> (%)</td><td>0 (0)</td><td>9 (3.8)</td><td>0.88</td><td>0.94</td><td>6 (3.5)</td><td>3 (4.1)</td><td>0.81</td><td>0.72</td><td>8 (4.3)</td><td>1 (1.7)</td><td>0.38</td><td>0.56</td><td>0 (0)</td><td>9 (3.8)</td><td>0.63</td><td>0.97</td></tr><tr><td>Small for gestational age, <i>n</i> (%)</td><td>1 (11.1)</td><td>35 (14.8)</td><td>0.76</td><td>0.40</td><td>27 (15.7)</td><td>9 (12.3)</td><td>0.50</td><td>0.80</td><td>31 (16.6)</td><td>5 (8.6)</td><td>0.14</td><td>0.19</td><td>0 (0)</td><td>36 (15.0)</td><td>0.68</td><td>0.50</td></tr><tr><td>Congenital abnormality, <i>n</i> (%)</td><td>0 (0)</td><td>14 (5.9)</td><td>0.89</td><td>0.83</td><td>10 (5.8)</td><td>4 (5.5)</td><td>0.92</td><td>0.84</td><td>11 (5.9)</td><td>3 (5.2)</td><td>0.84</td><td>0.94</td><td>0 (0)</td><td>14 (5.8)</td><td>0.83</td><td>0.95</td></tr></table> |
d8fc6a1591e0b3eae9086ba6f4a466bbe42ef0f92b8130e1b667a22441708606.png | complex | <table><tr><td></td><td colspan="3">All synolog pairs</td><td colspan="3">≥90% protein sequence identity between synolog pairs</td></tr><tr><td></td><td>Median ± MAD</td><td>Min</td><td>Max</td><td>Median ± MAD</td><td>Min</td><td>Max</td></tr><tr><td>Number of carbohydrate metabolism synologs</td><td>49.0 ± 35.0</td><td>0</td><td>394</td><td>0.0 ± 0.0</td><td>0</td><td>47</td></tr><tr><td>Number of carbohydrate metabolism synolog groups</td><td>20.0 ± 13.0</td><td>0</td><td>128</td><td>0.0 ± 0.0</td><td>0</td><td>16</td></tr><tr><td>Average protein sequence identity between synolog pairs<sup>2</sup> [%]</td><td>36.8 ± 4.2</td><td>13.4</td><td>100.0</td><td>97.3 ± 1.8</td><td>90.0</td><td>100.0</td></tr><tr><td>Synolog fraction of carbohydrate metabolism genes [%]</td><td>30.0 ± 9.7</td><td>0.0</td><td>85.7</td><td>0.0 ± 0.0</td><td>0.0</td><td>34.6</td></tr></table> |
771767437f360c6fb4f1bc3ab92b0498f04a7cf9383342556ee221e90579d311.png | complex | <table><tr><td>Source</td><td>Variable</td><td># Items</td><td>Response options</td><td>Cronbach’s α</td><td>Pearson’s <i>r</i></td><td>Potential Range</td><td>Actual Range</td><td>Mean (SD)</td></tr><tr><td></td><td colspan="8">Social Support for Healthy Eating</td></tr><tr><td>Child</td><td>Family Food Culture</td><td>4</td><td>0 (Never or almost never) to 2 (almost always or always)</td><td>.64</td><td>NA</td><td>0–8</td><td>0–8</td><td>5.36 (1.80)</td></tr><tr><td>Parent</td><td>Instrumental support for healthy eating</td><td>7</td><td>0 (No) to 1 (Yes)</td><td>.76</td><td>NA</td><td>0–7</td><td>0–7</td><td>4.38 (2.04)</td></tr><tr><td>Parent</td><td>Home availability and accessibility of FV</td><td>6</td><td>0 (Never) to 3 (All of the time)</td><td>.72</td><td>NA</td><td>0–18</td><td>1–18</td><td>10.75 (3.57)</td></tr><tr><td>Parent</td><td>Home availability of SSB</td><td>1</td><td>0 (Never) to 3 (All of the time)</td><td>NA</td><td>NA</td><td>0–3</td><td>0–3</td><td>1.59 (.87)</td></tr><tr><td>Parent</td><td>Emotional support for healthy eating</td><td>6</td><td>0 (Strongly disagree) to 4 (Strongly agree)</td><td>.71</td><td>NA</td><td>0–24</td><td>0–24</td><td>17.66 (3.82)</td></tr><tr><td>Parent</td><td>Rules for healthy eating</td><td>3</td><td>0 (Strongly disagree) to 4 (Strongly agree)</td><td>.77</td><td>NA</td><td>0–12</td><td>0–12</td><td>8.96 (2.46)</td></tr><tr><td>Parent</td><td>Modeling vegetable intake</td><td>1</td><td>0 (Never) to 4 (About once a day)</td><td>NA</td><td>NA</td><td>0–4</td><td>0–4</td><td>3.48 (.84)</td></tr><tr><td>Parent</td><td>Modeling SSB</td><td>1</td><td>0 (Never) to 4 (About once a day)</td><td>NA</td><td>NA</td><td>0–4</td><td>0–4</td><td>2.79 (1.18)</td></tr><tr><td></td><td colspan="8">Social Support for Physical Activity</td></tr><tr><td>Parent</td><td>Instrumental support for PA</td><td>2</td><td>0 (Never) to 7 (7 days)</td><td>NA</td><td>.46</td><td>0–14</td><td>0–14</td><td>3.96 (3.38)</td></tr><tr><td>Parent</td><td>Emotional support for PA</td><td>4</td><td>0 (Strongly disagree) to 4 (Strongly agree)</td><td>.74</td><td>NA</td><td>0–16</td><td>0–16</td><td>12.73 (2.52)</td></tr><tr><td>Parent</td><td>Modeling PA</td><td>1</td><td>0 (Never) to 4 (About once a day)</td><td>NA</td><td>NA</td><td>0–4</td><td>0–4</td><td>3.55 (.82)</td></tr></table> |
962edad74c58bfeecfd1f1083b0c7e7bd1b4e7cae7c930e930c0987edefba161.png | complex | <table><tr><td colspan="5">FACTOR1</td></tr><tr><td>GO ID</td><td>GO Term</td><td>Size</td><td>Count</td><td>Pvalue</td></tr><tr><td>GO.0007051</td><td>spindle organization</td><td>6</td><td>2</td><td>8.20E-03</td></tr><tr><td>GO.0050931</td><td>pigment cell differentiation</td><td>7</td><td>2</td><td>0.011</td></tr><tr><td>GO.0000279</td><td>M phase of meiotic cell cycle</td><td>79</td><td>6</td><td>0.012</td></tr><tr><td>GO.0000079</td><td>regulation of cyclin dependent protein kinase activity</td><td>9</td><td>2</td><td>0.019</td></tr><tr><td>GO.0016570</td><td>histone modification</td><td>13</td><td>2</td><td>0.038</td></tr><tr><td>GO.0015698</td><td>inorganic anion transport</td><td>53</td><td>4</td><td>0.039</td></tr><tr><td>GO.0007156</td><td>homophilic cell adhesion</td><td>32</td><td>3</td><td>0.041</td></tr><tr><td>Kegg ID</td><td>Kegg pathway</td><td>Size</td><td>Count</td><td>Pvalue</td></tr><tr><td>map05216</td><td>Thyroid cancer</td><td>11</td><td>2</td><td>0.020</td></tr><tr><td>map05130</td><td>Pathogenic Escherichia coli infection</td><td>12</td><td>2</td><td>0.024</td></tr><tr><td>map04520</td><td>Adherens junction</td><td>31</td><td>3</td><td>0.024</td></tr><tr><td colspan="5">FACTOR2</td></tr><tr><td>GO ID</td><td>GO Term</td><td>Size</td><td>Count</td><td>Pvalue</td></tr><tr><td>GO.0006195</td><td>purine nucleotide catabolic process</td><td>5</td><td>3</td><td>2.23E-05</td></tr><tr><td>GO.0030168</td><td>platelet activation</td><td>7</td><td>3</td><td>7.65E-05</td></tr><tr><td>GO.0007051</td><td>spindle organization</td><td>6</td><td>2</td><td>2.55E-03</td></tr><tr><td>GO.0007596</td><td>blood coagulation</td><td>24</td><td>3</td><td>3.76E-03</td></tr><tr><td>GO.0030336</td><td>negative regulation of cell migration</td><td>12</td><td>2</td><td>0.011</td></tr><tr><td>GO.0032879</td><td>regulation of localization</td><td>103</td><td>5</td><td>0.012</td></tr><tr><td>GO.0001775</td><td>cell activation</td><td>74</td><td>4</td><td>0.016</td></tr><tr><td>GO.0001890</td><td>placenta development</td><td>18</td><td>2</td><td>0.023</td></tr><tr><td>GO.0017038</td><td>protein import</td><td>49</td><td>3</td><td>0.027</td></tr><tr><td>GO.0006403</td><td>RNA localization</td><td>22</td><td>2</td><td>0.034</td></tr><tr><td>GO.0006816</td><td>calcium ion transport</td><td>56</td><td>3</td><td>0.038</td></tr><tr><td>Kegg ID</td><td>Kegg pathway</td><td>Size</td><td>Count</td><td>Pvalue</td></tr><tr><td>map00230</td><td>Purine metabolism</td><td>64</td><td>4</td><td>0.013</td></tr></table> |
7da1f135f939b2e3b3566b8d865a19ee8b7a64bda94ec696b3730422cd7fe549.png | complex | <table><tr><td>Complication</td><td>Incidence [25]</td><td>Cost for treatment</td></tr><tr><td rowspan="2">Re-operation (any reason) (including infection)</td><td rowspan="2">0.30% (3 out of 1,000)</td><td>- CPT 29871 (surgical, for infection, lavage and drainage); $521.91</td></tr><tr><td>- APC 0041(knee arthroscopy/drainage); $2,111.62</td></tr><tr><td>Venous thromboembolism (VTE)</td><td>0.19% (1.9 out of 1,000)</td><td>Costs over a 12 month timeframe for treating VTE; $14,865</td></tr><tr><td>Deep vein thrombosis (DVT)</td><td>0.12% (1.2 out of 1,000)</td><td>Costs over a 12 month timeframe for treating DVT [43]; $14,865</td></tr><tr><td>Pulmonary embolism (PE)</td><td>0.08% (0.8 out of 1,000)</td><td>Costs over a 12 month timeframe for treating PE [43]; $22,900</td></tr></table> |
0d6e5f1f1b376ca4087c2165e43002fa0d9643bf2429d51c3c8e0602951da007.png | complex | <table><tr><td rowspan="2">Markers</td><td rowspan="2">Chromosome</td><td rowspan="2">Position (bp)</td><td colspan="4">Number of individuals</td></tr><tr><td>a</td><td>h</td><td>b</td><td>Total</td></tr><tr><td>mSI_26</td><td>CH1</td><td>3 377 732</td><td>5</td><td>228</td><td>118</td><td>351</td></tr><tr><td>mSI_88</td><td>CH1</td><td>3 499 444</td><td>5</td><td>224</td><td>111</td><td>340</td></tr><tr><td>mSI_89</td><td>CH1</td><td>3 525 756</td><td>5</td><td>233</td><td>114</td><td>352</td></tr><tr><td>mSI_32</td><td>CH1</td><td>3 649 333</td><td>4</td><td>236</td><td>120</td><td>361</td></tr><tr><td>mTcCIR15</td><td>CH1</td><td>3 711 664</td><td>4</td><td>227</td><td>117</td><td>348</td></tr><tr><td>mSI_73</td><td>CH1</td><td>3 790 637</td><td>4</td><td>291</td><td>138</td><td>429</td></tr><tr><td>mSI_101</td><td>CH1</td><td>3 935 902</td><td>3</td><td>243</td><td>119</td><td>365</td></tr><tr><td>mSI_102</td><td>CH1</td><td>3 966 163</td><td>2</td><td>249</td><td>119</td><td>370</td></tr><tr><td>mSI_140</td><td>CH1</td><td>3 988 656</td><td>2</td><td>217</td><td>125</td><td>344</td></tr><tr><td>mSI_141</td><td>CH1</td><td>4 010 921</td><td>2</td><td>308</td><td>138</td><td>448</td></tr><tr><td>mSI_103</td><td>CH1</td><td>4 021 267</td><td>3</td><td>387</td><td>228</td><td>618</td></tr><tr><td>mSI_366</td><td>CH1</td><td>4 053 385</td><td>0</td><td>508</td><td>253</td><td>761</td></tr><tr><td>mSI_367</td><td>CH1</td><td>4 054 418</td><td>0</td><td>366</td><td>216</td><td>582</td></tr><tr><td>mSI_369</td><td>CH1</td><td>4 057 532</td><td>0</td><td>419</td><td>221</td><td>640</td></tr><tr><td>mSI_440</td><td>CH1</td><td>4 066 036</td><td>0</td><td>476</td><td>253</td><td>729</td></tr><tr><td>mSI_370</td><td>CH1</td><td>4 070 474</td><td>0</td><td>466</td><td>266</td><td>732</td></tr><tr><td>mSI_372</td><td>CH1</td><td>4 073 585</td><td>0</td><td>297</td><td>170</td><td>467</td></tr><tr><td>mSI_375</td><td>CH1</td><td>4 091 577</td><td>2</td><td>429</td><td>228</td><td>659</td></tr><tr><td>mSI_107</td><td>CH1</td><td>4 130 575</td><td>4</td><td>374</td><td>212</td><td>590</td></tr><tr><td>mTcCIR356</td><td>CH1</td><td>4 149 062</td><td>6</td><td>232</td><td>118</td><td>354</td></tr><tr><td>mSI_112</td><td>CH1</td><td>4 233 257</td><td>6</td><td>339</td><td>163</td><td>502</td></tr><tr><td>mSI_113</td><td>CH1</td><td>4 252 975</td><td>6</td><td>284</td><td>172</td><td>456</td></tr><tr><td>mSI_462</td><td>CH4</td><td>1414</td><td>222</td><td>425</td><td>2</td><td>649</td></tr><tr><td>mSI_466</td><td>CH4</td><td>4737</td><td>191</td><td>385</td><td>0</td><td>576</td></tr><tr><td>mSI_474</td><td>CH4</td><td>10 127</td><td>198</td><td>380</td><td>0</td><td>578</td></tr><tr><td>mSI_7</td><td>CH4</td><td>20 673</td><td>259</td><td>488</td><td>0</td><td>747</td></tr><tr><td>mSI_34</td><td>CH4</td><td>28 166</td><td>238</td><td>487</td><td>0</td><td>725</td></tr><tr><td>mSI_8</td><td>CH4</td><td>28 166</td><td>142</td><td>270</td><td>0</td><td>412</td></tr><tr><td>mTcCir312</td><td>CH4</td><td>32 259</td><td>277</td><td>516</td><td>0</td><td>793</td></tr><tr><td>mSI_35</td><td>CH4</td><td>33 618</td><td>183</td><td>348</td><td>0</td><td>531</td></tr><tr><td>mSI_2</td><td>CH4</td><td>43 494</td><td>191</td><td>335</td><td>0</td><td>526</td></tr><tr><td>mSI_542</td><td>CH4</td><td>63 388</td><td>33</td><td>68</td><td>0</td><td>101</td></tr><tr><td>mSI_303</td><td>CH4</td><td>119 995</td><td>299</td><td>578</td><td>0</td><td>877</td></tr><tr><td>mSI_458</td><td>CH4</td><td>136 890</td><td>208</td><td>399</td><td>0</td><td>607</td></tr><tr><td>mSI_460</td><td>CH4</td><td>139 590</td><td>198</td><td>406</td><td>0</td><td>604</td></tr><tr><td>mSI_308</td><td>CH4</td><td>139 780</td><td>211</td><td>408</td><td>0</td><td>619</td></tr><tr><td>mSI_309</td><td>CH4</td><td>141 679</td><td>205</td><td>411</td><td>0</td><td>616</td></tr><tr><td>mSI_310</td><td>CH4</td><td>142 517</td><td>193</td><td>383</td><td>0</td><td>576</td></tr><tr><td>mSI_315</td><td>CH4</td><td>233 706</td><td>301</td><td>563</td><td>0</td><td>864</td></tr><tr><td>mSI_402</td><td>CH4</td><td>246 098</td><td>259</td><td>506</td><td>0</td><td>765</td></tr><tr><td>mSI_535</td><td>CH4</td><td>252 815</td><td>110</td><td>232</td><td>0</td><td>342</td></tr><tr><td>mSI_411</td><td>CH4</td><td>258 684</td><td>125</td><td>242</td><td>1</td><td>368</td></tr><tr><td>mS_413</td><td>CH4</td><td>270 916</td><td>118</td><td>253</td><td>1</td><td>372</td></tr><tr><td>mSI_39</td><td>CH4</td><td>278 179</td><td>277</td><td>421</td><td>1</td><td>699</td></tr><tr><td>mSI_42</td><td>CH4</td><td>343 424</td><td>109</td><td>233</td><td>2</td><td>345</td></tr><tr><td>mSI_46</td><td>CH4</td><td>428 250</td><td>119</td><td>230</td><td>2</td><td>352</td></tr><tr><td>mSI_54</td><td>CH4</td><td>751 986</td><td>55</td><td>127</td><td>4</td><td>521</td></tr><tr><td>mSI_294</td><td>CH4</td><td>1 686 245</td><td>109</td><td>248</td><td>16</td><td>373</td></tr></table> |
c13b2e5336325446ae686fc870a1a0770ab4aca61430d0a2ccbdca738f6278dc.png | simple | <table><tr><td>Location</td><td>PT-INR tests</td><td>Range stated</td><td>Cause stated</td></tr><tr><td>PHCC Östergötland</td><td>499</td><td>480</td><td>495</td></tr><tr><td>PHCC Eksjö</td><td>65</td><td>65</td><td>65</td></tr><tr><td>PHCC total (men/women)</td><td>564 (289/275)</td><td>545 (282/263)</td><td>560 (289/271)</td></tr><tr><td>ACC Östergötland</td><td>470</td><td>470</td><td>464</td></tr><tr><td>ACC Eksjö</td><td>58</td><td>58</td><td>58</td></tr><tr><td>ACC Värnamo</td><td>399</td><td>399</td><td>393</td></tr><tr><td>ACC Total (men/women)</td><td>927 (540/387)</td><td>927 (540/387)</td><td>915 (531/384)</td></tr></table> |
4de7c341ed7b06322765c0fa055972cc198e37baa3f1c76e431c02d53b63b90e.png | complex | <table><tr><td>Parameters</td><td>Cases ± SD</td><td>Controls ± SD</td><td><i>p</i> value</td></tr><tr><td>Total SOD Activity (U/ml)</td><td>285.44 ± 114.36</td><td>319.79 ± 126.12</td><td>0.144</td></tr><tr><td>SOD Activity (U/ml) of cases on Metformin only<sup><i>a</i></sup></td><td>274.81 ± 122.73</td><td>-</td><td>a*b*c =0.771</td></tr><tr><td>SOD Activity (U/ml) of cases on Metformin and other drugs<sup><i>b</i></sup></td><td>281.75 ± 111.91</td><td>-</td><td><i>Post hoc:</i></td></tr><tr><td rowspan="3">SOD Activity (U/ml) of cases on other drugs aside Metformin<sup><i>c</i></sup></td><td rowspan="3">307.98 ± 133.40</td><td rowspan="3"></td><td>a*b =0.824 ;</td></tr><tr><td>a*c =0.499;</td></tr><tr><td>b*c =0.5265</td></tr></table> |
7fccce226e76b4ac28a9167c8ab592ce4f6f92e88b7ab4bc23491edf88da8e2f.png | simple | <table><tr><td>Group</td><td>A</td><td>B</td><td>C</td><td>D</td></tr><tr><td>Parameters</td><td>Mean ± SD</td><td>Mean ± SD</td><td>Mean ± SD</td><td>Mean ± SD</td></tr><tr><td>Normal Morphology</td><td>97.44 ± 0.94</td><td>91.09 ± 2.91***</td><td>91.60 ± 3.37***</td><td>94.56 ± 1.12***</td></tr><tr><td>Abnormal Head</td><td>1.74 ± 0.69</td><td>3.87 ± 1.64**</td><td>3.73 ± 2.49*</td><td>1.84 ± 0.61</td></tr><tr><td>Abnormal Tail</td><td>0.82 ± 0.39</td><td>5.04 ± 2.65***</td><td>4.67 ± 2.06***</td><td>3.6 ± 1.04***</td></tr></table> |
8905a86c90ba99e696f371a0acc2104fc7a64431eeb1fed85326ad98d18c9620.png | complex | <table><tr><td></td><td colspan="2">Derivation set (<i>N</i> = 38)</td><td><i>P</i>-value (Wilcoxon)</td></tr><tr><td></td><td>No response (<i>N</i> = 21)</td><td>Response (<i>N</i> = 16)</td><td></td></tr><tr><td>miR375</td></tr><tr><td>Mean ± STD</td><td>5.2 ± 2.2</td><td>7.1 ± 1.8</td><td>0.01</td></tr><tr><td>Median (min–max)</td><td>5.8 (−0.5–7.9)</td><td>7.3 (4.2–9.8)</td><td></td></tr><tr><td>miR149</td></tr><tr><td>Mean ± STD</td><td>7.2 ± 1.4</td><td>4.8 ± 1.8</td><td><0.001</td></tr><tr><td>Median (min–max)</td><td>6.5 (5.0–9.5)</td><td>4.8 (1.8–7.8)</td><td></td></tr><tr><td></td><td colspan="2">Validation set (<i>N</i> = 22)</td><td><i>P</i>-value (Wilcoxon)</td></tr><tr><td></td><td>No response (<i>N</i> = 13)</td><td>Response (<i>N</i> = 9)</td><td></td></tr><tr><td>miR375</td></tr><tr><td>Mean ± STD</td><td>3.8 ± 1.7</td><td>2.3 ± 2.3</td><td>0.07</td></tr><tr><td>Median (min–max)</td><td>2.8 (2.0–6.6)</td><td>1.7 (−0.2–7.6)</td><td></td></tr><tr><td>miR149</td></tr><tr><td>Mean ± STD</td><td>5.4 ± 1.7</td><td>4.2 ± 1.2</td><td>0.11</td></tr><tr><td>Median (min–max)</td><td>5.3 (1.8–7.2)</td><td>4.3 (2.4–5.8)</td><td></td></tr></table> |
fdf60ced0717b9d4a17d64cf0952f6807e9ca004a4050678f67d6567fcf2f23e.png | simple | <table><tr><td>Variant</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td></tr><tr><td>Length (bp)</td><td>1536</td><td>1425</td><td>1419</td><td>1425</td><td>1230</td><td>1326</td><td>1188</td><td>1425</td></tr><tr><td><i>M </i>(%)</td><td>94</td><td>99</td><td>96</td><td>99</td><td>98</td><td>99</td><td>98</td><td>100</td></tr><tr><td><i>m </i>(%)</td><td>54</td><td>51</td><td>64</td><td>76</td><td>54</td><td>51</td><td>61</td><td>76</td></tr></table> |
9b6efedca42e2efe9716c185f0aff3d54fe36284a26ce8b441ab579ba86e3ac4.png | complex | <table><tr><td>Type of analysis</td><td>HR</td><td>SE</td><td>95% CI</td><td>P-value</td></tr><tr><td colspan="5">VTE risk</td></tr><tr><td>Crude analysis</td><td>0.66</td><td>0.29</td><td>(0.28-1.54)</td><td>0.33</td></tr><tr><td>PS stratified analysis*</td><td>0.63</td><td>0.29</td><td>(0.25-1.57)</td><td>0.33</td></tr><tr><td colspan="5">Hospital Mortality</td></tr><tr><td>Crude analysis</td><td>1.26</td><td>0.18</td><td>(0.95-1.68)</td><td>0.10</td></tr><tr><td>PS stratified analysis*</td><td>0.98</td><td>0.16</td><td>(0.72-1.36)</td><td>0.94</td></tr></table> |
53f19bdb51e49eaef25ab55ce53ea61b38595a872c6c29489bcc8aa12743d844.png | complex | <table><tr><td></td><td colspan="2">Mating systems</td><td>Promiscuity</td></tr><tr><td colspan="4">Humans included in the model</td></tr><tr><td>Relative brain size</td><td><i>F</i> = 6.59</td><td><i>p</i> = 0.002</td><td><i>p</i> = 0.570</td></tr><tr><td>Relative testis size</td><td><i>F</i> = 26.93</td><td><i>p</i><0.0001</td><td><i>p</i><0.0001</td></tr><tr><td>Sexual dimorphism</td><td><i>F</i> = 3.83</td><td><i>p</i> = 0.021</td><td><i>p</i> = 0.721</td></tr><tr><td colspan="4">Humans excluded from the model</td></tr><tr><td>Relative brain size</td><td><i>F</i> = 3.93</td><td><i>p</i> = 0.019</td><td><i>p</i> = 0.341</td></tr><tr><td>Relative testis size</td><td><i>F</i> = 26.52</td><td><i>p</i><0.0001</td><td><i>p</i><0.0001</td></tr><tr><td>Sexual dimorphism</td><td><i>F</i> = 3.83</td><td><i>p</i> = 0.023</td><td><i>p</i> = 0.818</td></tr></table> |
059990f915dfb877741b3b385a9d6d5fcb64fa573e089a7857b6a89ae6ee7a53.png | complex | <table><tr><td> </td><td colspan="2">First-born children born in 2008</td><td colspan="2">The 2008 birth cohort</td><td colspan="2">The 2006 birth cohort*</td></tr><tr><td> </td><td>Total <i>n</i></td><td>%</td><td>Total <i>n</i></td><td>%</td><td>Total <i>n</i></td><td>%</td></tr><tr><td>MS score negative (=0)</td><td>617</td><td>91</td><td>1525</td><td>89**</td><td>955</td><td>85**</td></tr><tr><td> F group (oral hygiene and fluoride)</td><td>242</td><td>91</td><td>686</td><td>87</td><td>419</td><td>83</td></tr><tr><td> X group (diet and xylitol)</td><td>176</td><td>89</td><td>390</td><td>88</td><td>231</td><td>89</td></tr><tr><td> Control group</td><td>199</td><td>92</td><td>449</td><td>93</td><td>305</td><td>86</td></tr><tr><td> <i>P</i></td><td> </td><td>0.658</td><td> </td><td>0.011</td><td> </td><td>0.129</td></tr></table> |
569bb3f4772de0f287ccca5af315319a356b06f6c727d74dc9ba32ffccac3040.png | simple | <table><tr><td>Transcript support</td><td>5' end</td><td>3' end</td></tr><tr><td>FANTOM3</td><td>3,211</td><td>3,211</td></tr><tr><td>PUBLIC</td><td>2,666</td><td>2,666</td></tr><tr><td>5' ESTs</td><td>20,866</td><td>-</td></tr><tr><td>3' ESTs</td><td>-</td><td>32,166</td></tr><tr><td>Public ESTs</td><td>41,543</td><td>15,989</td></tr><tr><td>GIS</td><td>1,279</td><td>1,279</td></tr><tr><td>GSC</td><td>27,616</td><td>27,616</td></tr><tr><td>CAGE</td><td>162,707</td><td>-</td></tr><tr><td>Total count</td><td>259,888</td><td>82,927</td></tr></table> |
0183110170c067ef5891bb378274202272d0832714fa66746e5826848dead43a.png | complex | <table><tr><td rowspan="2">Type of drug related questions</td><td colspan="3">Response <i>N</i> (%)</td></tr><tr><td>Never</td><td>Sometimes</td><td>Always</td></tr><tr><td>Price</td><td>5 (10.4)</td><td>14 (29.2)</td><td>29 (60.4)</td></tr><tr><td>Dosage</td><td>0</td><td>27 (56.2)</td><td>21 (43.8)</td></tr><tr><td>Drug identification</td><td>2 (4.2)</td><td>32 (66.7)</td><td>14 (29.1)</td></tr><tr><td>Efficacy of drugs</td><td>8 (16.6)</td><td>27 (56.3)</td><td>13 (27.1)</td></tr><tr><td>Adverse drug reactions</td><td>4 (8.3)</td><td>33 (68.8)</td><td>11 (22.9)</td></tr><tr><td>Contraindications</td><td>4 (8.4)</td><td>34 (70.8)</td><td>10 (20.8)</td></tr><tr><td>Drug interactions</td><td>7 (14.6)</td><td>34 (70.8)</td><td>7 (14.6)</td></tr><tr><td>Pharmaceutical compatibility and stability</td><td>32 (66.7)</td><td>11 (22.9)</td><td>5 (10.4)</td></tr><tr><td>Poisoning</td><td>21 (43.8)</td><td>26 (54.1)</td><td>1 (2.1)</td></tr><tr><td>Herbal drugs</td><td>25 (52.1)</td><td>22 (45.8)</td><td>1 (2.1)</td></tr></table> |
66ccaed42eb251d283d1fd6b4c7acf5e44b7361c87cd3fe9b1f95bba588c14ac.png | complex | <table><tr><td></td><td colspan="4">Non-injection drug users</td><td colspan="4">Injection drug users</td></tr><tr><td></td><td><i>Total</i></td><td><i>Current IM use</i></td><td><i>No current IM use</i></td><td></td><td><i>Total</i></td><td><i>Current IM use</i></td><td><i>No current IM use</i></td><td></td></tr><tr><td></td><td><i>n = 955</i></td><td><i>n = 113</i></td><td><i>n = 842</i></td><td></td><td><i>n = 460</i></td><td><i>n = 157</i></td><td><i>n = 303</i></td><td></td></tr><tr><td></td><td><i>n(%)</i><sup><i>d</i></sup></td><td><i>n(%)</i></td><td><i>n(%)</i></td><td><i>p-value</i><sup><i>a</i></sup></td><td><i>n(%)</i><sup><i>d</i></sup></td><td><i>n(%)</i></td><td><i>n(%)</i></td><td><i>p-value</i><sup><i>a</i></sup></td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> <i>Male</i></td><td>664 (69.5)</td><td>76 (67.3)</td><td>588 (69.8)</td><td>0.576</td><td>370 (80.4)</td><td>125 (79.6)</td><td>245 (80.9)</td><td>0.751</td></tr><tr><td> <i>Female</i></td><td>289 (30.3)</td><td>37 (32.7)</td><td>252 (29.9)</td><td>0.541</td><td>88 (19.1)</td><td>30 (19.1)</td><td>58 (19.1)</td><td>0.993</td></tr><tr><td> <i>Transgender</i></td><td>2 (0.2)</td><td>0 (0)</td><td>2 (0.2)</td><td>1.000<sup>b</sup></td><td>2 (0.4)</td><td>2 (1.3)</td><td>0 (0)</td><td>0.120<sup>b</sup></td></tr><tr><td>Race</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> <i>Hispanic</i></td><td>430 (45.0)</td><td>67 (59.3)</td><td>363 (43.1)</td><td>0.001</td><td>373 (81.1)</td><td>133 (84.7)</td><td>240 (79.2)</td><td>0.172</td></tr><tr><td> <i>Black</i></td><td>436 (45.7)</td><td>36 (31.9)</td><td>400 (47.5)</td><td>0.002</td><td>21 (4.6)</td><td>5 (3.2)</td><td>16 (5.3)</td><td>0.304</td></tr><tr><td> <i>White</i></td><td>25 (2.6)</td><td>1 (0.9)</td><td>24 (2.9)</td><td>0.960<sup>b</sup></td><td>51 (11.1)</td><td>16 (10.2)</td><td>35 (11.6)</td><td>0.651</td></tr><tr><td> <i>Other</i></td><td>64 (6.7)</td><td>9 (8.0)</td><td>55 (6.5)</td><td>0.567</td><td>14 (3.0)</td><td>3 (1.9)</td><td>11 (3.6)</td><td>0.398<sup>b</sup></td></tr><tr><td>Mean age (SD)<sup>c</sup></td><td>30.1 (6.5)</td><td>31.8 (6.2)</td><td>29.8 (6.5)</td><td>0.002</td><td>26.4 (5.3)</td><td>26.1 (4.9)</td><td>26.6 (5.5)</td><td>0.388</td></tr><tr><td>Sexual orientation</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> <i>Heterosexual</i></td><td>786 (82.3)</td><td>100 (88.5)</td><td>686 (81.5)</td><td>0.033</td><td>395 (85.9)</td><td>133 (84.7)</td><td>262 (86.5)</td><td>0.961</td></tr><tr><td> <i>MSM</i><sup><i>e</i></sup></td><td>90 (9.4)</td><td>5 (4.4)</td><td>85 (10.1)</td><td>0.051</td><td>13 (8.3)</td><td>32 (10.6)</td><td>13 (8.3)</td><td>0.447</td></tr><tr><td> <i>WSW</i><sup><i>f</i></sup></td><td>102 (10.7)</td><td>9 (8.0)</td><td>93 (11.0)</td><td>0.327</td><td>11 (7.0)</td><td>21 (6.9)</td><td>11 (7.0)</td><td>0.955</td></tr><tr><td>< High school education</td><td>526 (55.1)</td><td>68 (60.2)</td><td>458 (54.4)</td><td>0.246</td><td>190 (41.3)</td><td>67 (42.7)</td><td>123 (40.6)</td><td>0.709</td></tr><tr><td>Homeless in last 6 months</td><td>549 (57.5)</td><td>60 (53.1)</td><td>489 (58.1)</td><td>0.315</td><td>332 (72.2)</td><td>117 (74.5)</td><td>215 (71.0)</td><td>0.419</td></tr><tr><td>Main source of income</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Employed</td><td>180 (18.8)</td><td>18 (15.9)</td><td>162 (19.2)</td><td>0.334</td><td>59 (12.8)</td><td>20 (12.7)</td><td>39 (12.9)</td><td>0.925</td></tr><tr><td> <i>Illegal</i></td><td>386 (40.4)</td><td>53 (46.9)</td><td>333 (39.5)</td><td>0.203</td><td>254 (55.2)</td><td>99 (63.1)</td><td>155 (51.2)</td><td>0.021</td></tr><tr><td> <i>Public Assistance</i></td><td>221 (23.1)</td><td>27 (23.9)</td><td>194 (23.0)</td><td>0.956</td><td>65 (14.1)</td><td>16 (10.2)</td><td>49 (16.2)</td><td>0.071</td></tr><tr><td> <i>Other</i></td><td>146 (15.3)</td><td>15 (13.3)</td><td>131 (15.6)</td><td>0.459</td><td>72 (15.7)</td><td>20 (12.7)</td><td>52 (17.2)</td><td>0.194</td></tr><tr><td>Have children</td><td>547 (57.3)</td><td>77 (68.1)</td><td>470 (55.8)</td><td>0.013</td><td>216 (47.0)</td><td>70 (44.6)</td><td>146 (48.2)</td><td>0.463</td></tr><tr><td>Ever been incarcerated</td><td>661 (69.2)</td><td>88 (77.9)</td><td>573 (68.1)</td><td>0.044</td><td>323 (70.2)</td><td>112 (71.3)</td><td>211 (69.6)</td><td>0.632</td></tr><tr><td>Site</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Bronx</td><td>348 (36.4)</td><td>43 (38.1)</td><td>305 (36.2)</td><td>0.704</td><td>232 (50.4)</td><td>83 (52.9)</td><td>149 (49.2)</td><td>0.453</td></tr><tr><td> <i>Harlem</i></td><td>449 (47.0)</td><td>53 (46.9)</td><td>396 (47.0)</td><td>0.980</td><td>171 (37.2)</td><td>59 (37.6)</td><td>112 (37.0)</td><td>0.907</td></tr><tr><td> <i>Brooklyn</i></td><td>67 (7.0)</td><td>11 (9.7)</td><td>56 (6.7)</td><td>0.228</td><td>22 (4.8)</td><td>6 (3.8)</td><td>16 (5.3)</td><td>0.487</td></tr><tr><td> <i>Queens</i></td><td>47 (4.9)</td><td>5 (4.4)</td><td>42 (5.0)</td><td>0.880</td><td>6 (1.3)</td><td>3 (1.9)</td><td>3 (1.0)</td><td>0.415</td></tr><tr><td> <i>Lower East Side</i></td><td>40 (4.2)</td><td>0 (0)</td><td>40 (4.8)</td><td>1.000<sup>b</sup></td><td>27 (5.9)</td><td>6 (3.8)</td><td>21 (6.9)</td><td>0.178</td></tr><tr><td>HIV+</td><td>101 (10.6)</td><td>6 (5.3)</td><td>95 (11.3)</td><td>0.056</td><td>22 (4.8)</td><td>6 (3.8)</td><td>16 (5.3)</td><td>0.457</td></tr><tr><td>HBV+</td><td>211 (22.1)</td><td>24 (21.2)</td><td>187 (22.2)</td><td>0.832</td><td>141 (30.7)</td><td>47 (29.9)</td><td>94 (31.0)</td><td>0.763</td></tr><tr><td><i>HCV+</i></td><td>36 (3.8)</td><td>6 (5.3)</td><td>30 (3.6)</td><td>0.247<sup>b</sup></td><td>255 (55.4)</td><td>86 (54.8)</td><td>169 (55.8)</td><td><i>0.596</i></td></tr></table> |
e3985ff5df60d1cc170c10569f4300f94b5bc3f301c64243eff88f5346ec6aaf.png | complex | <table><tr><td>Variables</td><td>Stroke <i>n</i> = 358</td><td>Non-stroke <i>n</i> = 58</td><td><i>P</i></td></tr><tr><td>Age</td><td>69.2 ± 13.8</td><td>70.6 ± 11.4</td><td>0.397</td></tr><tr><td>Male, <i>n</i> (%)</td><td>210 (58.7)</td><td>37 (63.8)</td><td>0.460</td></tr><tr><td>SBP, mmHg</td><td>168.8 ± 31.9</td><td>147.8 ± 27.6</td><td><0.001*</td></tr><tr><td>DBP, mmHg</td><td>91.8 ± 20.7</td><td>80.8 ± 14.3</td><td><0.001*</td></tr><tr><td>bpm</td><td>80.9 ± 18.1</td><td>80.0 ± 13.3</td><td>0.742</td></tr><tr><td colspan="4">Medical history, <i>n</i> (%)</td></tr><tr><td> Smoker</td><td>146 (40.8)</td><td>20 (34.5)</td><td>0.339</td></tr><tr><td> Hypertension</td><td>202 (56.4)</td><td>34 (58.6)</td><td>0.992</td></tr><tr><td> Diabetes</td><td>58 (16.2)</td><td>14 (24.1)</td><td>0.157</td></tr><tr><td> Hyperlipidemia</td><td>40 (11.2)</td><td>9 (15.5)</td><td>0.407</td></tr><tr><td> Ischemic heart disease</td><td>36 (10.1)</td><td>8 (13.8)</td><td>0.434</td></tr><tr><td> Atrial fibrillation</td><td>28 (7.8)</td><td>1 (1.7)</td><td>0.148</td></tr><tr><td colspan="4">Symptoms & signs, <i>n</i> (%)</td></tr><tr><td> Asymmetric facial weakness</td><td>181 (50.6)</td><td>8 (13.8)</td><td><0.001*</td></tr><tr><td> Asymmetric arm weakness</td><td>217 (60.6)</td><td>7 (12.1)</td><td><0.001*</td></tr><tr><td> Asymmetric leg weakness</td><td>228 (63.7)</td><td>9 (15.5)</td><td><0.001*</td></tr><tr><td> Speech disturbance</td><td>195 (54.5)</td><td>17 (29.3)</td><td><0.001*</td></tr><tr><td> Visual field defect</td><td>68 (19.0)</td><td>1 (1.7)</td><td>0.001*</td></tr><tr><td> gaze palsy</td><td>115 (32.1)</td><td>5 (8.6)</td><td><0.001*</td></tr><tr><td> Sensory deficits</td><td>78 (21.8)</td><td>8 (13.8)</td><td>0.163</td></tr><tr><td> Loss of consciousness or syncope</td><td>119 (33.2)</td><td>10 (17.2)</td><td>0.015*</td></tr><tr><td> Seizure activity</td><td>21 (5.9)</td><td>6 (10.3)</td><td>0.319</td></tr><tr><td> Pathologic reflex</td><td>102 (28.5)</td><td>8 (13.8)</td><td>0.019*</td></tr><tr><td> Meningeal irritation</td><td>22 (6.1)</td><td>0 (0)</td><td>0.102</td></tr><tr><td> Vertigo</td><td>26 (7.3)</td><td>19 (32.8)</td><td><0.001*</td></tr><tr><td> Headache</td><td>25 (7.0)</td><td>3 (5.2)</td><td>0.816</td></tr><tr><td> Nausea</td><td>59 (16.5)</td><td>26 (44.8)</td><td><0.001*</td></tr><tr><td> Vomiting</td><td>51 (14.2)</td><td>23 (39.7)</td><td><0.001*</td></tr><tr><td colspan="4">Score</td></tr><tr><td> GCS > 8, <i>n</i> (%)</td><td>297 (83)</td><td>56 (96.6)</td><td>0.007*</td></tr><tr><td> GCS ≤ 8, <i>n</i> (%)</td><td>61 (17)</td><td>2 (3.4)</td><td>0.007*</td></tr><tr><td> GCS, median (IQR)</td><td>15 (12–15)</td><td>15 (15–15)</td><td><0.001*</td></tr></table> |
c84d13aa2a0399d8453886fc7ba12267d6ec5bdcad6ea83b585195536dcfc0f1.png | complex | <table><tr><td>Primer</td><td>Sequence</td></tr><tr><td rowspan="2">miR-182</td><td>F: 5′-GGCAATGGTAGAACTCACACT-3′</td></tr><tr><td>R: 5′-AACATGTACAGTCCATGGATG-3′</td></tr><tr><td rowspan="2">HOXA9</td><td>F: 5′-TGCCCTCCAGCCGGCCTTAT-3′</td></tr><tr><td>R: 5′-CCGCTTTGTGCGGGGATGGT-3</td></tr><tr><td rowspan="2">Wnt</td><td>F: 5′-GCTAGCGAAAGTCATTGGC -3′</td></tr><tr><td>R: 5′-CATTGCATCGAAGTCGTG-3′</td></tr><tr><td rowspan="2">CTNNB1</td><td>F: 5′-ACAAACTGTTTTGAAAATCCA-3′</td></tr><tr><td>R: 5′-CGAGTCATTGCATACTGTCC-3′</td></tr><tr><td rowspan="2">WIF-1</td><td>F: 5′-CCGAAATGGAGGCTTTTGTA-3′</td></tr><tr><td>R: 5′-TGGTTGAGCAGTTTGCTTTG-3′</td></tr><tr><td rowspan="2">Survivin</td><td>F: 5′-CCGAGGGACTGTGTGGGGGTC-3′</td></tr><tr><td>R: 5′-CCAGGCACAGACCAAGGACGC-3′</td></tr><tr><td rowspan="2">CCND1</td><td>F: 5′-AATGGGCCTTAGAATGACTGC-3′</td></tr><tr><td>R: 5′-ATGCCAACACAGATGGCTTT-3′</td></tr><tr><td rowspan="2">C-myc</td><td>F: 5′-CTACCAGCAGCAGCAGCAGAGC-3′</td></tr><tr><td>R: 5′-CGTCCGGGTCGCACATGAA-3′</td></tr><tr><td rowspan="2">BIM</td><td>F: 5′-CGTAGCGCATGCGATA-3′</td></tr><tr><td>R: 5′-CATGCCGTATAAGCTAGTT-3′</td></tr><tr><td rowspan="2">Bax</td><td>F: 5′-GGCCCACCAGCTCTGAGCAGA-3′</td></tr><tr><td>R: 5′-GCCACGTGGGGGTCCCAAAGT-3′</td></tr><tr><td rowspan="2">Mcl-1</td><td>F: 5′-AGAAAGCTGCATCGAACCATTA-3′</td></tr><tr><td>R: 5′-GGAAGAACAACTCCACAAACCCATC-3′</td></tr><tr><td rowspan="2">Bcl-xl</td><td>F: 5′-TTGGACAATGGACTGGTTGA-3′</td></tr><tr><td>R: 5′-GTAGAGTGGATGGTCAGTG-3′</td></tr><tr><td rowspan="2">Snail</td><td>F: 5′-CTCCTCTACTTCAGCCTCTT-3′</td></tr><tr><td>R: 5′-CTTCATCAACGTCCTGTGGG-3′</td></tr><tr><td rowspan="2">GAPDH</td><td>F: 5′-CCACCCATGGCAAATTCCATGGCA-3′</td></tr><tr><td>R: 5′-TCTAGACGGCAGGTCAGGTCCAC-3′</td></tr><tr><td rowspan="2">U6</td><td>F: 5′-CTCGGCTTCGGCAGCACA-3′</td></tr><tr><td>R: 5′-AACGCTTCACGAATTTGCGT-3′</td></tr></table> |
59f6ea98b689ee289aa254ce3907a440044f520a91f41fc32dee53825c855385.png | simple | <table><tr><td>Subgroup (Number of studies)</td><td></td><td>Summary DOR (95% CI)</td></tr><tr><td>Study design</td><td>Case-control (24)</td><td>134.4 (65.2 – 213.1)</td></tr><tr><td></td><td>Cross-sectional (60)</td><td>171.1 (106.7 – 274.2)</td></tr><tr><td>Blinding</td><td>Single or double blinded (29)</td><td>90.2 (46.2 – 176.2)</td></tr><tr><td></td><td>Unblinded or NR (55)</td><td>221.2 (137.7 – 355.2)</td></tr><tr><td>DNA extraction method</td><td>Chemical (55)</td><td>153.7 (90.1 – 262.4)</td></tr><tr><td></td><td>Physical (29)</td><td>171.7 (96.2 – 306.6)</td></tr><tr><td>Amplification method</td><td>PCR/multiplex (68)</td><td>139.3 (89.2 – 217.7)</td></tr><tr><td></td><td>Nested PCR (16)</td><td>266.6 (140.8 – 504.6)</td></tr><tr><td>Target sequence</td><td>IS6110 (54)</td><td>236.1 (152.9 – 364.6)</td></tr><tr><td></td><td>Other target (30)</td><td>77.4 (38.2 – 156.9)</td></tr><tr><td>Detection method</td><td>Probe (49)</td><td>130.6 (78.4 – 217.6)</td></tr><tr><td></td><td>Gel-UV (35)</td><td>215.4 (115.1 – 403.2)</td></tr><tr><td>Sputum smear status</td><td>Pos/Both/NR (78)</td><td>161.5 (107.5 – 242.6)</td></tr><tr><td></td><td>Negative (6)</td><td>128.6 (33.4 – 495.1)</td></tr></table> |
fd8f46c2ad9eb615f9510a3c9c4e8919eae7dc19192006b6624841e0ea26fad4.png | complex | <table><tr><td rowspan="2">Region</td><td colspan="3">Value added of export spillover (100 million yuan)<sup>a</sup></td><td colspan="3">Proportion of export spillover<sup>b</sup> (%)</td></tr><tr><td>1997</td><td>2002</td><td>2007</td><td>1997</td><td>2002</td><td>2007</td></tr><tr><td colspan="7"><i>Eastern provinces</i></td></tr><tr><td>Beijing</td><td>127</td><td>237</td><td>1211</td><td>27</td><td>34</td><td>38</td></tr><tr><td>Tianjin</td><td>136</td><td>306</td><td>858</td><td>39</td><td>40</td><td>48</td></tr><tr><td>Hebei</td><td>77</td><td>115</td><td>562</td><td>33</td><td>34</td><td>45</td></tr><tr><td>Shanghai</td><td>334</td><td>518</td><td>2234</td><td>31</td><td>24</td><td>34</td></tr><tr><td>Jiangsu</td><td>340</td><td>495</td><td>2563</td><td>31</td><td>19</td><td>26</td></tr><tr><td>Zhejiang</td><td>173</td><td>784</td><td>3148</td><td>20</td><td>36</td><td>39</td></tr><tr><td>Fujian</td><td>174</td><td>185</td><td>868</td><td>22</td><td>16</td><td>26</td></tr><tr><td>Shandong</td><td>172</td><td>269</td><td>1019</td><td>18</td><td>18</td><td>17</td></tr><tr><td>Guangdong</td><td>1457</td><td>1430</td><td>6078</td><td>33</td><td>24</td><td>34</td></tr><tr><td>Hainan</td><td>21</td><td>11</td><td>18</td><td>28</td><td>28</td><td>13</td></tr><tr><td colspan="7"><i>Central provinces</i></td></tr><tr><td>Shanxi</td><td>45</td><td>25</td><td>76</td><td>27</td><td>13</td><td>15</td></tr><tr><td>Anhui</td><td>53</td><td>69</td><td>240</td><td>34</td><td>38</td><td>41</td></tr><tr><td>Jiangxi</td><td>21</td><td>21</td><td>90</td><td>22</td><td>27</td><td>24</td></tr><tr><td>Henan</td><td>32</td><td>34</td><td>145</td><td>20</td><td>18</td><td>23</td></tr><tr><td>Hubei</td><td>36</td><td>27</td><td>103</td><td>19</td><td>18</td><td>19</td></tr><tr><td>Hunan</td><td>38</td><td>26</td><td>117</td><td>25</td><td>19</td><td>28</td></tr><tr><td colspan="7"><i>Western provinces</i></td></tr><tr><td>Inner Mongolia</td><td>18</td><td>14</td><td>49</td><td>28</td><td>20</td><td>20</td></tr><tr><td>Guangxi</td><td>42</td><td>46</td><td>102</td><td>25</td><td>33</td><td>26</td></tr><tr><td>Chongqing</td><td>18</td><td>35</td><td>96</td><td>32</td><td>42</td><td>35</td></tr><tr><td>Sichuan</td><td>27</td><td>35</td><td>79</td><td>16</td><td>17</td><td>17</td></tr><tr><td>Guizhou</td><td>15</td><td>10</td><td>47</td><td>34</td><td>22</td><td>36</td></tr><tr><td>Yunnan</td><td>30</td><td>17</td><td>35</td><td>24</td><td>20</td><td>23</td></tr><tr><td>Shaanxi</td><td>37</td><td>2</td><td>128</td><td>32</td><td>32</td><td>36</td></tr><tr><td>Gansu</td><td>10</td><td>38</td><td>101</td><td>33</td><td>33</td><td>25</td></tr><tr><td>Qinghai</td><td>5</td><td>12</td><td>10</td><td>39</td><td>41</td><td>17</td></tr><tr><td>Ningxia</td><td>6</td><td>4</td><td>37</td><td>34</td><td>37</td><td>32</td></tr><tr><td>Xinjiang</td><td>12</td><td>19</td><td>46</td><td>28</td><td>22</td><td>17</td></tr><tr><td colspan="7"><i>Northeastern provinces</i></td></tr><tr><td>Liaoning</td><td>122</td><td>175</td><td>596</td><td>19</td><td>20</td><td>28</td></tr><tr><td>Jilin</td><td>36</td><td>55</td><td>98</td><td>27</td><td>38</td><td>39</td></tr><tr><td>Heilongjiang</td><td>69</td><td>33</td><td>76</td><td>23</td><td>18</td><td>21</td></tr></table> |
d50b5112afd96b229fd7aa1894517f6ff62601acb88cea6b4a5c6146bb2d9f8c.png | simple | <table><tr><td>Nanoparticle (NP)</td><td>Size of NP (nm)</td><td>Ligand/receptor</td><td>Drug/agent</td><td>Method to trace NP/drug/agent</td><td>Ref.</td></tr><tr><td>Polymer</td><td>70</td><td>Protein/TfR</td><td>siRNA</td><td>PCR</td><td>[236]</td></tr><tr><td>Liposome</td><td>ns</td><td>Ab/TfR</td><td>p53</td><td>p53 via PCR</td><td>[271]</td></tr></table> |
1fdf5cc02e2cd63dcbed47cf782aee47cd443d285d8527febf52698b517f2b9b.png | simple | <table><tr><td>No of patients</td><td>61</td></tr><tr><td>No of CTCs</td><td>1262</td></tr><tr><td>Age</td><td></td></tr><tr><td>Median (range)</td><td>62 (23–82)</td></tr><tr><td></td><td>N (%)</td></tr><tr><td>Menopausal status</td><td></td></tr><tr><td>Pre</td><td>17 (27.9)</td></tr><tr><td>Post</td><td>41 (67.2)</td></tr><tr><td>UN</td><td>3 (4.9)</td></tr><tr><td>ER</td><td></td></tr><tr><td>Positive</td><td>38 (62.3)</td></tr><tr><td>Negative</td><td>20 (32.8)</td></tr><tr><td>UN</td><td>3 (4.9)</td></tr><tr><td>PR</td><td></td></tr><tr><td>Positive</td><td>30 (49.2)</td></tr><tr><td>Negative</td><td>28 (45.9)</td></tr><tr><td>UN</td><td>3 (4.9)</td></tr><tr><td>HER 2</td><td></td></tr><tr><td>Positive</td><td>14 (22.9)</td></tr><tr><td>Negative</td><td>44 (72.1)</td></tr><tr><td>UN</td><td>3 (4.9)</td></tr><tr><td>Triple negative</td><td>11 (18.0)</td></tr><tr><td>Histology grade</td><td></td></tr><tr><td>1</td><td>1 (1.6)</td></tr><tr><td>2</td><td>16 (26.2)</td></tr><tr><td>3</td><td>26 (42.6)</td></tr><tr><td>UN</td><td>18 (29.5)</td></tr><tr><td>No of CTCs/patients</td><td></td></tr><tr><td>Median (range)</td><td>2- 162</td></tr><tr><td>2-4</td><td>21 (34.4)</td></tr><tr><td>≥5</td><td>40 (65.6)</td></tr></table> |
518bfe87f3e91e5326787751b52c0bf3265c0e144f62e579ac88ec1d0c4dd822.png | simple | <table><tr><td><i>V. albo</i>-<i>atrum</i></td><td><i>V. longisporum</i></td><td><i>V. dahliae</i></td><td><i>V. tricorpus</i></td></tr><tr><td>234</td><td>Bob-7</td><td>2341</td><td>2933</td></tr><tr><td>CBS-8</td><td>Vd-1</td><td>330</td><td>2901 A</td></tr><tr><td>CBS-7</td><td>43-3</td><td>G12-1</td><td>CBS-12</td></tr><tr><td>2934</td><td>Vd-11</td><td>Vd-7</td><td>1901</td></tr><tr><td></td><td></td><td>G12-2</td><td></td></tr></table> |
f543e49c5456183e74dade077398df80164a534b76f7371ce58af83be5e1b197.png | complex | <table><tr><td>Factor</td><td>Category</td><td>Attendees</td><td>Non-attendees</td><td>OR (95 % CI)</td><td>OR (95 % CI)</td><td>OR (95 % CI)</td></tr><tr><td></td><td></td><td><i>N</i> (%)</td><td><i>N</i> (%)</td><td>Crude</td><td>Age-adjusted</td><td>Adjusted<sup>a</sup></td></tr><tr><td rowspan="3">Cancer in family</td><td>No</td><td>647 (48.7)</td><td>57 (46.0)</td><td>1.00 (reference)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td>Yes</td><td>681 (51.3)</td><td>67 (54.0)</td><td>1.12 (0.77–1.61)</td><td>1.12 (0.77–1.62)</td><td>1.10 (0.76–1.60)</td></tr><tr><td>Missing</td><td>0</td><td>0</td><td>–</td><td>–</td><td>–</td></tr><tr><td rowspan="3">Cancer in close relations</td><td>No</td><td>656 (49.4)</td><td>62 (50.0)</td><td>1.00 (reference)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td>Yes</td><td>672 (50.6)</td><td>62 (50.0)</td><td>0.98 (0.68–1.41)</td><td>1.04 (0.72–1.51)</td><td>1.07 (0.74–1.56)</td></tr><tr><td>Missing</td><td>0</td><td>0</td><td>–</td><td>–</td><td>–</td></tr><tr><td rowspan="3">Breast cancer in family</td><td>No</td><td>1144 (86.1)</td><td>104 (83.9)</td><td>1.00 (reference)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td>Yes</td><td>184 (13.9)</td><td>20 (16.1)</td><td>1.20 (0.72–1.98)</td><td>1.17 (0.71–1.94)</td><td>1.18 (0.72–1.97)</td></tr><tr><td>Missing</td><td>0</td><td>0</td><td>–</td><td>–</td><td>–</td></tr><tr><td rowspan="3">Breast cancer in close relations</td><td>No</td><td>761 (57.3)</td><td>74 (59.7)</td><td>1.00 (reference)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td>Yes</td><td>567 (43.1)</td><td>50 (40.3)</td><td>0.91 (0.62–1.32)</td><td>0.98 (0.67–1.43)</td><td>1.04 (0.71–1.53)</td></tr><tr><td>Missing</td><td>0</td><td>0</td><td>–</td><td>–</td><td>–</td></tr><tr><td rowspan="3">Have had cancer</td><td>No</td><td>994 (74.8)</td><td>89 (71.8)</td><td>1.00 (reference)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td>Yes</td><td>334 (25.2)</td><td>35(28.2)</td><td>1.17 (0.78–1.76)</td><td>1.16 (0.77–1.75)</td><td>1.16 (0.77–1.75)</td></tr><tr><td>Missing</td><td>0</td><td>0</td><td>–</td><td>–</td><td>–</td></tr><tr><td rowspan="3">Have had breast cancer</td><td>No</td><td>1224 (92.2)</td><td>120 (96.8)</td><td>1.00 (reference)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td>Yes</td><td>104 (7.8)</td><td>4 (3.2)</td><td>0.39 (0.14–1.08)</td><td>0.40 (0.14–1.10)</td><td>0.41 (0.15–1.15)</td></tr><tr><td>Missing</td><td>0</td><td>0</td><td>–</td><td>–</td><td>–</td></tr></table> |
bbb77184b6e62b058840928c3e629725e33cf851d8959a7091e9b1bc80c88b5b.png | complex | <table><tr><td> </td><td colspan="7"><i>Percentage of cell positive for MHC class II</i></td></tr><tr><td><i>MSCs: horse (ELA haplotype; age)</i></td><td>P2</td><td>P3</td><td>P4</td><td>P5</td><td>P6</td><td>P7</td><td>P8</td></tr><tr><td>1 (A3; 20 years)</td><td>58.36</td><td>54.67</td><td>63.07</td><td>53.54</td><td>46.22</td><td>51.72</td><td>38.44</td></tr><tr><td>2 (A2; 12 years)</td><td>59.95</td><td>78.58</td><td>98.14</td><td>97.25</td><td>91.45</td><td>94.47</td><td>97.62</td></tr><tr><td>3 (A3; 3 years)</td><td>70.31</td><td>1.53</td><td>1.35</td><td>1.75</td><td>0.86</td><td>0.85</td><td>0.68</td></tr><tr><td>3 (A3; 3 years) 2nd harvest</td><td>76.09</td><td>65.22</td><td>59.74</td><td>64.83</td><td>50.49</td><td>48.56</td><td>45.14</td></tr><tr><td>4 (A2; 3 years)</td><td>32.42</td><td>8.19</td><td>4.03</td><td>4.52</td><td>2.56</td><td>0.49</td><td>0.50</td></tr><tr><td>4 (A2; 3 years) 2nd harvest</td><td>82.60</td><td>59.25</td><td>56.05</td><td>65.31</td><td>64.85</td><td>67.08</td><td>68.96</td></tr><tr><td>5 (A3; 6 years)</td><td>0.18</td><td>0.57</td><td>0.29</td><td>0.77</td><td>0.44</td><td>0.08</td><td>1.38</td></tr><tr><td>5 (A3; 6 years) 2nd harvest</td><td>10.05</td><td>1.05</td><td>0.90</td><td>1.59</td><td>0.47</td><td>0.51</td><td>0.45</td></tr><tr><td>6 (A2; 5 years)</td><td>70.68</td><td>72.32</td><td>64.62</td><td>22.10</td><td>2.32</td><td>1.93</td><td>1.29</td></tr><tr><td>7 (A3; 19 years)</td><td>74.67</td><td>66.49</td><td>93.13</td><td>94.54</td><td>93.68</td><td>93.33</td><td>95.43</td></tr><tr><td>8 (A9; 11 years)</td><td>74.36</td><td>71.32</td><td>67.04</td><td>41.82</td><td>25.97</td><td>8.16</td><td>0.90</td></tr><tr><td>9 (A2; 6 years)</td><td>58.75</td><td>41.79</td><td>4.92</td><td>0.78</td><td>0.76</td><td>0.48</td><td>0.46</td></tr><tr><td>10 (A2; 5 years)</td><td>98.35</td><td>91.92</td><td>95.69</td><td>96.15</td><td>94.89</td><td>91.39</td><td>85.01</td></tr></table> |
7c7d344aad90ac4a09c99f75a28ff5c82cfe34cac28eaafb12a6ebd34e990f3b.png | simple | <table><tr><td>Essential public health operation</td><td>Climate change and foodborne pathogens example</td></tr><tr><td>1: Food and foodborne disease surveillance</td><td>Enhanced cross country surveillance through the establishment of the European Centre for Disease Prevention and Control. This is tasked with collecting, examining and disseminating surveillance data on over 50 infectious diseases from EU and European Economic Area</td></tr><tr><td>2: Monitoring and response to food and health hazards and emergencies</td><td>Bodies such as INFOSAN, through which the WHO, enable countries to rapidly share information during food safety emergencies to limit the spread of food hazards</td></tr><tr><td>3: Health protection including food safety and others</td><td>Regulations including EU General Food Law which specifies the general principles that food producers and retailers should adhere to in order to provide safe food. It also ensures the traceability of food and outlines measures detailing how unsafe food should be withdrawn or recalled</td></tr><tr><td>4: Health promotion including action to address social determinants and health inequity</td><td>Health promotion campaigns to inform, educate and empower people about health issues that may be associated with climate change</td></tr><tr><td>5: Food and foodborne disease prevention, including early detection of illness</td><td>Enhance use of rapid diagnostic techniques, such as real-time PCR for rapid and hence early detection of foodborne pathogens</td></tr><tr><td>6: Assuring governance for health and wellbeing</td><td>Organisations such as the Med-Vet-Net Association for Zoonoses Research which promote cross national and multidisciplinary approaches bringing together veterinary, medical and food scientists</td></tr><tr><td>7: Assuring a sufficient and competent public health workforce</td><td>Support by organisations such as the WHO and ECDC for materials and activities which increase awareness and build capacity within countries to understand and prevent the negative impacts of climate change on health</td></tr><tr><td>8: Assuring sustainable organisational structures and financing</td><td>Long-term and sustainable funding for measures to prevent climate-sensitive foodborne diseases</td></tr><tr><td>9: Advocacy communication and social mobilisation for health</td><td>The European Strategy for the control of non-communicable diseases which highlights the importance of patient empowerment and patient’s rights</td></tr><tr><td>10: Advancing public health research to inform policy and practice</td><td>UK funding for a series of Health Protection Research Units (HPRUs); partnerships between academics and public health practitioners. The Environmental Change and Health HPRU is tasked with the joint development of knowledge, foresight and tools to mitigate against and adapt to environmental change</td></tr></table> |
dca4d18a7bab8b4d6ee41162be88d556cf6fc959d9488de9bc7652ced3bd278e.png | complex | <table><tr><td rowspan="3">Parental Dietary Pattern</td><td colspan="9">Children’s Dietary Pattern</td></tr><tr><td colspan="3">Sweet & Fat </td><td colspan="3">Ref. Cereals</td><td colspan="3">Animal Products</td></tr><tr><td><i>N</i></td><td>OR</td><td>95%CI</td><td><i>N</i></td><td>OR</td><td>95%CI</td><td><i>N</i></td><td>OR</td><td>95%CI</td></tr><tr><td>Maternal dietary pattern (<i>N</i> = 1607)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Different & soft drink not available (reference)</td><td>742</td><td>1.00</td><td></td><td>1017</td><td>1.00</td><td></td><td>767</td><td>1.00</td><td></td></tr><tr><td>Different & soft drink is available</td><td>138</td><td>1.97</td><td>1.20; 3.25</td><td>294</td><td>0.46</td><td>0.25; 0.84</td><td>256</td><td>0.95</td><td>0.65; 1.38</td></tr><tr><td>Identical & soft drink not available</td><td>521</td><td>2.04</td><td>1.49; 2.80</td><td>246</td><td>2.48</td><td>1.43; 4.27</td><td>496</td><td>2.16</td><td>1.59; 2.92</td></tr><tr><td>Identical & soft drink is available</td><td>206</td><td>2.78</td><td>1.80; 4.28</td><td>50</td><td>1.67</td><td>0.66; 4.22</td><td>88</td><td>1.42</td><td>0.82; 2.47</td></tr><tr><td>Paternal dietary pattern (<i>N</i> = 763)</td><td></td><td></td><td colspan="4"></td><td></td><td></td><td></td></tr><tr><td>Different & soft drink not available (reference)</td><td>465</td><td>1.00</td><td></td><td>407</td><td>1.00</td><td></td><td>360</td><td>1.00</td><td></td></tr><tr><td>Different & soft drink is available</td><td>92</td><td>1.55</td><td>0.90; 2.68</td><td>122</td><td>0.43</td><td>0.18; 1.04</td><td>80</td><td>0.83</td><td>0.45; 1.52</td></tr><tr><td>Identical & soft drink not available</td><td>151</td><td>2.48</td><td>1.58; 3.87</td><td>209</td><td>2.05</td><td>1.22; 3.45</td><td>256</td><td>2.48</td><td>1.62; 3.79</td></tr><tr><td>Identical & soft drink is available</td><td>55</td><td>4.26</td><td>2.16; 8.41</td><td>25</td><td>1.97</td><td>0.61; 6.39</td><td>67</td><td>1.80</td><td>0.96; 3.36</td></tr></table> |
ecd2b9a3146c106f8b54927e8183f65fb34dc197acf2f33ca9c97940f05acc85.png | complex | <table><tr><td rowspan="2">Variables</td><td colspan="5">Quintiles of household income per capita (mean values)</td><td rowspan="2">Brazil</td></tr><tr><td>1st</td><td>2nd</td><td>3rd</td><td>4th</td><td>5th</td></tr><tr><td>Area (%)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Rural</td><td>31.1</td><td>18.5</td><td>14.6</td><td>9.0</td><td>4.7</td><td>15.6</td></tr><tr><td> Urban</td><td>68.9</td><td>81.5</td><td>85.4</td><td>91.0</td><td>95.3</td><td>84.4</td></tr><tr><td>Region (%)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> North and Northeast</td><td>61.4</td><td>40.2</td><td>28.3</td><td>19.0</td><td>15.8</td><td>33.0</td></tr><tr><td> Mid-South</td><td>38.6</td><td>59.8</td><td>71.7</td><td>81.0</td><td>84.2</td><td>67.1</td></tr><tr><td>Number of dwellers in households</td><td>4.5</td><td>3.7</td><td>3.0</td><td>2.8</td><td>2.5</td><td>3.3</td></tr><tr><td>Proportion of children under 2 years of age in family unit (%)</td><td>6.4</td><td>4.0</td><td>2.5</td><td>1.9</td><td>1.4</td><td>3.2</td></tr><tr><td>Proportion of children 2–9 years of age in family unit (%)</td><td>17.2</td><td>11.2</td><td>6.9</td><td>5.6</td><td>3.7</td><td>8.9</td></tr><tr><td>Proportion of adolescents (10–19 years) in family unit (%)</td><td>23.0</td><td>18.1</td><td>12.3</td><td>9.7</td><td>7.5</td><td>14.1</td></tr><tr><td>Proportion of elderly (65 years or older) in family unit (%)</td><td>2.6</td><td>7.1</td><td>16.8</td><td>15.9</td><td>15.7</td><td>11.6</td></tr><tr><td>Proportion of women in family unit (%)</td><td>50.7</td><td>51.3</td><td>51.6</td><td>52.7</td><td>52.6</td><td>51.8</td></tr><tr><td>Monthly household income per capita (US$)</td><td>97.22</td><td>213.22</td><td>353.00</td><td>591.38</td><td>1968.82</td><td>644.70</td></tr><tr><td>Proportion of monthly household income per capita dedicated to monthly medicine expenses per capita (out-of-pocket expenditure) (%)</td><td>5.1</td><td>3.6</td><td>3.3</td><td>2.9</td><td>2.0</td><td>3.4</td></tr></table> |
324d0baf45ae208d0950fd2ddf6ba289ba321a79439211f254e0bb2de7494553.png | simple | <table><tr><td>Threshold</td><td>False positives</td><td>True positives</td></tr><tr><td>0</td><td>21.2%</td><td>89.5%</td></tr><tr><td>5</td><td>16.9%</td><td>86.3%</td></tr><tr><td>10</td><td>13.5%</td><td>85.1%</td></tr><tr><td>15</td><td>10.7%</td><td>82.8%</td></tr><tr><td>20</td><td>8.5%</td><td>81.1%</td></tr></table> |
c1c9862447ff78fcf60b338b12577e70c86e43bea49833460d7a56c556247a9e.png | complex | <table><tr><td colspan="2">Additional inclusion criteria</td></tr><tr><td>Pain intensity of 20 mm or more by VAS in the previous 48 hours when walking on a flat surface;At least grade II to III on the Kellgren-Lawrence scale by an X-ray taken within 6 months;</td><td>And reluctant to continue on previous drug but willing to change drug treatment.</td></tr><tr><td>Exclusion criteria</td><td></td></tr><tr><td colspan="2">Patients presenting with any of the following will be excluded from the study.</td></tr><tr><td>Grade I or Grade IV severity of the index knee based on the Kellgren and Lawrence radiographic criteria as applicable;Use of intra-articular injections or arthroscopy of the index knee within 3 months prior to screening;Evidence of crystalline-induced synovitis in the index knee;History, physical examination, or radiographic results suggestive of acute inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, septic arthritis, gout, pseudogout, fibromyalgia, systemic lupus erythematosus, or other types of inflammatory arthritis of the index knee;Pain in either knee of neurologic origin;</td><td>Signs of clinically important active inflammation in the index knee joint including redness, warmth, and/or a large, bulging effusion with the loss of normal contour at the screening and/or baseline visits;History of acute inflammatory arthritis or pseudogout of the study joint;Cancer/metastatic disease;Systemic or intra-articular corticosteroid use within 60 days of the Screening visit;Known sensitivity to any of the ingredients listed in the treatments under investigation;Significant medical and skin conditions which, in the opinion of the investigator, will interfere with study participation and patch adherence;Replacement of the knee joint.</td></tr></table> |
e250d46804dd00b1686f41a4fceb53f1ec25381c3f6ff4ffd256662ffe297628.png | simple | <table><tr><td>Pathway name</td><td>No. genes*</td><td>ES</td><td>NES</td><td>FDR<i>q </i>value</td></tr><tr><td>PHONG_TNF_RESPONSE_VIA_P38_COMPLETE</td><td>13</td><td>0.583</td><td>1.743</td><td>0.580</td></tr><tr><td>DELYS_THYROID_CANCER_DN</td><td>11</td><td>0.612</td><td>1.748</td><td>0.599</td></tr><tr><td>CORRE_MULTIPLE_MYELOMA_DN</td><td>3</td><td>0.897</td><td>1.733</td><td>0.603</td></tr><tr><td>SHEPARD_BMYB_MORPHOLINO_UP</td><td>10</td><td>0.609</td><td>1.712</td><td>0.617</td></tr><tr><td>LI_INDUCED_T_TO_NATURAL_KILLER_UP</td><td>17</td><td>0.537</td><td>1.724</td><td>0.617</td></tr><tr><td>WILCOX_PRESPONSE_TO_ROGESTERONE_UP</td><td>6</td><td>0.705</td><td>1.700</td><td>0.621</td></tr><tr><td>WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN</td><td>13</td><td>0.562</td><td>1.674</td><td>0.632</td></tr><tr><td>KEGG_RENIN_ANGIOTENSIN_SYSTEM</td><td>3</td><td>0.932</td><td>1.761</td><td>0.632</td></tr><tr><td>OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_DN</td><td>11</td><td>0.605</td><td>1.751</td><td>0.633</td></tr><tr><td>REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION</td><td>16</td><td>0.535</td><td>1.685</td><td>0.644</td></tr></table> |
27afb5d6c4117421aea6c7dc5b1849ef4945f58e6be4693434eabc8ef662922e.png | simple | <table><tr><td>N = 7</td><td>Mean</td><td>SD</td><td>Range</td></tr><tr><td>Age [yrs]</td><td>71.3</td><td>8.3</td><td>59-85</td></tr><tr><td>Height [cm]</td><td>171</td><td>5.6</td><td>163.0-177.0</td></tr><tr><td>Weight [kg]</td><td>70.85</td><td>10.1</td><td>58.0-90.0</td></tr><tr><td>BMI [kg/m<sup>2</sup>]</td><td>25.1</td><td>4.5</td><td>21.7-33.9</td></tr><tr><td>MOCA [0-30]</td><td>21.4</td><td>1.4</td><td>20-24</td></tr><tr><td>Age of disease onset [yrs]</td><td>61.0</td><td>2.6</td><td>47-70</td></tr><tr><td>Duration of disease [yrs]</td><td>10.3</td><td>5.7</td><td>4-19</td></tr><tr><td>Hoehn and Yahr</td><td>2.5</td><td>0.5</td><td>2-3</td></tr></table> |
3fc626c5025803112d7d3c147679e9a071f35a90c60d9c65df957e465ffa40a2.png | simple | <table><tr><td></td><td>Harar HDSS</td><td>Kersa HDSS</td><td>Oromia*</td><td>Ethiopia*</td></tr><tr><td>TFR</td><td>1.9</td><td>5.3</td><td>4.85</td><td>4.8</td></tr><tr><td>GFR</td><td>64</td><td>166.8</td><td>153.30</td><td>128.80</td></tr><tr><td>CBR</td><td>20.3</td><td>37.2</td><td>33.90</td><td>30.10</td></tr></table> |
daa89b1add79dcd4fc7b967f7c09d6f2db8560be5a27fdc2b41bbafb9c822e28.png | complex | <table><tr><td></td><td colspan="2">AMSA NaCl</td><td colspan="2">AMSA EPI All</td><td>P-value</td><td colspan="2">AMSA EPI 0.02 mg/kg/dose</td><td>P-value</td><td colspan="2">AMSA EPI 0.03 mg/kg/dose</td><td>P-value</td></tr><tr><td>MCC 20 s</td><td>12.1</td><td>(9.6-14.0)<sup>b</sup></td><td>13.0</td><td>(10.9-16.0)<sup>d</sup></td><td>0.4099</td><td>13.0</td><td>(11.8-13.0)<sup>c</sup></td><td>0.3913</td><td>13.1</td><td>(10.6-15.0)<sup>a</sup></td><td>0.5752</td></tr><tr><td>MCC 60 s</td><td>12.4</td><td>(10.8-15.3)<sup>b</sup></td><td>14.4</td><td>(11.4-16.8)<sup>d</sup></td><td>0.4990</td><td>13.7</td><td>(10.8-17.6)<sup>c</sup></td><td>0.7751</td><td>14.6</td><td>(13.0-15.8)<sup>a</sup></td><td>0.4288</td></tr><tr><td>MCC 120 s</td><td>13.8</td><td>(12.1-16.3)<sup>b</sup></td><td>16.0</td><td>(14.2-18.7)<sup>d</sup></td><td>0.1974</td><td>16.0</td><td>(14.2-19.8)<sup>c</sup></td><td>0.1779</td><td>15.5</td><td>(13.8-17.6)<sup>a</sup></td><td>0.3734</td></tr><tr><td>MCC 180 s</td><td>14.7</td><td>(13.3-17.9)<sup>b</sup></td><td>17.0</td><td>(12.8-19.0)<sup>d</sup></td><td>0.3749</td><td>17.0</td><td>(12.8-19.3)<sup>c</sup></td><td>0.4877</td><td>17.0</td><td>(15.3-18.3)<sup>a</sup></td><td>0.4288</td></tr><tr><td>Inj #1</td><td>14.3</td><td>(12.7-16.8)<sup>b</sup></td><td>15.9</td><td>(13.9-16.7)<sup>d</sup></td><td>0.4725</td><td>15.4</td><td>(9.7-16.7)<sup>c</sup></td><td>0.4142</td><td>16.1</td><td>(13.3-16.7)<sup>a</sup></td><td>0.6682</td></tr><tr><td>Peak #1</td><td>14.7</td><td>(11.5-15.9)<sup>b</sup></td><td>14.6</td><td>(13.0-16.2)<sup>d</sup></td><td>0.6121</td><td>14.6</td><td>(13.8-15.9)<sup>c</sup></td><td>0.7133</td><td>14.7</td><td>(12.7-16.2)<sup>a</sup></td><td>0.6444</td></tr><tr><td>Inj #2</td><td>13.9</td><td>(11.0-15.4)<sup>b</sup></td><td>14.0</td><td>(11.6-14.5)<sup>d</sup></td><td>0.8824</td><td>14.3</td><td>(13.0-14.9)<sup>c</sup></td><td>0.7751</td><td>13.8</td><td>(11.6-14.3)<sup>a</sup></td><td>0.6209</td></tr><tr><td>Peak #2</td><td>13.5</td><td>(10.4-14.7)<sup>b</sup></td><td>12.5</td><td>(11.0-14.6)<sup>d</sup></td><td>1.0000</td><td>13.1</td><td>(11.9-17.5)<sup>c</sup></td><td>0.5956</td><td>12.2</td><td>(10.4-13.9)<sup>a</sup></td><td>0.6682</td></tr><tr><td>Inj #3</td><td>13.7</td><td>(11.4-14.8)<sup>b</sup></td><td>11.5</td><td>(9.7-13.8)<sup>d</sup></td><td>0.2285</td><td>11.5</td><td>(10.2-20.9)<sup>c</sup></td><td>0.5676</td><td>11.2</td><td>(9.5-11.7)<sup>a</sup></td><td>0.1616</td></tr><tr><td>Peak #3</td><td>12.7</td><td>(10.6-15.5)<sup>b</sup></td><td>12.5</td><td>(11.1-14.5)<sup>d</sup></td><td>0.9831</td><td>13.1</td><td>(10.2-20.9)<sup>c</sup></td><td>0.5954</td><td>12.2</td><td>(11.3-14.3)<sup>a</sup></td><td>0.7169</td></tr><tr><td>Inj # 4</td><td>13.9</td><td>(11.3-15.3)<sup>b</sup></td><td>11.0</td><td>(9.7-13.5)<sup>d</sup></td><td>0.1696</td><td>11.8</td><td>(10.5-14.3)<sup>c</sup></td><td>0.6534</td><td>10.6</td><td>(8.8-12.2)<sup>a</sup></td><td>0.0806</td></tr><tr><td>Peak #4</td><td>14.0</td><td>(11.4-15.3)<sup>e</sup></td><td>11.0</td><td>(8.9-15.9)<sup>d</sup></td><td>0.8841</td><td>16.8</td><td>(9.9-11.1)<sup>c</sup></td><td>0.3165</td><td>9.9</td><td>(8.8-14.3)<sup>a</sup></td><td>0.2814</td></tr></table> |
a6ce7ec5aee044977a4823a675d9d9a4cca994919033c4b400ef8421e183bfe3.png | simple | <table><tr><td>Reference value</td><td>day 1</td><td>day 2</td><td>day 5</td><td>day 8</td><td>day 11</td><td>day 15</td><td>day 21</td><td>day 28</td></tr><tr><td>PLT:100–400 *10<sup>9</sup>/L</td><td>48</td><td>37</td><td>12</td><td>106</td><td>173</td><td>177</td><td>212</td><td><i>268</i></td></tr><tr><td>HB:110–155 g/L</td><td>79</td><td>75</td><td>85</td><td>86</td><td>87</td><td>91</td><td>105</td><td><i>119</i></td></tr><tr><td>ESR:0–20 mm/h</td><td></td><td>56</td><td>122</td><td>124</td><td>111</td><td>119</td><td>78</td><td><i>64</i></td></tr><tr><td>CRP: < 1 mg/L</td><td>> 160</td><td></td><td>44</td><td>14</td><td>< 1</td><td>< 1</td><td></td><td><i>< 1</i></td></tr><tr><td>GPT:5–50 U/L</td><td>64</td><td></td><td></td><td>1645</td><td>642</td><td>183</td><td>90</td><td><i>109</i></td></tr><tr><td><i>GOT:</i>5–55 U/L</td><td>35</td><td></td><td></td><td>866</td><td>142</td><td>48</td><td>93</td><td><i>79</i></td></tr><tr><td><i>GGT:5–50 U/L</i></td><td><i>15</i></td><td></td><td></td><td><i>182</i></td><td><i>107</i></td><td><i>57</i></td><td><i>38</i></td><td><i>29</i></td></tr></table> |
f6703c5eb83b9bc287e43862e7bdb2bb7c7e6cc38fef8c9c73a5d560412d9699.png | complex | <table><tr><td rowspan="3">Model description</td><td rowspan="3">Category</td><td rowspan="3">Numberof deaths</td><td rowspan="3">Person-years</td><td colspan="2">SPM (μg/m<sup>3</sup>)</td><td colspan="2">PM<sub>2.5</sub> (μg/m<sup>3</sup>)<sup>b</sup></td><td colspan="2">SO<sub>2</sub> (ppb)</td><td colspan="2">NO<sub>2</sub> (ppb)</td></tr><tr><td>HR</td><td>95% CI</td><td>HR</td><td>95% CI</td><td>HR</td><td>95% CI</td><td>HR</td><td>95% CI</td></tr><tr><td>Sex- and age-adjusted</td><td>(All)</td><td>518</td><td>550 339</td><td>1.18</td><td>(1.13–1.24)</td><td>1.27</td><td>(1.19–1.36)</td><td>1.36</td><td>(1.20–1.54)</td><td>1.20</td><td>(1.17–1.24)</td></tr><tr><td>Base model<sup>c</sup></td><td>(All)</td><td>518</td><td>550 339</td><td>1.16</td><td>(1.08–1.25)</td><td>1.24</td><td>(1.12–1.37)</td><td>1.26</td><td>(1.07–1.48)</td><td>1.17</td><td>(1.10–1.26)</td></tr><tr><td>Full model<sup>d</sup></td><td>(All)</td><td>421</td><td>472 762</td><td>1.16</td><td>(1.06–1.25)</td><td>1.23</td><td>(1.09–1.38)</td><td>1.19</td><td>(0.97–1.45)</td><td>1.15</td><td>(1.06–1.24)</td></tr><tr><td>By sex<sup>e</sup></td><td>Male</td><td>407</td><td>257 120</td><td>1.17</td><td>(1.09–1.26)</td><td>1.26</td><td>(1.14–1.39)</td><td>1.30</td><td>(1.12–1.52)</td><td>1.18</td><td>(1.11–1.26)</td></tr><tr><td> </td><td>Female</td><td>111</td><td>293 219</td><td>1.12</td><td>(0.99–1.26)</td><td>1.17</td><td>(0.98–1.39)</td><td>1.11</td><td>(0.88–1.40)</td><td>1.13</td><td>(1.01–1.27)</td></tr><tr><td>By sex and smoking status<sup>f</sup></td><td>Male current smokers</td><td>292</td><td>146 031</td><td>1.23</td><td>(1.14–1.34)</td><td>1.35</td><td>(1.20–1.52)</td><td>1.36</td><td>(1.06–1.75)</td><td>1.23</td><td>(1.12–1.35)</td></tr><tr><td> </td><td>Male former smokers</td><td>90</td><td>63 092</td><td>1.08</td><td>(0.83–1.39)</td><td>1.11</td><td>(0.77–1.60)</td><td>1.25</td><td>(0.75–2.10)</td><td>1.13</td><td>(0.88–1.44)</td></tr><tr><td> </td><td>Female never smokers</td><td>73</td><td>254 145</td><td>1.11</td><td>(1.01–1.22)</td><td>1.16</td><td>(1.02–1.33)</td><td>1.09</td><td>(0.92–1.29)</td><td>1.11</td><td>(1.02–1.20)</td></tr><tr><td>Base model, excluding participants with a history of respiratory diseases<sup>c,g</sup></td><td>(No history of respiratory disease)</td><td>438</td><td>509 369</td><td>1.15</td><td>(1.06–1.26)</td><td>1.23</td><td>(1.08–1.39)</td><td>1.22</td><td>(1.02–1.45)</td><td>1.16</td><td>(1.07–1.25)</td></tr><tr><td>Base model, using average concentrations during the follow-up period<sup>c,h</sup></td><td>(All)</td><td>518</td><td>550 339</td><td>1.27</td><td>(1.14–1.41)</td><td>1.41</td><td>(1.21–1.64)</td><td>1.97</td><td>(1.41–2.75)</td><td>1.21</td><td>(1.10–1.33)</td></tr></table> |
b6fd683eab5ed5190ef352e78ff21f19a188c3f725e59e1a3e437ae706fb88e4.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">IMRT</td><td colspan="2">3DRT</td></tr><tr><td>Mean maximum</td><td>Mean average</td><td>Mean maximum</td><td>Mean average</td></tr><tr><td colspan="5">Tongue cancer</td></tr><tr><td colspan="5"> Lower teeth</td></tr><tr><td>Anterior</td><td>56.9</td><td>42.8</td><td>36.4</td><td>32.5</td></tr><tr><td>Pre-molars</td><td>51.5</td><td>43.6</td><td>56.9</td><td>49.5</td></tr><tr><td>Molars</td><td>50.8</td><td>42.3</td><td>64.7</td><td>59.1</td></tr><tr><td colspan="5"> Upper teeth</td></tr><tr><td>Anterior</td><td>41.0</td><td>26.4</td><td>23.7</td><td>19.0</td></tr><tr><td>Pre-molars</td><td>42.7</td><td>36.1</td><td>20.9</td><td>16.8</td></tr><tr><td>Molars</td><td>47.5</td><td>36.7</td><td>43.7</td><td>37.7</td></tr><tr><td colspan="5">Oral cavity cancer</td></tr><tr><td colspan="5"> Lower teeth</td></tr><tr><td>Anterior</td><td>47.0</td><td>34.6</td><td>48.9</td><td>43.7</td></tr><tr><td>Pre-molars</td><td>43.5</td><td>37.2</td><td>46.1</td><td>39.9</td></tr><tr><td>Molars</td><td>46.3</td><td>39.2</td><td>66.8</td><td>51.6</td></tr><tr><td colspan="5"> Upper teeth</td></tr><tr><td>Anterior</td><td>38.4</td><td>24.0</td><td>37.2</td><td>34.3</td></tr><tr><td>Pre-molars</td><td>34.7</td><td>26.1</td><td>47.7</td><td>42.6</td></tr><tr><td>Molars</td><td>44.7</td><td>35.5</td><td>56.7</td><td>52.2</td></tr><tr><td colspan="5">Oropharynx cancer</td></tr><tr><td colspan="5"> Lower teeth</td></tr><tr><td>Anterior</td><td>32.3</td><td>25.0</td><td>24.9</td><td>18.3</td></tr><tr><td>Pre-molars</td><td>36.5</td><td>31.3</td><td>40.6</td><td>34.5</td></tr><tr><td>Molars</td><td>50.5</td><td>41.0</td><td>57.0</td><td>52.1</td></tr><tr><td colspan="5"> Upper teeth</td></tr><tr><td>Anterior</td><td>28.0</td><td>19.6</td><td>20.6</td><td>13.2</td></tr><tr><td>Pre-molars</td><td>34.1</td><td>28.4</td><td>47.5</td><td>39.9</td></tr><tr><td>Molars</td><td>46.8</td><td>36.6</td><td>55.7</td><td>49.2</td></tr><tr><td colspan="5">Nasopharynx cancer</td></tr><tr><td colspan="5"> Lower teeth</td></tr><tr><td>Anterior</td><td>30.2</td><td>22.3</td><td>32.2</td><td>21.5</td></tr><tr><td>Pre-molars</td><td>37.1</td><td>28.0</td><td>44.9</td><td>37.5</td></tr><tr><td>Molars</td><td>54.6</td><td>39.9</td><td>65.6</td><td>57.2</td></tr><tr><td colspan="5"> Upper teeth</td></tr><tr><td>Anterior</td><td>31.7</td><td>23.6</td><td>28.6</td><td>18.2</td></tr><tr><td>Pre-molars</td><td>35.1</td><td>28.7</td><td>40.7</td><td>30.3</td></tr><tr><td>Molars</td><td>52.5</td><td>38.8</td><td>60.8</td><td>50.3</td></tr></table> |
1d746620634e5f9032ead48d3b70d931ba948b1f71f4a844d9ab368f4d5e8b26.png | simple | <table><tr><td> </td><td>Number of subjects</td><td>Mean</td><td>Standard deviation</td><td>Median</td><td>Minimum</td><td>Maximum</td></tr><tr><td>Age (years)</td><td>98</td><td>36.00</td><td>8.44</td><td>37.00</td><td>18.00</td><td>50.00</td></tr><tr><td>Height (cm)</td><td>98</td><td>158.67</td><td>5.19</td><td>158.35</td><td>146.00</td><td>169.60</td></tr><tr><td>Weight (kg)</td><td>98</td><td>81.84</td><td>19.32</td><td>80.45</td><td>47.00</td><td>127.40</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>98</td><td>32.6</td><td>7.69</td><td>31.12</td><td>17.84</td><td>49.30</td></tr><tr><td>Waist circumference (cm)</td><td>91</td><td>96.68</td><td>14.67</td><td>94.00</td><td>64.00</td><td>135.00</td></tr><tr><td>VO<sub>2</sub> max (Bruce test)</td><td>74</td><td>23.67</td><td>6.12</td><td>24.46</td><td>9.24</td><td>41.07</td></tr><tr><td>Body fat (%)</td><td>96</td><td>46.16</td><td>6.56</td><td>46.80</td><td>29.00</td><td>56.90</td></tr></table> |
1de2e5f8439f8e4804b1b08ce189022d79bee4ba313db117f061c664a510e699.png | simple | <table><tr><td>Scoring used in the study</td><td></td></tr><tr><td>The patient has resumed work-related and other activities with slight or no symptoms.</td><td>3: Excellent</td></tr><tr><td>The patient has resumed work-related and other activities but occasionally feels pain in the back or lower limbs after strenuous work.</td><td>2: Good</td></tr><tr><td>The patient has reduced work-related and other activities because of residual pain in the back or lower limbs.</td><td>1: Fair</td></tr><tr><td>The patient cannot work or carry out activities of daily living and is considered to be disabled.</td><td>0: Poor</td></tr></table> |
3919eeac5edf42d11b78777feaac1028aaa9a590f560c01dd9ed26f6c55fdac4.png | complex | <table><tr><td colspan="6">Exocyclic M<sub>1</sub>dG and 8-oxodG Adducts</td></tr><tr><td></td><td><i>N</i></td><td>M<sub>1</sub>dG ± SE</td><td><i>p</i>-Value</td><td>8-oxodG ± SE</td><td><i>p</i>-Value</td></tr><tr><td colspan="6">Adduct background in presence or absence of AMF exposures</td></tr><tr><td>Control cells</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nonexposed to AMF</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Incubation times</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>24 h <sup>a</sup></td><td>10</td><td>0.4 ± 0.1</td><td></td><td>3.2 ± 0.2</td><td></td></tr><tr><td>48 <sup>a</sup></td><td>10</td><td>0.4 ± 0.1</td><td></td><td>3.1 ± 0.2</td><td></td></tr><tr><td>Exposed to AMF (20 min)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Incubation times </td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>24 h <sup>a</sup></td><td>10</td><td>0.5 ± 0.1</td><td></td><td>3.2 ± 0.2</td><td></td></tr><tr><td>48 <sup>a</sup></td><td>10</td><td>0.5 ± 0.1</td><td></td><td>3.3 ± 0.3</td><td></td></tr><tr><td>Exposed to AMF (40 min)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Incubation times </td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>24 h <sup>a</sup></td><td>10</td><td>0.5 ± 0.1</td><td></td><td>3.4 ± 0.2</td><td></td></tr><tr><td>48 <sup>a</sup></td><td>10</td><td>0.5 ± 0.1</td><td></td><td>3.9 ± 0.3</td><td></td></tr><tr><td colspan="6">Adduct levels of treated cells in presence or absence of AMF exposures</td></tr><tr><td>NP treated cells </td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nonexposed to AMF </td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Incubation times </td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>24 h <sup>a</sup></td><td>10</td><td>0.7 ± 0.1</td><td><0.05 <sup>b</sup></td><td>16.7 ± 1.7</td><td><0.05 <sup>b</sup></td></tr><tr><td>48 <sup>a</sup></td><td>10</td><td>0.8 ± 0.1</td><td><0.05 <sup>b</sup></td><td>21.2 ± 1.9</td><td><0.05 <sup>b</sup></td></tr><tr><td>Exposed to AMF (20 min)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Incubation times </td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>24 h <sup>a</sup></td><td>10</td><td>4.6 ± 0.5</td><td><0.05 <sup>b</sup></td><td>40.3 ± 3.3</td><td><0.05 <sup>b</sup></td></tr><tr><td>48 <sup>a</sup></td><td>10</td><td>6.9 ± 0.6</td><td><0.05 <sup>b</sup></td><td>69.3 ± 1.4</td><td><0.05 <sup>b</sup></td></tr><tr><td>Exposed to AMF (40 min)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Incubation times </td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>24 h <sup>a</sup></td><td>10</td><td>6.4 ± 1.4</td><td><0.05 <sup>b</sup></td><td>36.5 ± 4.0</td><td><0.05 <sup>b</sup></td></tr><tr><td>48 <sup>a</sup></td><td>10</td><td>15.9 ± 6.7</td><td><0.05 <sup>b</sup></td><td>79.3 ± 1.1</td><td><0.05 <sup>b</sup></td></tr></table> |
ed64c6bc0f092927b5d14594e0f4f93aa4bffbc2c61ae8c244369bc7986a1260.png | complex | <table><tr><td rowspan="2">StandardOrder </td><td rowspan="2">Isoeugenol</td><td rowspan="2">Tween 80</td><td rowspan="2">NaCl</td><td rowspan="2">Dry Biomass</td><td colspan="2">Vanillin yield (g/L)</td></tr><tr><td>Observed</td><td>Predicted</td></tr><tr><td>1</td><td>-1</td><td>-1</td><td>0</td><td>0</td><td>1.53</td><td>1.48</td></tr><tr><td>2</td><td>+1</td><td>-1</td><td>0</td><td>0</td><td>1.79</td><td>1.78</td></tr><tr><td>3</td><td>-1</td><td>+1</td><td>0</td><td>0</td><td>1.07</td><td>1.11</td></tr><tr><td>4</td><td>+1</td><td>+1</td><td>0</td><td>0</td><td>1.87</td><td>1.96</td></tr><tr><td>5</td><td>0</td><td>0</td><td>-1</td><td>-1</td><td>1.79</td><td>1.73</td></tr><tr><td>6</td><td>0</td><td>0</td><td>+1</td><td>-1</td><td>1.34</td><td>1.37</td></tr><tr><td>7</td><td>0</td><td>0</td><td>-1</td><td>+1</td><td>1.29</td><td>1.25</td></tr><tr><td>8</td><td>0</td><td>0</td><td>+1</td><td>+1</td><td>2.11</td><td>2.16</td></tr><tr><td>9</td><td>-1</td><td>0</td><td>0</td><td>-1</td><td>1.56</td><td>1.63</td></tr><tr><td>10</td><td>+1</td><td>0</td><td>0</td><td>-1</td><td>1.89</td><td>1.89</td></tr><tr><td>11</td><td>-1</td><td>0</td><td>0</td><td>+1</td><td>1.46</td><td>1.47</td></tr><tr><td>12</td><td>+1</td><td>0</td><td>0</td><td>+1</td><td>2.43</td><td>2.37</td></tr><tr><td>13</td><td>0</td><td>-1</td><td>-1</td><td>0</td><td>1.32</td><td>1.40</td></tr><tr><td>14</td><td>0</td><td>+1</td><td>-1</td><td>0</td><td>1.12</td><td>1.07</td></tr><tr><td>15</td><td>0</td><td>-1</td><td>+1</td><td>0</td><td>1.43</td><td>1.44</td></tr><tr><td>16</td><td>0</td><td>+1</td><td>+1</td><td>0</td><td>1.69</td><td>1.58</td></tr><tr><td>17</td><td>-1</td><td>0</td><td>-1</td><td>0</td><td>1.73</td><td>1.75</td></tr><tr><td>18</td><td>+1</td><td>0</td><td>-1</td><td>0</td><td>1.78</td><td>1.83</td></tr><tr><td>19</td><td>-1</td><td>0</td><td>+1</td><td>0</td><td>1.53</td><td>1.53</td></tr><tr><td>20</td><td>+1</td><td>0</td><td>+1</td><td>0</td><td>2.58</td><td>2.61</td></tr><tr><td>21</td><td>0</td><td>-1</td><td>0</td><td>-1</td><td>1.40</td><td>1.37</td></tr><tr><td>22</td><td>0</td><td>+1</td><td>0</td><td>-1</td><td>1.04</td><td>1.04</td></tr><tr><td>23</td><td>0</td><td>-1</td><td>0</td><td>+1</td><td>1.28</td><td>1.29</td></tr><tr><td>24</td><td>0</td><td>+1</td><td>0</td><td>+1</td><td>1.39</td><td>1.43</td></tr><tr><td>25</td><td>0</td><td>0</td><td>0</td><td>0</td><td>2.15</td><td>2.14</td></tr><tr><td>26</td><td>0</td><td>0</td><td>0</td><td>0</td><td>2.19</td><td>2.14</td></tr><tr><td>27</td><td>0</td><td>0</td><td>0</td><td>0</td><td>2.18</td><td>2.14</td></tr></table> |
9b7c48fe0b0cb481a5dfde20715b25ce7642e8cd8825eb1e3d5d5d93b515f60c.png | complex | <table><tr><td>Time (days)</td><td>Treatment</td><td>Calcium (mg/dl)</td></tr><tr><td rowspan="2">21</td><td>Control</td><td>9.468 ± 0.275</td></tr><tr><td>Osteoinduced</td><td>13.496 ± 0.892**</td></tr></table> |
8b1a5f3d1706a2f250d06ac196a7e9ef48c0637611810b5531aec413a327152a.png | simple | <table><tr><td> </td><td>Pre-injury</td><td>5-months post-injury</td><td>12-months post-injury</td><td>NZ general population survey</td></tr><tr><td>Total</td><td>2842</td><td>1470</td><td>2262</td><td>1250</td></tr><tr><td>Age:</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>18-24</td><td>14.4%</td><td>13.1%</td><td>12.1%</td><td>7.0%</td></tr><tr><td>25-34</td><td>20.8%</td><td>19.5%</td><td>19.5%</td><td>13.3%</td></tr><tr><td>35-44</td><td>22.5%</td><td>23.5%</td><td>22.5%</td><td>20.4%</td></tr><tr><td>45-54</td><td>24.5%</td><td>26.5%</td><td>26.3%</td><td>20.2%</td></tr><tr><td>55-64</td><td>17.8%</td><td>17.4%</td><td>19.6%</td><td>16.4%</td></tr><tr><td>65+</td><td>–</td><td>–</td><td>–</td><td>21.0%</td></tr><tr><td>Not reported</td><td>–</td><td>–</td><td>–</td><td>1.8%</td></tr><tr><td>Sex:</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Male</td><td>61.4%</td><td>60.8%</td><td>58.9%</td><td>42.7%</td></tr><tr><td>Female</td><td>38.6%</td><td>39.2%</td><td>41.1%</td><td>56.0%</td></tr><tr><td>Not reported</td><td>–</td><td>–</td><td>–</td><td>1.3%</td></tr><tr><td>Recovery Status:</td><td> </td><td>n = 1248</td><td>n = 1937</td><td> </td></tr><tr><td>Recovered</td><td> </td><td>23.0%</td><td>36.4%</td><td> </td></tr><tr><td>Not recovered</td><td> </td><td>77.0%</td><td>63.6%</td><td> </td></tr><tr><td>Injury Type:</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Intracranial</td><td>3.7%</td><td>3.7%</td><td>3.8%</td><td> </td></tr><tr><td>Head/neck superficial</td><td>3.6%</td><td>3.2%</td><td>3.6%</td><td> </td></tr><tr><td>Spine dislocation, sprain, or strain</td><td>16.1%</td><td>15.3%</td><td>15.9%</td><td> </td></tr><tr><td>Upper extremity fracture</td><td>17.7%</td><td>20.5%</td><td>17.6%</td><td> </td></tr><tr><td>Upper extremity dislocation, sprain, or strain</td><td>14.3%</td><td>15.1%</td><td>13.7%</td><td> </td></tr><tr><td>Upper extremity open wound</td><td>6.0%</td><td>6.1%</td><td>5.8%</td><td> </td></tr><tr><td>Upper extremity superficial</td><td>5.0%</td><td>4.8%</td><td>4.9%</td><td> </td></tr><tr><td>Lower extremity fracture</td><td>17.2%</td><td>18.0%</td><td>18.1%</td><td> </td></tr><tr><td>Lower extremity dislocation, sprain, or strain</td><td>24.6%</td><td>21.9%</td><td>25.2%</td><td> </td></tr><tr><td>Lower extremity open wound</td><td>4.0%</td><td>3.9%</td><td>3.9%</td><td> </td></tr><tr><td>Lower extremity superficial</td><td>6.6%</td><td>6.3%</td><td>6.5%</td><td> </td></tr><tr><td>Other injury region/nature</td><td>17.1%</td><td>19.3%</td><td>17.4%</td><td> </td></tr><tr><td>UnadjustedEQ-5D social tariff</td><td>0.94</td><td>0.75</td><td>0.78</td><td>0.82</td></tr></table> |
26db279fc0cedcd0b04a9c861b3a86962212a99a8b4982bee860de6a4a329f9d.png | simple | <table><tr><td>Classifier</td><td>Accuracy (%)</td><td>Sensitivity (%)</td><td>Specificity (%)</td><td>Strength (%)</td><td>ROCAUC</td></tr><tr><td>BindN-RF</td><td>80.00</td><td>73.08</td><td>80.63</td><td>76.86</td><td>0.8495</td></tr><tr><td>BindN</td><td>70.81</td><td>68.70</td><td>71.01</td><td>69.85</td><td>0.7648</td></tr><tr><td>DP-Bind</td><td>78.89</td><td>65.89</td><td>80.76</td><td>73.32</td><td>0.8149</td></tr><tr><td>DBS-PSSM</td><td>67.91</td><td>37.48</td><td>70.72</td><td>54.10</td><td>0.5528</td></tr></table> |
13dcfa0b696cfa8384a99921f9e739a75206f78d23de7bca5cde5f6a34f6b597.png | complex | <table><tr><td rowspan="2">The Tested Compounds </td><td colspan="3">Side Effects of Rats Treated with Artesunate and Artemisinin, Respectively</td></tr><tr><td>The Loss of Body Weight</td><td>Vomiting</td><td>Diarrhea</td></tr><tr><td>Artesunate</td><td>−</td><td>−</td><td>−</td></tr><tr><td>Artemisinin</td><td>−</td><td>−</td><td>−</td></tr></table> |
e4e6f457c77217aefb1c9f1baf6b2811ba1080e18282cf1400024d772ebd060f.png | simple | <table><tr><td>Characteristics</td><td>Frequencies (n=271)</td><td>Percentage (%)</td></tr><tr><td>Household Members Ever Suffer Jigger Infestation:</td><td></td><td></td></tr><tr><td>Yes</td><td>239</td><td>88.2</td></tr><tr><td>Households reported with jiggers infested persons:</td><td></td><td></td></tr><tr><td>Yes</td><td>64</td><td>23.6</td></tr><tr><td>Number of household members infested</td><td></td><td></td></tr><tr><td>1 Member</td><td>40</td><td>14.8</td></tr><tr><td>2 Members</td><td>19</td><td>7.0</td></tr><tr><td>3 Members</td><td>4</td><td>1.5</td></tr><tr><td>5 Members</td><td>1</td><td>0.3</td></tr><tr><td>Number of households with jiggers infested persons seen during the study:</td><td></td><td></td></tr><tr><td>Yes</td><td>51</td><td>18.8</td></tr><tr><td>Number of infested household members</td><td></td><td></td></tr><tr><td>1Person</td><td>32</td><td>11.8</td></tr><tr><td>2 Persons</td><td>15</td><td>5.5</td></tr><tr><td>3 Persons</td><td>4</td><td>1.5</td></tr></table> |
351c112b5b619da781f6b0b0b7e540bcf34218c7e9b9949059c2b058dd659c12.png | complex | <table><tr><td rowspan="3">Severity of retinopathy</td><td colspan="7">Retinal findings in severe malaria (indirect ophthalmoscopy; <i>n</i> = 139)</td></tr><tr><td rowspan="2">Any retinopathy</td><td colspan="2">Hemorrhages</td><td rowspan="2">Papilloedema*</td><td colspan="3">Whitening</td></tr><tr><td>White-centered</td><td>Any</td><td>Macular</td><td>Peripheral</td><td>Any</td></tr><tr><td>Fatal (<i>n</i> = 21)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mild</td><td>6 (29%)</td><td>15 (71%)</td><td>8 (38%)</td><td></td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>Moderate to severe</td><td>12 (57%)</td><td>0 (0%)</td><td>8 (38%)</td><td>9 (43%)</td><td>2 (10%)</td><td>1 (5%)</td><td>2 (10%)</td></tr><tr><td>Total</td><td>18 (86%)</td><td>15 (71%)</td><td>16 (76%)</td><td>9 (43%)</td><td>2 (10%)</td><td>1 (5%)</td><td>2 (10%)</td></tr><tr><td>Non-fatal (<i>n</i> = 118)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mild</td><td>23 (19%)</td><td>29 (25%)</td><td>25 (21%)</td><td></td><td>0 (0%)</td><td>1 (1%)</td><td>0 (0%)</td></tr><tr><td>Moderate to severe</td><td>6 (5%)</td><td>0 (0%)</td><td>4 (3%)</td><td>0 (0%)</td><td>2 (2%)</td><td>0 (0%)</td><td>2 (2%)</td></tr><tr><td>Total</td><td>29 (25%)</td><td>29 (25%)</td><td>29 (25%)</td><td>0 (0%)</td><td>2 (2%)</td><td>1 (1%)</td><td>2 (2%)</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.